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ABSTRACT 
Objectives: To measure total days of hospitalization, length of stay (LOS) and 
readmission risk for patients with schizophrenia following the introduction of an 
umestricted reimbursement policy for costly atypical antipsychotic medications. 
Methods: A province-wide, observational, retrospective hospital chart review, using a 
before and after design, was used to identify all hospital admissions and quantify data on 
risk factors associated with LOS and readmission for acute episodes of schiZophrenia. 
Three time periods were studied: 1) 1995/96 at the beginning of restricted access to 
atypical agents; 2) 1998 at the last year of restricted access; and 3) 2000 the second year 
of open access. Multivariable Cox proportional hazards and logistic regression models 
were used to identify risk factors influencing LOS and readmission within one year of 
discharge respectively. Retrospective administrative prescription claims provided data on 
the use of and expenditure for atypical agents before and after the policy change. 
Results: Total days hospitalization for schizophrenia in 1995/96 was 15,089, 16,318 in 
1998 and 15,691 in 2000. There were 57 (18.2%) fewer patients admitted to hospital and 
98 (16.7%) fewer admissions during the period of open access (2000) when compared to 
baseline (1995/96). However, median LOS in 2000 was significantly longer than in 
1995/96 (22.0 vs. 15.0 days, P<0.001). Being admitted in 2000 compared to baseline 
was a significant predictor of increased LOS (HR: 3.04, CI=1.57-5.86, P=0.0009); 
independent of requiring ECT (HR: 2.49, CI=1.69-3.66, P<O.OOl); seclusion (HR: 1.87, 
CI=1.41-2.50, P<0.001); thought disorder (HR: 1.41, CI=l.ll-1.81, P=0.006); suicidal 
11 
ideation on admission (HR: 0.70, CI=0.57-0.86, P=0.0007) and discharging against 
medical advice (HR: 0.38; CI=0.27-0.54, P<0.001). No change m the number of 
readmissions was observed over the study period. 
Expenditures for atypical agents were $217,273 in 1995/96, $1.3 million in 1998, 
and 3.8 million in 2000, a 17.5 fold increase. 
Conclusions: The unrestricted reimbursement policy for atypical antipsychotic 
medications was associated with a large increase in government expenditure for these 
drugs, which was not associated with a decrease in hospital utilization in the province by 
schizophrenia sufferers. Although a decrease in hospital admissions occurred, this was 
negated by an increase in LOS. 
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ACKNOWLEDGMENTS 
I gratefully acknowledge the assistance and guidance provided by the members of 
my Supervisory Committee, Drs Brendan Barrett, David Craig and Leslie Philips. I am 
particularly appreciative of their criticisms and encouragement throughout the duration of 
this research project. 
I am indebted to the Pharmaceutical Manufacturers Association of Canada for 
providing financial support for this research project. 
The completion of this research project owes much to the guidance, support, 
criticism and advice of my supervisor, Dr. Patrick Parfrey. I have been very fortunate in 
coming to know him as a teacher, mentor and friend. 
I dedicate this dissertation to my parents, Tom and Joan O'Reilly, who have 
provided much needed support throughout this long journey and to my boyfriend, Mike 
Miller, who embodies the true meaning of significance. 
IV 
TABLE OF CONTENTS 
Page 
Abstract. ............................................................................................. .ii 
Acknowledgments .................................................................................. .i v 
Table of Contents ..................................................................................... v 
List of Tables ........................................................................................ xii 
List of Figures ....................................................................................... xiii 
List of Abbreviations ............................................................................... xiv 
Chapter I - Introduction ............................................................................. 1 
1.1 Background of Study ............................................................................ 1 
1.2 Purpose of Study ................................................................................ 5 
Chapter II- Literature Review ..................................................................... 7 
2.1 Burden of Schizophrenia ....................................................................... 7 
2.2 Treatment for Schizophrenia ................................................................... 7 
2.2.1 Pharmacotherapies ................................................................... 8 
2.2.1.1 Clinical Evidence for Atypical Antipsychotics in 
Schizophrenia ............................................................... 1 0 
2.2.1.2 Psychometric Rating Scales ............................................. 11 
2.2.1.3 Literature Search and Study Selection ................................. 13 
2.2.1.4 Atypical versus Conventional Antipsychotics ........................ 14 
v 
Clozapine .................................................................. 14 
Studies published prior to policy implementation ........... 15 
Studies published following policy implementation ....... 18 
Risperidone ................................................................ 19 
Studies published prior to policy implementation .......... 19 
Studies published following policy implementation ........ 24 
Olanzapine ................................................................ 24 
Studies published prior to policy implementation .......... 25 
Studies published following policy implementation ........ 28 
Quetiapine ............................................................................. 28 
Studies published prior to policy implementation ............. 29 
Studies published following policy implementation ........ 30 
2.2.1.5 Head-to-Head Comparisons of Atypical Antipsychotics ............ 31 
Clozapine versus risperidone ........................................... 31 
Studies published prior to policy implementation .......... 31 
Studies published following policy implementation ........ 32 
Risperidone versus olanzapine .......................................... 33 
Studies published prior to policy implementation .......... 33 
Studies published following policy implementation ........ 33 
Quetiapine versus risperidone .......................................... 34 
Studies published following policy implementation ........ 34 
Clozapine versus olanzapine versus risperidone ..................... 35 
Studies published following policy implementation ........ 35 
2.2.1.6 Quality of Studies Reviewed ........................................... 36 
2.2.1. 7 Summary of Studies Reviewed ........................................ .42 
2.2.1.8 Economic Evaluations of Atypical Antipsychotic Medications .. .43 
2.2.1.9 Literature Search and Study Selection ................................. 43 
Vl 
Full economic evaluations ............................................. .45 
Partial economic evaluations ........................................... 54 
2.2.2.1 Quality of the Studies Reviewed ....................................... 59 
2.2.2.2 Summary of the Studies Reviewed .................................... 61 
2.3 Access to and Utilization of Pharmacotherapies ........................................... 62 
2.3.1 Defining Access ...................................................................... 62 
2.3 .1.1 Patient-Level Restrictions: Cost-sharing and Prescription 
Limits ................................................................................ 63 
2.3.1.2 Administrative Restrictions on Prescribing ........................... 65 
Special Authorization .................................................... 66 
Interchangeability .......................................................... 6 7 
Global Budgets ............................................................. 69 
Fundholding ............................................................... 70 
Outcomes Guarantee ..................................................... 72 
2.3 .1.3 Differential Access to Prescription Medicines in Canada ........... 72 
2.3.1.4 Summary ..................................................................... 75 
2.3.2 Defining Utilization ............................................................... 75 
2.3 .2.1 Physician Prescribing Behaviour. ...................................... 7 5 
2.3.2.2 Patient Adherence ........................................................ 79 
2.3.2.3 Summary .................................................................. 80 
Chapter III Design and Methods .............................................................. 82 
3.1 Introduction ...................................................................................... 82 
3.2 Ethical Considerations ......................................................................... 83 
Vll 
3.3 Hospital Utilization in Newfoundland ............................................. 0 0 0 0 .. 0 .. 084 
3.301 Data Source and Study Population ................ 0 ......... 00 ................. 84 
3.3.2 Data Collection .......................... 00 .... 00.00 ................... 00 0 ......... 85 
3.3.3 Outcome Measures ... 0. 00 ........ 0 ...... 0 0 ................... 00.00 .... 00 ...... 0 00.87 
3.3.4 Demographic Characteristics ........ 00 .......... 0 .............. 00.00. 00 .... 00 ... 87 
3.3.5 Psychiatric Symptoms and Clinical Presentation ...................................... 87 
3.3.6 Pharmacotherapy .. 00.00 .. 00 00 ....... 00 .......... 00 .... 00 .... 00.00 .... 00 ........... 88 
3.3.7 Analytic Approach ... 00 ............ 00.00 ......... 0 ... 00.00. 00 .... 00.00 0 00.00. 00 ... 89 
3.4 Patterns of Antipsychotic Medication Utilization and Expenditure in the Province of 
Newfoundland (NLPDP), 1995-2003 ..... 00. 00 .......... 00. 00 ...... 0 00 .... 00 .... 0. 0. 0 0 00 0 ... 92 
3.4.1 Utilization and Expenditure ......................... 0 0 ............ 0 .... 0 .. 0 .. 0 ... 92 
3.4.2 Indication for Use of Atypical Antipsychotic Medications for Claims 
Reimbursed by the NLPDP ....................................................... 93 
3 .4.2.1 Identification of Prescribing Physicians ................................... 93 
3.4.2.2 Method of Data Collection ....... 0. 0 0 0. 0 ............................ 0 ....... 95 
3.4.3 Atypical Antipsychotic Utilization in Canada .................................. 96 
Chapter IV- Results ............... 0 .. 0. 00 ............... 0. 0 ........... 0. 0 0. 00 .... 00 0 00. 0 0 0. 0. 00 .... 98 
4.1 Acute Care Hospital Utilization Over Time in Newfoundland .. 0 .............. 0. 0. 0 ..... 98 
4.1.1 Summary of the Three Study Years ............................................... 98 
401.2 Sociodemographic Characteristics .......................................... 0 .... 99 
V111 
4.1.3 Psychiatric Status .................................................................... 101 
4.1.4 Level of Care Required During Admission .................................... 1 02 
4.1.5 Pharmacotherapy Prescribed on Hospital Discharge ......................... 1 02 
4.1.6 Length of Stay in Hospital. ................................................ 0 ••••• 1 03 
4.1.6.1 Comparison of Patients Admitted in Multiple Years vs. Patients 
Admitted in One Year .................................................. 1 05 
4.1.6.2 Significant Factors Influencing Length of Stay ...................... 1 08 
4.1.6.3 Length of Stay Associated with the Class of Antipsychotic Agent 
Prescribed on Admission and Discharge for Each of the Study 
Years ............................................................... 0 ••••• 110 
4.1. 7 Readmission to Hospital. ......................................................... 112 
4.1.7.1 Rates of Readmission to Hospital. ................................... 112 
4.1. 7.2 Factors Influencing Early Hospital Readmission for all Study 
Years ..................................................................... 112 
4.2 Utilization of Newer Antipsychotic Medications by NLPDP 1995-2003 ............ 117 
4.3 Indication for Atypical Antipsychotic Use in Newfoundland .................. 0 ...... .120 
4.4 NLPDP Beneficiaries Started on an Atypical Antipsychotic in 2000 ................. 120 
4.5 Atypical Antipsychotic Utilization in Canada, 2000 .................................... 121 
Chapter V- Unrestricted Access: A Policy Analysis and Economic Implications. 0. 0. 0.124 
5.1 The Open Access to Atypical Antipsychotic Medications in Newfoundland: A Policy 
Analysis .......................................................................................... 124 
5.2 The Open Access to Atypical Antipsychotic Medications in Newfoundland: Potential 
Economic Implications of an Unrestricted Policy .................................................. 128 
lX 
5.2.1 Economic Efficiency ............................................................. 128 
5.2.2 Implications ...................................................................... 130 
Chapter VI - Conclusions and Discussion ...................................................... 132 
6.1 Acute Care Hospital Utilization in Newfoundland ........................................ 132 
6.2 Utilization ofNewer Antipsychotic Medications in Newfoundland .................. .137 
6.3 Summary of Results ........................................................................... 140 
6.4 Policy Options ................................................................................. 141 
Chapter VII -Appendices ......................................................................... 144 
Appendix A Health & Community Services Regions/Integrated Boards boundaries and 
corresponding demographic Profiles ............................................................ 144 
Appendix B Characteristics of comparative studies of clozapine with conventional 
antipsychotic medications ......................................................................... 145 
Appendix C Characteristics of comparative studies of risperidone with conventional 
antipsychotics medications ....................................................................... 149 
Appendix D Characteristics of comparative studies of olanzapine with conventional 
antipsychotic medications ........................................................................ 154 
Appendix E Characteristics of comparative studies of quetiapine with conventional 
antipsychotic medications ........................................................................ 15 8 
Appendix F Characteristics of head-to-head comparisons of atypical antipsychotic 
medications ......................................................................................... 160 
Appendix G Cost comparisons of full economic evaluations of atypical antipsychotic 
medications ......................................................................................... 165 
Appendix H Letter of intent to prescribing physicians ....................................... 173 
Appendix I Physician consent form ............................................................ 175 
X 
Appendix J Health record review for hospitalized patients ............................................ 178 
Appendix K Outpatient interview with prescribing physician .............................. 184 
Appendix L Algorithms to determine indication for use by Brogan Inc .................. 186 
Chapter VIII - References ........................................................................ 187 
Xl 
LIST OF TABLES 
Page 
Table 1. Summary of the three study years .................................................. 99 
Table 2. Characteristics of patients admitted to hospital during each study year ...... 1 00 
Table 3. Pharmacotherapy prescribed during annual index admission .................. 1 03 
Table 4. Time spent in hospital in each study year ......................................... 104 
Table 5. Patients admitted in one study period compared to patients admitted in more 
than one study period ........................................................................... 1 06 
Table 6. Comparison of patients admitted in multiple study years with patients admitted 
in one study year .................................................................................. 1 07 
Table 7. Multivariate Cox Proportional Hazards Model of the independent variables 
predicting an increased length of stay by study index admission for 1995/96, 1998, & 
2000 (n=509/645, 78.9%) ........................................................................ 109 
Table 8. Length of stay associated with the class of antipsychotic agent prescribed on 
admission and discharge for each study year .................................................. 111 
Table 9. Index admission analysis for readmission to hospital. ........................... 112 
Table 10. Comparison of patients readmitted within one year of hospital discharge with 
patients not readmitted within one year ofhospital discharge (1995/96, 1998, and 
2000)(n=639) .............................................................................. 114 
Table 11. Multivariable Logistic Regression Model for predictors influencing 
hospitalization within 1-year of discharge from the index admission 1995/96, 
1998, & 2000 (5211639, 81.5%) ...................................................... .116 
Xll 
LIST OF FIGURES 
Page 
Figure 1. Length of stay for the index admission for each study year .................... 1 05 
Figure 2. NLPDP expenditures for atypical antipsychotic medications vs. conventional 
antipsychotic medications, 1995-2003 ........................................................ 118 
Figure 3. Share of the NLPDP expenditure by antipsychotic medication, 2000/01 .... 119 
Figure 4. Number ofbeneficiaries and total antipsychotic prescriptions reimbursed by 
NLPDP 1992-2003 ................................................................................. 119 
Figure 5. National atypical antipsychotic medication utilization in 2000 ................. 122 
Figure 6. National atypical antipsychotic medication expenditure in 2000 ............... 123 
Figure 7. Total number of claims for atypical antipsychotic medications by diagnosis in 
Canada, 2000 ............................................................................ 123 
Xlll 
LIST OF ABBREVIATIONS 
ADHD 
AHFS 
AIMS 
AMA 
ANOVA 
BAS 
BPRS 
CA 
CBA 
CCA 
CCOHTA 
CEA 
CGI 
CMA 
CME 
CPGs 
CUA 
DHCS 
Attention Deficit Hyperactivity Disorder 
American Hospital Formulary System 
Abnormal Involuntary Movement Scale 
Against Medical Advice 
Analysis of Variance 
Barnes Akathisia Scale 
Brief Psychiatric Rating Scale 
Cost Analysis 
Cost Benefit Analysis 
Cost-consequence Analysis 
Canadian Coordinating Office for Health Technology Assessment 
Cost-Effectiveness Analysis 
Clinical Global Impression (scale) 
Cost Minimization Analysis 
Continuing Medical Education 
Clinical Practice Guidelines 
Cost Utility Analysis 
Department ofHealth and Community Services 
XIV 
DSM-III-R 
ECT 
EPS 
ESRS 
GAF 
GIS 
HAM-D 
ICD-9 
ICER 
IPA 
LOCF 
LOS 
MADRS 
MSE 
NHS 
NICE 
NLMA 
NLPDP 
NOS IE 
NPA 
Diagnostic and Statistical Manual of Mental Disorders, Third 
Edition, Revised 
Electroconvulsive Therapy 
Extrapyramidal Side Effects 
Extrapyramidal Symptom Rating Scale 
Global Assessment Functions 
Guaranteed Income Supplement 
Hamilton Rating Scale for Depression 
International Classification of Diseases, Ninth Revision 
Incremental Cost Effectiveness Ratio 
Independent Practitioner Association 
Last-Observation-Carried-Forward 
Length of Stay 
Montgomery-Asberg Depression Rating Scale 
Mental Status Exam 
National Health Service 
National Institute for Clinical Excellence 
Newfoundland and Labrador Medical Association 
Newfoundland and Labrador Prescription Drug Program 
Nurses' Observation Scale for Inpatient Evaluation 
Newfoundland Psychiatric Association 
XV 
ODB 
PANSS 
PANSS-GPS 
PANSS-P 
PANSS-N 
PAS 
QALY 
QLS 
RCT 
SADS-C 
SANS 
SARS 
SSNL 
Ontario Drug Benefits 
Positive and Negative Syndrome Scale for Schizophrenia 
Positive and Negative Syndrome Scale for Schizophrenia-General 
Psychopathology 
Positive and Negative Syndrome Scale for Schizophrenia-Positive 
Symptoms 
Positive and Negative Syndrome Scale for Schizophrenia-
Negative Symptoms 
Psychotic Anxiety Scale 
Quality Adjusted Life Year 
Quality of Life Scale 
Randomized Controlled Trial 
Schedule for Affective Disorders and Schizophrenia-Change 
Version 
Scale for the Assessment ofNegative Symptoms 
Simpson-Angus Rating Scale 
Schizophrenia Society ofNewfoundland and Labrador 
XVI 
CHAPTER I- INTRODUCTION 
1.1 Background of Study 
Prescription drugs play an important role in Canada's health care system and are 
often used as a substitution for other treatments and medical interventions, including 
surgeries. 1 As their role in the health care system expands, so does their cost. In 1980, 
5.8% ($1.3 billion) of total spending on health care in the country was spent on 
prescription drugs. By 2001, this percentage increased to 12% representing a total of 
$12.3 billion for prescription medications. 1 
Prescription drug costs will continue to rise in the future. To slow the growth in 
pharmaceutical expenditures, drug benefit programs have implemented a variety of 
utilization control mechanisms that are intended to have no impact on access to effective 
health care.2 Examples include: restricted formularies (i.e., lists of pharmaceuticals 
approved for reimbursement that may include only the older, less expensive 
medications); limits on the numbers of prescriptions or units allowed; high deductibles 
and co-payments; reference drug pricing; and prior authorization requirements for newer 
medications. The main concerns about drug cost-containment is that patients may switch 
to less effective treatments, become non-adherent, or be hospitalized more frequently. 3 4 
Antipsychotic medication is the cornerstone of treatment for schizophrenia. 
These medications help manage the positive symptoms of the disease and delay or 
prevent relapse. In the last decade, new "atypical" antipsychotics have been introduced. 
Compared to the older "conventional", "classical" or "traditional" antipsychotics these 
medications appear to be equally effective for helping reduce the positive symptoms like 
hallucinations and delusions-but may be better than the older medications at relieving 
the negative symptoms of the illness. The primary advantage of these new drugs is the 
decreased risk of developing extrapyramidal side effects (EPS) such as parkinsonism, 
akathisia, acute dystonia, and tardive dyskinesia.5 6 Medications with fewer and/or milder 
adverse effects may improve patient adherence with therapy, which may lead to 
improved effectiveness when used in clinical practice. As a result, the value of reduced 
or absent side effects and/or enhanced efficacy may have economic implications by 
reducing the need for hospital admission that may justify the higher drug acquisition 
costs. 
For example, the Canadian Coordinating Office of Health Technology 
Assessment (CCOHTA) commissioned the economic evaluations of risperidone and 
clozapine? One analysis estimated an annual cost savings of approximately $389 million 
in direct health care expenditures when clozapine is compared to chlorpromazine or 
haloperidol in hospitalized patients with treatment-resistant schizophrenia with moderate 
symptomatology. The second analysis concluded that the use of risperidone compared to 
haloperidol, haloperidol decanoate or fluphenazine decanoate in the treatment of 
hospitalized patients with chronic schizophrenia who had experienced an exacerbation of 
2 
symptoms was associated with $662 million in annual cost savmgs. The potential 
'savings' in both instances were mainly due to reduced hospitalization offsetting the 
associated incremental increase in drug expenditure for clozapine of $63 million and 
$113 million for risperidone? 
Prior to December 23, 1998, the Newfoundland and Labrador Prescription Drug 
Program (NLPDP), which provides prescription drug coverage for all residents of the 
province who are either on social assistance or are aged 65 and older in receipt of the 
Guaranteed Income Supplement (GIS), relied on a restricted access policy for these new, 
expensive atypical antipsychotic medications. In order for a pharmacist to get 
reimbursed for dispensing an atypical antipsychotic prescription by the NLPDP, a 
physician was required to submit a written request to prescribe them and approval was 
based on defined criteria: a diagnosis of schizophrenia and either failure to respond to 
two adequate trials of conventional agents, or intolerance of conventional agents. During 
1998, there was mounting pressure from the schizophrenia community, psychiatrists, the 
pharmaceutical industry and the media to allow unrestricted access to these new 
medications, and the results of the CCOHTA economic analyses supported such a policy 
change. The response by the Department of Health and Community Services, 
Governrnent of Newfoundland and Labrador, was the introduction of an unrestricted 
reimbursement policy for the atypical antipsychotic medications (risperidone 
3 
(Risperidal®), clozapine (Clozaril®), quetiapine (Seroquel®) and olanzapine (Zyprexa®)), 
provided the impact of open access on hospitalization for schizophrenia was studied. 
In the province ofNewfoundland and Labrador (provincial population= 541,000) 
hospital services are the responsibility of six Institutional Boards: 1) Health Care 
Corporation of St. John's; 2) Avalon Health care Institutions Board; 3) Peninsulas Health 
Care Corporation; 4) Central East Health Care Institutions Board; 5) Central West Health 
Corporation; and 6) Western Health Care Corporation. Additionally, there are two 
Integrated Boards: 1) Grenfell Regional Health Services; and 2) Health Labrador 
Corporation. These Institutional Boards are contained in six health care regions: St. 
John's, Eastern, Central, Western, Grenfell and Labrador (Appendix A). The St. John's 
region is served by three acute care divisions and a number of chronic care divisions 
within the Mental Health Program, is predominantly urban and has a population of 
approximately 195,000. Additionally, this region has the only psychiatric hospital in the 
province. The Eastern regwn is served by three secondary care hospitals, IS 
predominantly rural and has a population of 109,682. The Central region Is 
predominantly rural and has a population of 106,682. The Western region is served by 
one tertiary care hospital and 5 community hospitals, is predominantly rural and has a 
population of 87,736. Both the Grenfell and Labrador regions are rural and are served by 
one secondary hospital with a combined population of 42,453(Appendix A). 8 
4 
1.2 Purpose of Study 
The current study was undertaken at the request of the Department of Health and 
Community Services, Government of Newfoundland and Labrador to evaluate the impact 
of open access to atypical antipsychotic medications on hospital utilization for 
schizophrenia in the province. Government and various sectors of the pharmaceutical 
industry agreed to collaborate in this research endeavour. Other stakeholders such as the 
Schizophrenia Society of Newfoundland and Labrador, the Newfoundland and Labrador 
Psychiatric Association, the Newfoundland and Labrador Medical Association (NLMA) 
endorsed the study. 
This study has been designed to determine whether the increased utilization of 
expensive atypical antipsychotic medications resulting from the implementation of the 
unrestricted reimbursement policy would be associated with a reduction in hospital 
utilization by patients with schizophrenia in Newfoundland and Labrador. The primary 
objective was to measure changes in hospitalization and time to readmission by 
schizophrenia sufferers as well as changes in drug utilization and expenditures before and 
after the advent of unrestricted access to atypical agents. As multiple factors influence 
hospitalization, length of stay and readmission, multivariable modelling permitted the 
examination of the impact of study year while taking account of other factors that 
influence these outcomes. The main hypothesis was that as the utilization of atypical 
antipsychotic medications increases, patients with a diagnosis of schizophrenia will 
5 
experience fewer episodes of relapse requiring admission to hospital and a reduced length 
of hospital stay. In addition, as the penetration of atypical antipsychotic medications in 
the marketplace increased so the number of admissions would decrease. Consequently 
all admissions to both acute and psychiatric hospitals for schizophrenia during three 12-
month periods were studied: 1) at the beginning of restricted access to atypical 
antipsychotic drugs in 1995/96; 2) at the end of restricted access in 1998; and 3) during 
the second year of unrestricted access in 2000. A secondary objective was to measure the 
impact of the policy change on the NLPDP budget. 
To our knowledge no comprehensive studies have assessed hospital utilization 
patterns and drug use following an unrestricted access policy for atypical antipsychotic 
medications within Canada. 
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CHAPTER II- LITERATURE REVIEW 
2.1 Burden of Schizophrenia 
Schizophrenia is an expensive disease. Although it occurs in only 1% of the 
general population, it has a much greater impact on the national budget than the numbers 
suggest.9 Patients with schizophrenia are at significantly increased risk for suicide, 
violence, substance abuse/dependence, unemployment and homelessness. The disease 
has an early age of onset and causes long-term morbidity; necessitates maintenance drug 
therapy, and frequent admission to hospital occurs. In 1996, the direct and indirect cost 
associated with schizophrenia was estimated to be $1.12 billion in Canada.9 The largest 
single category of direct costs was acute care hospitalizations (29%), followed by 
provincial psychiatric hospitalizations (21 %). By 2002, the annual direct and indirect 
cost of schizophrenia in Canada has been estimated to have reached $4.35 billion. 10 
2.2 Treatment for Schizophrenia 
At present, there is no cure for schizophrenia. As a result, the goals of treatment 
include the improvement of symptoms, patient rehabilitation, improved quality of life, 
and the prevention of relapse and re-hospitalization. In addition to clinical needs (e.g., 
symptom reduction), treatment for persons with schizophrenia must address a variety of 
needs related to the illness including housing, income support, psychological 
interventions, family interventions, vocational rehabilitation, assertive community 
treatment and case management. However, pharmacotherapy is the cornerstone of 
7 
treatment for schizophrenia and the most extensively evaluated type of intervention for 
the disease. 
2.2.1 Pharmacotherapies 
The modem era of pharmacotherapy for schizophrenia began in the early 1950s 
when the antipsychotic properties of chlorpromazine were discovered. 11 Following this 
discovery, numerous other antipsychotic drugs have been developed. In clinical trials, 
these agents have been shown to be more effective than placebo in controlling the 
positive symptoms of schizophrenia (e.g. auditory hallucinations and delusions) and in 
moderating acute episodes of the condition. 12 13 Despite being the mainstay of 
psychopharmacological treatment for patients with schizophrenia for more than four 
decades, these antipsychotics are only moderately effective in treating the positive 
symptoms of 70 to 80% of schizophrenia sufferers. 11 Treatment responders still have a 
high rate of nonadherence that is thought to be due in part to limited insight into their 
illness and to the increased risk of inducing acute and tardive extrapyramidal side effects 
(EPS). 11 14 In addition, these antipsychotic agents appear to have little effect on the 
negative symptoms (e.g. blunted affect and emotional withdrawal) of schizophrenia. 
Whilst representing a major step forward in the treatment of schizophrenia when 
introduced, the overall impact of conventional antipsychotics is still marred by the 
frequency and severity of side effects. 
8 
In response to the problems of conventional therapies outlined above, the 
pharmaceutical industry has put considerable effort into developing new, 'atypical', or 
second generation, antipsychotics. The term 'atypical' was originally used to describe 
drugs that in animal models predict antipsychotic effects but do not produce catalepsy 
(the behavioural equivalent of EPS). At present, an atypical agent is generally defined as 
one that has a low propensity to produce EPS or other movement disorders and elevated 
serum prolactin levels. 15 Additionally, they are promoted as reducing both the negative16 
17 
and positive symptoms of schizophrenia. 56 
Antipsychotic medications affect specific brain receptors in specific regions and 
block dopamine D2 receptors. While this does not prove a causal relationship between D2 
blockade and antipsychotic response, it is believed that the association between the two is 
undeniable. 18 Prospective studies have largely confirmed that a "threshold" D2 
occupancy is required to induce antipsychotic response. However, it is unclear exactly 
what this threshold is and whether the threshold for inducing response is the same as the 
one for maintaining it. 19 Nonetheless, there is a mechanism of antipsychotic response 
that relies on D2 occupancy alone. Additionally, it has been noted that as D2 occupancy 
increases, especially as it rises above 80%, the incidence of extrapyramidal side effects 
increases. Elevation of prolactin levels may also show a threshold relationship with 
respect to D2 occupancy. While D2 occupancy may be necessary for response, it is not 
always sufficient, as there are patients who do not respond despite adequate D2 
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occupancy.20 However, Kapur et al. 18 claim that it is fair to say that D2 occupancy 
provides a reliable pharmacological predictor of response to antipsychotic medications, 
extrapyramidal side effects, and elevation of prolactin levels. 
Drugs that demonstrate clinical features associated with atypical antipsychotics 
(i.e., low extrapyramidal side effects and prolactin elevation) have higher ratios of 
serotonin 5-HT 2 ( 5-hydroxytryptamine) receptor to dopamine D2 receptor blockade in 
vitro, in comparison with conventional antipsychotics such as haloperidol, due to their 
lower affinity at the D2 receptor.21 Compounds such as risperidone may share features of 
both typical and atypical agents with some differences, disappearing at higher doses.22 23 
Thus, criteria for an atypical agent are somewhat flexible. 
2.2.1.1 Clinical Evidence for Atypical Antipsychotics in Schizophrenia 
The introduction of novel antipsychotics has been heralded as a major advance in 
the treatment of schizophrenia and as a result has raised expectations of improved 
outcomes for individuals with schizophrenia. Initial evidence supporting the efficacy of 
atypical antipsychotic medications has been obtained, in large part, from studies of 
clozapine, which have demonstrated its increased efficacy in patients with treatment-
resistant schizophrenia in which conventional antipsychotics were no longer 
efficacious.24 25 Second generation antipsychotic medications introduced subsequently 
are also widely believed to have greater efficacy compared to conventional antipsychotic 
10 
drugs, although the evidence for this is variable. The following sections will provide 
review of this evidence for each drug affected by the policy change and will be divided 
into two sections: 1) evidence available to inform the initial policy decision; and 2) 
evidence published after the implementation of the unrestricted policy, as the latter 
influences atypical antipsychotic utilization for the treatment of schizophrenia. This 
review compares the efficacy of atypical antipsychotics with older antipsychotics as well 
as with other atypical agents. Many psychometric rating scales have been used in clinical 
trials to assess the impact of various treatment regimes on patients with schizophrenia 
and in order to compare the studies, a basic knowledge of the psychometric instruments 
used for measuring efficacy is necessary. 
2.2.1.2 Psychometric Rating Scales 
All efficacy measures are clinician-administered, but some measure global 
symptoms while others measure symptoms more specific to psychotic disorders. The 
Clinical Global Impression Scale (CGI) measures severity of illness, clinical 
improvement, and therapeutic efficacy of treatment by comparing conditions of the 
person standardized against other people with the same diagnosis.26 A seven-point 
scoring system is usually used, with low scores showing decreased severity and/or overall 
improvement. Also global in nature, the Schedule for Affective Disorders and 
Schizophrenia-Change Version (SADS-C)27 is a structured interview that measures 
change in symptoms and assesses anxiety, depression, manic features, and delusions or 
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disorganization. The Nurses' Observation Scale for Inpatient Evaluation (NOSIE) is a 
global observational tool that consists of 30 specific patient behaviors, each rated on a 5-
point scale ranging from 0 = 'never' to 4 = 'always' .Z8 The Brief Psychiatric Rating 
Scale (BPRS) 29 consists of 24 symptom constructs, each rated on a 7-point scale of 
severity ranging from 1 = 'not present' to 7 ='extremely severe'. Scores can range from 
0-168, with high scores indicating more severe symptoms. The Positive and Negative 
Symptom Scale for Schizophrenia (P ANSS)30 is a semi-structured patient interview based 
on the BPRS. This validated rating scale is a 30-item scale with 16 general 
psychopathology symptom items (P ANSS-GPS), seven positive-symptom items (P ANSS-
P), and seven negative symptom items (PANSS-N). Each item is scored on the same 
seven-point severity scale varying from 1-absent to 7-extreme, resulting in a range of 
possible scores from 30 to 210. In contrast to the P ANSS, the Scale for Assessment of 
Negative Symptoms (SANS) is a specific scale that measures negative symptoms only.31 
This six-point scale gives a global rating of the following negative symptoms: alogia, 
affect blunting, avolition-apathy, anhedonia-asociality, and impaired attention. Higher 
scores indicate more symptoms. The Montgomery-Asberg Depression Rating Scale 
(MADRS)32 , a depression instrument particularly sensitive to measuring drug-related 
changes, may be used to assess the depressive features of schizophrenia. Another scale 
used to assess depression is the Hamilton Rating Scale for Depression (HAM-D).33 This 
scale rates the severity of depression in patients who are already diagnosed as depressed. 
The higher the score on the scale, the more severe the depression. The Bunney-Hamburg 
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rating scale for psychosis is based on a 15-point scale, and has a range such that 1-3 is 
normal, 4-6 is mildly psychotic, 7-9 moderately psychotic, 10-12 severely psychotic and 
13-15 very severely psychotic. 34 
2.2.1.3 Literature Search and Study Selection 
Randomized controlled trials were identified that compared the new generation 
antipsychotics listed on the Newfoundland and Labrador Prescription Drug Program 
formulary ( clozapine, risperidone, o lanzapine, and quetiapine) with conventional 
antipsychotics or alternative atypical antipsychotics in patients with schizophrenia. A 
combination of text and index terms of MEDLINE, EMBASE, PsyciNFO, and the 
Cochrane Library were used to locate randomised trials comparing the efficacy of 
atypical and conventional antipsychotic drugs. The review was based only on data 
obtained from controlled trials and meta-analyses in English-speaking journals published 
between 1988 and 2002 inclusive. 
The titles and abstracts were screened and articles were excluded if they included 
geriatric and childhood/adolescent schizophrenia patients or if they did not use an active 
comparator. Articles that compared the efficacy of atypical antipsychotics and placebo 
were not reviewed. If the primary focus of the paper could not be clearly identified by 
reviewing the title or abstract, the article was obtained for further review. 
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Descriptive information on the population, interventions evaluated, the study year, 
country of study, and results were extracted from each study and are summarized in 
appendices B, C, D, E and F. 
2.2.1.4 Atypical versus Conventional Antipsychotics 
Clozapine 
Clozapine, a dibenzodiazepine derivative, is an atypical antipsychotic due to its 
preferential occupancy of 5-HT2 receptors versus D2 receptors and the ability to 
completely occupy 5-HT2 receptors when compared with conventional antipsychotics. 
This antipsychotic was developed over 45 years ago and was the first atypical agent to 
become available in Canada. Early controlled trials indicated that clozapine is an 
effective antipsychotic agent for acutely and chronically ill inpatients with schizophrenia 
and the drug demonstrated a low incidence of extrapyramidal side effects.35-38 
Clozapine's use in the clinical setting was hampered in the 1970s when it was discovered 
that the drug was associated with an increased risk of agranulocytosis, a potentially life 
threatening side effect. Treatment with clozapine necessitated the introduction of regular 
blood monitoring for those taking the drug. All of the clozapine studies reviewed are 
summarized in appendix B. 
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Studies published prior to policy implementation 
Interest in clozapine surfaced again in the 1980s following a pivotal multicentre 
study by Kane et a1. 25 , which compared clozapine (500-900 mg/day) with chlorpromazine 
(1000-1800 mg/day) in 268 hospitalized treatment-resistant schizophrenic patients. The 
study found that after six weeks, 38 percent of the patients taking clozapine showed 
clinically important improvement, as compared with only 5 percent of patients taking 
chlorpromazine. The study also showed that EPS were generally absent. 
Two other double blind, randomized studies assessed the antipsychotic efficacy of 
clozapine versus chlorpromazine in hospitalized patients. Claghom et al. 39 randomly 
assigned 151 schizophrenic patients to clozapine treatment (150-900 mg/day) or 
chlorpromazine (300-1800 mg/day). The authors found that clozapine-treated patients 
exhibited unequivocally superior efficacy to that of patients in the chlorpromazine group. 
Throughout and at the end of the study, clozapine patients were significantly better, using 
the Brief Psychiatric Rating Scale (BPRS) items and Clinical Global Impression (CGI) 
scores. A decade later, a second study, also conducted in treatment-resistant patients, 
randomly assigned forty patients to clozapine (100-900 mg/day) or chlorpromazine 
treatment (200-1800 mg/day).40 Six clozapine-treated patients (28.6%) showed more 
than 20% improvement in BPRS score and were classified as responders. No 
chlorpromazine-treated patient showed improvements. There were significant 
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differences between clozapine and chlorpromazine as measured by changes in the BPRS, 
P ANSS, positive and general symptoms. 
In an open-label study by Essock et al.41 , the effectiveness of clozapine was 
examined in long stay hospitalized patients by comparing clozapine to an alternative 
antipsychotic chosen by the clinician at a mean dose of 1386 mg/day chlorpromazine 
equivalent. Participants (n=227) were followed for 2 years and the authors reported that 
compared with usual care, clozapine was associated with significantly greater reductions 
in side effects, disruptiveness, and hospitalization, but was not more effective in reducing 
symptoms or improving quality of life. The groups did not differ in likelihood of being 
discharged; however, once discharged, clozapine patients were less likely to be 
readmitted. The authors concluded that clozapine did not produce dramatic 
improvements in symptomatology or hospital utilization. Additionally, the study 
revealed that clozapine treatment resulted in an increase in symptom severity of about 2.7 
points based on the BPRS. 
There was one study which compared clozapine with fluphenazine. 42 In this 
crossover, placebo-controlled, double-blind comparison, twenty-one patients with 
treatment-resistant schizophrenia were treated with optimal doses of clozapine (mean, 
542.9 mg/day), which resulted in significantly lower BPRS total scores than in the 
fluphenazine treatment group (mean, 28.9 mg/day). 
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Two double-blind, randomized controlled trials compared the efficacy of 
clozapine with haloperidol in treatment refractory schizophrenic patients.43 44 Rosenheck 
et al.43 randomly assigned 423 hospitalized patients to receive clozapine (100-900 
mg/day) or haloperidol (5-30 mg/day) for 1 year. Symptom outcome was assessed using 
the Positive and Negative Syndrome Scale for Schizophrenia (PANSS), with a 20 percent 
reduction considered to represent clinically important improvement. After six weeks and 
six months of treatment, significantly more patients assigned to clozapine had a clinically 
important improvement in symptoms than those assigned to haloperidol. The differences 
between the groups were not significant at the end of the study. However, the study did 
show that clozapine was associated with markedly greater reductions in the tardive-
dyskinesia (P=0.005), akathisia (P<0.001) and extrapyramidal symptoms (P<O.OOl) over 
time. Additionally, patients assigned to clozapine treatment had, on average, 24.3 fewer 
days in the hospital for psychiatric reasons in a year than those patients assigned to 
haloperidol (143.8 days vs. 168.1 days, ?=0.03).43 
The second, much smaller study (n=39) included treatment resistant community 
dwelling schizophrenia patients in a 10-week study.44 Nineteen patients were given 
clozapine, and 20 patients were given haloperidol. Doses at the end of the trial were 
410.5 mg/day and 24.8 mg/day for clozapine and haloperidol, respectively. This study 
found a minor difference between clozapine and haloperidol, using the Scale for the 
Assessment of Negative Symptoms (SANS). Response was defined a priori as a 20% or 
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greater decrease in BPRS positive symptom scores and a BPRS positive symptom score 
of less than 8. Response rates were 44.4% for clozapine compared with 5.6% for 
haloperidol, a difference of 39 percentage points (?=0.017). The authors concluded that 
clozapine was superior to haloperidol for treating positive symptoms in outpatients with 
chronic schizophrenia who are partially responsive to neuroleptics. 
Overall, the studies of clozapine prior to the policy change demonstrated that 
clozapine has some advantages over conventional antipsychotic medications in mostly 
hospitalized, treatment-resistant patients with schizophrenia. 
Studies published following policy implementation 
The results from a study by Kane et al.45 who, in 2001, examined the efficacy of 
clozapine with moderate-dose haloperidol in partially responsive schizophrenic patients, 
are consistent with those found in Rosenheck et al.43 and Brier et a1.44 Thirty-seven 
subjects were randomized to receive a target dose 500 mg/day (200-800 mg/day) of 
clozapine and thirty-four subjects to receive 10 mg/day (4-16 mg/day) of haloperidol. 
This multicentre, double blind study discovered that subjects randomized to clozapine 
were significantly more likely to complete 29 weeks of receiving study medication than 
were subjects assigned to haloperidol (P=0.03). Additionally, the authors found that 
56.6% ofthe clozapine group improved (defined as a BPRS score reduction by 20% from 
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baseline for at least 2 consecutive assessments), compared with 24.8% for the haloperidol 
group (P=0.02). 
Risperidone 
Risperidone, a benzisoxazole derivative initially marketed in 1993, represents the 
second atypical antipsychotic approved in Canada. Risperidone has been shown to have 
a higher D2 occupancy than clozapine. 18 The potent antipsychotic effects of risperidone 
have been confirmed in patients with schizophrenia. Improvements have been seen not 
only in positive symptoms, but also in both negative and affective symptoms. The 
following section will provide an overview of 14 controlled studies that compared the 
efficacy of risperidone with that of other conventional antipsychotic agents. 86% of the 
studies used haloperidol as the comparator (Appendix C). 
Studies published prior to policy implementation 
Claus et al.46 recruited 44 chronic, hospitalized schizophrenic patients in a 12-
week double-blind trial of risperidone (12 mg/day) and haloperidol (10 mg/day). The 
risperidone group showed greater improvement on the Positive and Negative Symptom 
Scale for Schizophrenia (P ANSS), the Schedule for Affective Disorders and 
Schizophrenia-change version (SADS-C), and the Nurses Observation Scale for Inpatient 
Evaluation (NOSIE) but these did not reach significance by the end of the study. The 
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authors concluded that risperidone is at least as effective as haloperidol, but has a safer 
EPS profile. 
A large (n=1,362) 8-week, multinational, dose-finding trial of patients with 
chronic schizophrenia measured the efficacy advantages of risperidone over 
haloperidol.23 Patients from 15 countries were recruited into the study if they met DSM-
III-R criteria for schizophrenia and had a total PANSS score between 60 and 120. 
Eligible patients were then randomly assigned to risperidone 1, 4, 8, 12 or 16 mg/day or 
haloperidol 10 mg/day. Symptomatology and efficacy were assessed 6 times during the 
trial (days 0, 7, 14, 28, 42, and 56) using PANSS and the Clinical Global Impressions-
Severity of Illness scale (CGI-S). The results demonstrated that the difference in 
response rates in haloperidol-treated patients and risperidone-treated patients did not 
reach statistical significance. However, a later sub-analysis of the patients from 
Germany, Austria, and Switzerland (n=169) reported some advantages for risperidone-
treated patients over haloperidol-treated patients, according to P ANSS and its subscales, 
and on total BPRS scores.47 The authors concluded that the optimal dose of risperidone, 
in terms of efficacy, was 4 mg/day. 
A smaller study (n=35), using similar types of chronic patients (P ANSS scores 
>60 and <120) compared risperidone (5-10 mg/day) with haloperidol (5-10 mg/day) over 
8 weeks and reported no significant differences in outcome.48 
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An 8-week, double-blind, placebo-controlled, dose-finding study of hospital 
inpatients (n=388) randomized patients to four different doses of risperidone (2, 6, 10, 
and 16 mg/day), and 20 mg/day of haloperido1.22 The authors found that clinical 
improvement (defined as 2:20% reduction in total P ANSS scores) at the study end point 
was demonstrated by 35% of the patients receiving 2 mg of risperidone, 57% receiving 6 
mg, 40% receiving 10 mg, and by 30% receiving haloperidol. Statistically significant 
differences in responses were found between 6 mg/day and 16 mg/day of risperidone 
versus haloperidol, although no other efficacy differences between risperidone and 
haloperidol were identified. In addition, the incidence of extrapyramidal symptoms in 
patients receiving 6 mg ofrisperidone was no higher than placebo. 
The article described above reported the US arm of a US-Canadian collaborative 
investigation of risperidone in schizophrenia. Chouinard et a1.49 published the Canadian 
results for the 135 hospitalized patients with chronic schizophrenia (DSM-III-R). The 
authors also found that risperidone, 6 mg/day, was significantly superior to haloperidol 
on the total P ANSS, P ANSS-GPS, and BPRS scales. Of note, risperidone 6 mg/day was 
not shown to be significantly superior to haloperidol 20 mg/day on the primary efficacy 
outcome determined a priori of a 20% or greater reduction in the P ANSS total score. 
In another double-blind eight week study, hospitalized patients were treated with 
either risperidone 2-20 mg/day or haloperidol 2-20 mg/day. 50 A very good remission 
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( 50-100% relative change in BPRS from baseline) and a partial remissiOn (25-49% 
relative change in BPRS from baseline) were achieved in 45% and 32%, respectively of 
the risperidone group. The corresponding figures in the haloperidol group were 45% and 
42% respectively, revealing no statistical difference in therapeutic efficacy. The authors 
thought that this was most likely due to the high doses ofrisperidone used in the study. 
Borison and coworkers51 randomized 36 schizophrenic patients m acute 
exacerbation to receive risperidone (2-10 mg/day, mean, 9.7 mg/day) or haloperidol (4-20 
mg/day, mean, 18.0 mg/day). The authors found that risperidone-treated patients had a 
faster onset of antipsychotic activity than haloperidol-treated patients and showed a trend 
toward greater improvement. In addition, risperidone produced significantly fewer 
extrapyramidal side effects than did haloperidol. 
In 1996, Blin et al. 52 randomized 62 patients hospitalized for acute exacerbations 
to receive risperidone (mean dose, 7.4 mg/day), haloperidol (mean dose, 7.6 mg/day), or 
methotrimeprazine (mean dose, 100 mg/day) for 4 weeks. Clinical improvement, defined 
as a 20% reduction in total P ANSS scores at end point, was attained by 81% of the 
risperidone patients, 60% of the haloperidol patients, and 52% of the methotrimeprazine 
patients. The differences between risperidone and haloperidol and haloperidol and 
methotrimeprazine did not reach statistical significance. The reductions in total P ANSS 
and Clinical Global Impression Scale severity scores from baseline to end point were 
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significantly greater in the risperidone patients than in the other two groups (P<0.05). 
Extrapyramidal symptoms were more severe in the haloperidol patients than in the other 
two groups, but few differences were apparent between risperidone and 
methotrimeprazine patients. 
Two studies compared risperidone with conventional antipsychotics other than 
haloperidol. 53 54 The first was conducted in 1993 by Hoyberg et al. 53 The authors 
compared risperidone (5-15 mg/day, mean, 8.5 mg/day) with that ofperphenazine (16-48 
mg/day, mean, 28 mg/day), in an 8-week, double-blind, multicentre, parallel-group study 
in 107 chronic schizophrenics with acute exacerbation. The reduction in total P ANSS 
score to endpoint did not differ significantly, although there was a tendency in favour of 
risperidone. The researchers noted that the overall prevalence of side effects was similar 
in the two groups. 
The second study evaluated the respective efficacy of risperidone (mean, 8 
mg/day) and zuclopenthixol (mean, 38 mg/day) in a double-blind, randomized, 
multicentre study in 98 patients with acute exacerbations of schizophrenia or 
schizophreniform disorder in Finland.54 This 6-week study found that risperidone is at 
least as effective as zuclopenthixol for the treatment of acute schizophrenic episodes, 
with a trend towards greater improvement in the overall severity of symptoms and the 
rate of clinical improvement. 
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The studies comparing risperidone with conventional antipsychotic medications 
were, in general, of short duration dealing primarily with relatively few, hospitalized 
chronic schizophrenia patients. The results from the majority of these studies showed 
that there was no significant difference between the two therapies but some showed a 
trend toward improvement. 
Studies published following policy implementation 
In 2001, two post-hoc sub-analyses from Peuskens' study involving 
approximately 1,300 patients with chronic schizophrenia from 15 countries reported that 
patients receiving risperidone, 4 mg/day (n=227), improved more rapidly than patients 
receiving haloperidol (n=226) as measured by PANSS total and CGI-S scores 55 , and 
patients hospitalized for more than 60 days (median, 351 days) who received risperidone, 
4 mg/day (n=75), improved significantly more than patients treated with haloperidol 
(n=69).56 
Olanzapine 
Olanzapine, the third atypical antipsychotic medication, was approved in Canada 
for the treatment of schizophrenia and related psychotic disorders in 1996. Olanzapine 
displays high receptor affinity binding in vitro at serotonin 5-HT2, dopamine D1, Dz, D3, 
D4, muscarinic M1_5, adrenergic a 1, and histamine H1 receptors.
57 Appendix D outlines 
the studies reviewed in this section. 
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Studies published prior to policy implementation 
The antipsychotic efficacy of olanzapine has been evaluated in three large, 6-
week randomized controlled trials.58-60 In these studies, olanzapine was compared with 
haloperidol. The first multicentre trial used data from a North American population 
(n=335) to compare three dosage ranges of olanzapine (5±2.5 mg/day, 10±2.5 mg/day, 
and 15±2.5 mg/day) to a dosage range of haloperidol (15±2.5 mg/day) and to placebo. 58 
The authors concluded that olanzapine, 15±2.5 mg/day, was significantly better than 
haloperidol, 15±5 mg/day, in reducing negative symptoms in patients with schizophrenia 
after 6 weeks. 
The second acute phase study used the same methodology as above to examine 
international data to determine whether olanzapine demonstrated a dose-related ability to 
decrease overall psychopathology in patients with schizophrenia. 59 The primary efficacy 
analysis showed that there were no statistically significant differences in mean 
improvement in BPRS total score, CGI severity, P ANSS total, negative or general 
psychopathology scores between any of the treatment groups. 
The third study, an international double-blind randomized trial (n=1,996), was the 
largest. 60 The authors found that olanzapine, 5 to 20 mg/day was significantly better than 
haloperidol, 5 to 20 mg/day, over the 6-week study period in reducing overall 
psychopathology, positive symptoms, negative symptoms, and depressive symptoms. 
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Based on the mean change from baseline to endpoint in Brief Psychiatric Rating Scale 
(BPRS) score, the analysis revealed that olanzapine-treated patients had significantly 
higher response rates (52%) than haloperidol-treated patients (34%) (P<0.001). EPS was 
lower in the olanzapine group compared with the haloperidol group. Additionally, the 
proportions of patients discontinuing the treatment, both for lack of efficacy and for 
adverse events, were significantly smaller in the olanzapine group. 
Patients responding to treatment in Beasley et al. 58, the North American, 6-week 
acute phase trial, were eligible to enter a 46-week extension. Hamilton et a1. 61 used the 
first 24 weeks of this extension data and designed a study to address efficacy of 
olanzapine in altering the long-term course of schizophrenia. Of the 335 patients enrolled 
in the initial acute phase study, 95 (28.4%) continued into the responder extension. The 
completion rate for the total population was 42.1% (53.2% in olanzapine group, and 
22.2% in the haloperidol group). Data analyzed after 24 weeks of therapy showed that 
there was no significant difference in either the BPRS total scores or the CGI severity 
scores observed between the haloperidol treatment group and the three olanzapine 
treatment groups. The only significant difference was found on the Scale for the 
Assessment of Negative Symptoms (SANS) summary score among the patients 
randomized to the high dose olanzapine group (15±2.5 mg/day) and the haloperidol 
group. 
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Additionally, Tran et al.62 examined the long-term efficacy of olanzapine based 
on pooled data obtained from the double-blind extensions of all three acute phase studies. 
The authors measured the time to relapse and found that fewer patients treated with 
olanzapine relapsed during the 1 year follow-up period (19.7%), compared with patents 
receiving haloperidol (28%)(P=0.034). 
Only one study compared olanzapine to a conventional antipsychotic other than 
haloperidol. Conley et al. 63 designed a prospective, randomized, double-blind study to 
compare the efficacy of olanzapine versus chlorpromazine in treatment-resistant 
schizophrenia. This 8-week, fixed-dose trial of olanzapine, 25 mg/day, or 
chlorpromazine, 1200 mg/day, plus benztropine, 4 mg/day showed that there was no 
difference in efficacy (defined as at least a 20% reduction in the total BPRS score 
compared to the baseline score) between the two drugs. Of patients, 7% in the 
olanzapine group and none in the chlorpromazine group met a priori criteria for clinical 
response. There were also no differences in dropout rates. 
Much of the literature on the efficacy of olanzapine at this time was based on data 
from the same study protocol. The studies were of short duration and enrolled a 
combination of hospitalized and community-dwelling patients as well as different types 
of schizophrenic patients (i.e. treatment-resistant). The results are often conflicting with 
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olanzapine being superior to the conventional agent on some outcome measures and in 
some cases, the drugs proved to be equally efficacious. 
Studies published following policy implementation 
Breier and Hamilton64 compared the relative efficacy of olanzapine (dose range 5-
20 mg/day, mean of 11.1 mg/day) and haloperidol (5-20 mg/day, mean of 10.0 mg/day) 
for symptomatology and parkinsonian side effects in a group of treatment-resistant 
schizophrenic and schizoaffective patients. The authors examined a subpopulation of 
patients (n=526) meeting treatment-resistant criteria selected from the Tollefson et al., 
prospective, double-blind, 6-week study.60 Response was defined a priori as at least 20% 
improvement in BPRS total score from baseline and an endpoint BPRS total score less 
than or equal to 24. The results of the analysis demonstrated that olanzapine had a 
significantly greater mean improvement in P ANSS negative symptoms and comorbid 
depressive symptoms. Significantly greater response rates were observed in olanzapine-
treated (47%) than haloperidol-treated (35%) patients in the last observation carried 
forward (LOCF) analysis (P=0.008), but significance was not reached in the analysis of 
those who completed the study (P=0.093). 
Quetiapine 
Quetiapine is a dibenzothiazepine which, like clozapine and olanzapine, binds to a 
variety of neurotransmitter sites. Quetiapine exhibits a greater affinity for brain serotonin 
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S-HT2 receptors than for dopamine D2 receptors, together with considerable activity at 
histamine receptors and a-adrenoceptors. 65 Quetiapine was approved in Canada in 1997. 
The studies reviewed are summarized in appendix E. 
Studies published prior to policy implementation 
Arvanitis and Miller66 conducted a multiple fixed dose study of quetiapine (75, 
150, 300, 600, and 750 mg/day), haloperidol (12 mg/day), and placebo using 361 subjects 
over a 6-week period. Patients had their psychopathology and overall function rated 
weekly, using Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI) 
and Schedule for the Assessment of Negative Symptoms (SANS). Patients in this trial 
were all acutely unwell, with a long history of illness, multiple hospitalizations and 
considerable previous exposure to antipsychotic medications. In all measures of efficacy, 
quetiapine was comparable to haloperidol. 
The only complete published study that compared quetiapine with 
chlorpromazine, allowed flexible dosing ( quetiapine mean dosage, 404 mg/day and 
chlorpromazine mean dosage, 384 mg/day) and had a follow-up of 6 weeks.67 The 
analysis showed that quetiapine was at least as effective as chlorpromazine in improving 
the symptoms of acute schizophrenia, as indicated by changes in BPRS, P ANSS negative 
symptoms subscale and CGI severity of illness scores in the 201 hospitalized patients. 
However, using a pre-defined response criterion of a 50% improvement from baseline at 
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any time point within the trial, quetiapine was associated with a statistically greater 
response rate than chlorpromazine. Using this criterion, quetiapine was associated with a 
response rate of 65%, compared with 53% in the chlorpromazine group, a statistically 
significant difference (P=0.04). 
Studies published following policy implementation 
Copolvo et al.68 conducted a multinational, 6-week randomized controlled trial 
comparing quetiapine, at a mean daily dose of 455 mg/day, with haloperidol (8 mg/day) 
in the treatment of 448 hospitalized patients with acute exacerbations of schizophrenia. 
Both groups showed meaningful improvements in symptoms, as measured by the P ANSS 
total score and by responder rates (score reduction of 30% or more). There were no 
statistically significant differences between the two treatments in these efficacy measures, 
suggesting that the two treatments were equivalent. Quetiapine was better tolerated than 
haloperidol in terms of EPS. At the same time, quetiapine-treated patients mainly 
experienced somnolence and weight gain. 
An international, double-blind study compared the efficacy and tolerability of 8 
weeks' treatment of quetiapine 600 mg/day with haloperidol 20 mg/day in 288 patients 
who had a history of partial response to conventional antipsychotics. 69 The difference in 
PANSS total score after 8 weeks was not statistically significant (P=0.234). For the 
secondary endpoint, defined as the proportion of patients experiencing a decrease in 
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PANSS total score ~20% from baseline to endpoint, response rates were statistically 
higher in the quetiapine group than in the haloperidol group (P=0.043). 
2.2.1.5 Head-to-Head Comparisons of Atypical Antipsychotics 
Clozapine versus risperidone 
Despite the fact that clozapine and risperidone were the first two atypical 
antipsychotic drugs approved for schizophrenia, there is relatively little information about 
the comparative efficacy of the two atypical antipsychotic medications from head-to-head 
clinical trials. The studies described below are summarized in appendix F. 
Studies published prior to policy implementation 
The short-term efficacy and safety of risperidone was compared to clozapine in 
treatment-resistant chronic schizophrenic patients.70 This controlled double-blind, multi-
centre study randomly assigned 86 inpatients with chronic schizophrenia (DSM-III-R), 
resistant to or intolerant of conventional neuroleptics, to receive risperidone or clozapine 
for 8 weeks after a 7-day washout period. The final mean doses were 6.4 mg/day of 
risperidone and 291.2 mg/day of clozapine. At endpoint, 67% of the risperidone group 
and 65% of the clozapine group were clinically improved (reduction of 20% or more in 
total P ANSS) and in both groups, severity of schizophrenic symptoms was significantly 
ameliorated. Additionally, no significant differences between therapies were found at 
anytime. 
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Studies published following policy implementation 
Another short term study was designed to examine the comparative efficacy of 
clozapine and risperidone in chronically ill, partially responsive patients with 
schizophrenia.71 After a baseline 2-week treatment period with fluphenazine, 29 patients 
participated in a 6-week, double-blind, parallel-group comparison of the effects of 
clozapine and risperidone using flexible dosing. Clozapine was superior to risperidone 
for treating positive symptoms, but there were no significant differences between the 
drugs on two measures of negative symptoms (SANS and BPRS withdrawal/retardation 
score), BPRS total score, and depression scores. 
A more recent double-blind companson of clozapine with risperidone in 273 
chronically ill schizophrenic patients with poor previous treatment response72 showed 
that at follow-up; patients in the clozapine group had significantly lower symptom levels 
than did those in the risperidone group (BPRS, P=0.006 and CGI total scores, ?=0.008). 
The proportions of patients with decreases in mean BPRS total score of2:20% and 2:30% 
at the end of the study (12 weeks) were significantly higher in the clozapine group than in 
the risperidone group (P<O.Ol). 
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Risperidone versus olanzapine 
Studies published prior to policy implementation 
Risperidone and olanzapine have been compared in two multicentre randomized 
clinical trials.73 74 The first evaluated risperidone (4-12 mg/day) and olanzapine (10-20 
mg/day) in a double-blind, 28-week study involving 339 treatment refractory inpatients.73 
Both antipsychotics were found to be effective in reducing the severity of overall 
psychotic symptoms, although olanzapine exhibited significantly greater efficacy on 
negative and depressive symptoms. More olanzapine than risperidone participants were 
rated as treatment responders, defined as >40% reduction in scores on the P ANSS 
(olanzapine 36.8% vs. risperidone 26.7%, P=0.049). Moreover, fewer EPS were reported 
by the olanzapine-treated patients than by their risperidone-treated counterparts (P<0.05). 
Studies published following policy implementation 
The second randomized triaf4 investigated the relative efficacy of risperidone and 
olanzapine in schizophrenia sufferers. Participants' psychopathology was evaluated with 
the Positive and Negative Syndrome Scale with clinical improvement defined as a::=: 20% 
reduction in total score. The 377 eligible participants were randomly assigned to receive 
risperidone (2-6 mg/day) (n=188) or olanzapine (5-20 mg/day) (n=189) for 8 weeks. 
Clinical improvement was seen in 50.7% of the risperidone group (n=69) and 47.6% of 
the olanzapine group (n=68) at week 8. 
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In an open-label study by Ho et al.75 , 42 people with DSM-IV schizophrenia who 
had been treated with risperidone (n=21) or olanzapine (n=21) under actual clinical 
practice conditions were examined over a 6-month period. After an average of 4 weeks, 
improvements in negative, psychotic, and disorganized symptoms were noted with both 
risperidone and olanzapine groups. The only between-treatment difference was an 
increased severity of akathisia in the risperidone group. Further improvements in 
symptoms and quality-of-life scores were noted in both groups at 6 months, with. a 
substantial between-treatment difference: the improvement in psychotic symptoms was 
greater in the risperidone group. 
Quetiapine versus risperidone 
Studies published following policy implementation 
A four month, multicentre, randomized, flexible dose, open-label trial enrolled 
728 outpatients with DSM-IV diagnoses of schizophrenia, schizoaffective disorder, 
bipolar disorder, major depressive disorder, delusional disorder and Alzheimer's 
dementia to receive quetiapine or risperidone.76 Patients with schizophrenia, 
schizoaffective disorder and schizophreniform disorder made up 65.0% of the population 
and the researchers found that quetiapine (mean, 253.9 mg/day) was at least as effective 
as risperidone (mean, 4.4 mg/day). Both treatments produced similar improvements in 
the PANSS score, and its negative and positive sub-scales. 
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Clozapine versus olanzapine versus risperidone 
Studies published following policy implementation 
Clozapine, olanzapine, risperidone and haloperidol were compared in a randomized 
controlled trial comprising a sample of 157 patients with chronic schizophrenia who had 
not responded adequately to other antipsychotic medications. 77 Patients were randomly 
assigned to one of the four treatment arms: clozapine (n=40), olanzapine (n=39), 
risperidone (n=41), or haloperidol (n=37). Trial duration was 14 weeks (8 weeks' fixed 
dose, followed by 6 weeks flexible dose) with only 58% (n=91) of the subjects 
completing the study. The mean dose levels achieved by the end of the study period were 
30.4 mg/day for olanzapine, 11.6 mg/day for risperidone, 526.6 mg/day for clozapine, 
and 25.7 mg/day for haloperidol. Compared with haloperidol, there were significant 
advantages for clozapine and olanzapine regarding overall improvement (PANSS total) 
and general psychopathology, and for clozapine, risperidone, and olanzapine regarding 
negative symptoms. The overall pattern of results suggests that clozapine and olanzapine 
have similar general antipsychotic efficacy and that risperidone may be somewhat less 
effective. 
Despite the rapid acceptance of these new medications, few studies have 
compared the efficacy of the atypical antipsychotic agents in head-to-head trials. These 
studies were performed in relatively homogeneous populations and because of the 
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methodological differences, it is difficult to interpret the results of these studies and draw 
conclusions across them in terms of the comparative efficacy. 
2.2.1.6 Quality of Studies Reviewed 
A review of the published literature shows that in several key areas, evidence for 
the efficacy of atypical antipsychotics compared to older drugs and to each other is, in 
general, of poor quality. The most obvious criticism is that the overwhelming majority of 
the randomized controlled trials enrolled small numbers of patients (underpowered) and 
were short-term studies (4 to 8 weeks long). The severe clozapine-related side effect of 
loss of white blood cells (agranulocytosis) as well as other side-effects such as tardive 
dyskinesia may occur later than the first 4-8 weeks of treatment, and may thus be under-
reported in short-term studies. On the other hand, deficiencies of global and social 
functioning caused by schizophrenia may take much longer to improve, and the 
beneficial effect of the antipsychotic drugs under investigation may thus be 
underestimated in short RCTs. Thus, the conclusions that can be drawn from the 
majority of the studies are limited. 
All of the trials enrolled patients based on stringent inclusion criteria such as 
diagnosis (DSM or ICD classification), and response to previous treatment (resistant 
and/or intolerant). Rigid inclusion criteria ensure internal consistency, but exclude a 
large number of patients who have co-existing substance abuse disorders or other 
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comorbid mental disorders, such as depression, for example and reduce the 'real world' 
external validity, or generalizability, of the trial results. Also, an important characteristic 
of nearly all of the treatment-resistant studies is that patients are defined as treatment-
resistant based on trials with conventional antipsychotics. Patients are then randomly 
assigned to the newer agent or a conventional agent. This design clearly prejudices the 
results in favour of the newer agent. 
The setting also compromises the generalizability of the trials. Most of the 
research was undertaken in hospital and therefore is generalizable to people with acute 
episodes of schizophrenia. However the majority of people have chronic schizophrenia 
and are treated with maintenance doses of antipsychotic drugs in the community. 
The procedure by which concealment of allocation took place was seldom 
described. The trials usually declared only randomization and double-blind protocol but 
did not report how these procedures were performed. 
There was a poor consideration of statistical power on the part of study authors. 
In small studies, just because an 'atypical' drug and its comparator have not been shown 
to be significantly different does not mean that they are equivalent in effect. Studies 
which demonstrate equivalence need to be more highly powered than those which are 
designed to show a difference. Therefore although many of the atypicals were not shown 
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to be significantly different from typical drugs or each other on measures of efficacy we 
cannot say with confidence that they are as efficacious as the typical drugs or each other. 
Most clinical trials of medications for schizophrenia have used the classical rating 
scales, either the Positive and Negative Syndrome Scale (P ANSS) or the Brief Psychiatric 
Rating Scale (BPRS), in order to measure symptom reduction in schizophrenia patients. 
However, the definitions of improvement differ across trials. This warrants some caution 
in drawing conclusions, as it is difficult to decide whether the results concerning clinical 
improvement are comparable. Most trials did not address the effect of the new atypicals 
on negative symptoms, which is surprising given the claims made for efficacy with 
regard to these symptoms by many of the atypical antipsychotic manufacturers. In the 
small number of studies that do report on negative symptoms, they do not make it 
possible to establish whether the improvement on negative symptoms is due to the 
resolution of secondary symptomatology (due to EPS) or to a specific effect on primary 
negative symptoms of schizophrenia. Outcome reporting using the aforementioned 
scales means that improvement was mainly symptom and clinically oriented. Global and 
functional outcomes, such as being well enough to be discharged and working ability 
were seldom reported. Patient satisfaction was hardly ever reported and family burden 
was not reported at all. 
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Dosage of the drugs used in the trials is also very important. Comparator drugs 
may have been given in inappropriately high doses in some of the trials. This would 
most likely produce a high incidence of EPS in the haloperidol group and lead to bias in 
the result for 'movement' disorders/outcomes in favour of the new drug. A low dose of 
an atypical drug may give an overly negative view of its efficacy when compared to an 
appropriate dose of a comparator drug; however a high dose of the same drug may lead to 
overestimation of the incidence of side effects in comparison to an appropriate dose of a 
comparator drug. Moreover, it should be noted that in many trials the antipsychotic 
medication used as a comparator has been haloperidol, which may be associated with a 
higher incidence of EPS than other typical agents and therefore may not be considered 
the 'gold standard' in the evaluation of improvement of EPS and secondary negative 
symptoms. 
With respect to the reporting of adverse effects, most of the studies showed that 
the new antipsychotics do indeed seem to cause fewer movement disorders than typical 
antipsychotics, although variability in definition and reporting of symptoms limit the 
confidence that can be placed in these results. Also, weight gain is a common side effect 
of the newer antipsychotics that has been poorly reported. 
The high rates of attrition in most of the studies need to be kept in mind when 
interpreting the results of the studies, particularly as the majority of participants were 
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recruited and managed in an inpatient setting. Drop out may be the result of lack of 
efficacy or of adverse effects or neither. However, a number of trials reported tolerability 
differences between drugs using a drop out rate despite the fact that drop out is 
confounded by issues that relate to adverse effects. 
One solution to the lack of power in many RCTs may lie in the pooling of data 
from several studies in a meta-analysis. Meta-analysis is a statistical approach to the 
aggregation of independent research studies. This method synthesizes data from existing 
studies thereby increasing the sample size and overcoming the power limitations of 
undersized studies, or small treatment effects, and is intended to provide (relatively) 
unbiased quantitative summary estimates. Pooling the data from many trials of the same 
drug on different patient groups permits researchers to study the effects of the medication 
across much broader populations. 
There have been a number of meta-analyses published to evaluate the efficacy of 
atypical antipsychotic medications.78-85 The results of these studies concluded that the 
atypical antipsychotic medications were as effective or only slightly more effective than 
conventional antipsychotic medications according to the study criteria for efficacy. 
Head-to-head comparisons of atypicals usually showed that clozapine was more 
efficacious than other atypical antipsychotics but only in treatment-resistant 
schizophrenia. However, the results are only as good as the data that go into them. As a 
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result, the criticisms of the published trials will undoubtedly impact the interpretation of 
the results of a meta-analysis, particularly those that relate to short follow up and 
restricted study groups. 
One of the greatest limitations of a meta-analysis is that of publication bias, where 
trials with positive results are more likely to be published than those with neutral or 
negative results. Researchers commonly limit a meta-analysis to the inclusion of peer-
reviewed, published studies on a given intervention, which runs the risk of discounting 
unpublished studies in which the data may show less or even no benefit from the 
intervention being tested. Another potential problem inherent in a meta-analysis of 
antipsychotics occurs because the trials are not identical: some compare the newer 
antipsychotic medications with placebo, while others compare the drugs to an active 
comparator, most commonly haloperidol or chlorpromazine. In addition, meta-analyses 
cannot balance qualitative differences. 
In conclusion, more useful research is urgently needed: long-term trials involving 
large numbers of community-based people, with less rigid inclusion criteria, and 
outcomes that are relevant to patients with schizophrenia and their carers. Less rigid, 
more pragmatic trial protocols may help both to decrease attrition rates from the trial and 
to increase the generalizability of the results. The selection of an antipsychotic agent to 
treat people with schizophrenia is a complex decision for which the physician must weigh 
41 
individual patient factors and numerous drug factors, including efficacy, safety, 
tolerability, and cost in the context of long-term use. 
2.2.1. 7 Summary of Studies Reviewed 
Despite the numerous limitations outlined above, the results from the available 
evidence allow the following tentative conclusions to be drawn. Atypical antipsychotics 
are at least as effective as conventional antipsychotics. Generally, analyses employing 
conservative criteria report few efficacy differences between atypical and conventional 
agents. However, there are now many well-controlled studies indicating modest 
advantages for the atypical antipsychotics in specific symptom domains. For the 
treatment of negative symptoms, olanzapine seems most promising. Risperidone, 
olanzapine, and quetiapine display advantages in improving cognitive and depressive 
symptoms. In head-to-head comparisons of atypical antipsychotics, none have shown 
consistent efficacy advantages. In severely refractory patients, no atypical antipsychotic 
has consistently been shown to be as effective as clozapine or superior to conventional 
agents. There are indications, however, that risperidone, olanzapine, and quetiapine have 
advantages over conventional agents in less severely refractory patients. Efficacy 
advantages for atypical antipsychotics in prospective randomized controlled trials in first-
episode schizophrenia have not been reported. 
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2.2.1.8 Economic Evaluations of Atypical Antipsychotic Medications 
The introduction of atypical antipsychotics has provided a new but expensive tool 
for managing schizophrenia. Depending on dosage, the cost of clozapine can range 
between CD$4,000 and CD$12,000 for a one-year supply, plus additional costs for 
laboratory tests, and the cost of other newer atypicals range from CD$1,000-$5,000 per 
person per year. The classical, or conventional, antipsychotic agents are relatively cheap, 
the annual cost of the oral preparations being in the order of CD$54-CD$230 while that 
of the depot preparations is approximately CD$700. Thus, the difference in acquisition 
costs between the traditional and second-generation antipsychotics can be quite profound. 
The potential impact of these new drugs on provincial drug budgets is substantial and 
their increased use will add millions of dollars to the annual drug expenditure. The high 
acquisition costs of atypical antipsychotics add to the problem of how best to allocate 
scarce resources to provide optimal care for patients with schizophrenia. As a result, a 
review of the economic literature for atypical antipsychotics is warranted. 
2.2.1.9 Literature Search and Study Selection 
An initial search strategy was developed to identify studies that conducted an 
economic evaluation of atypical antipsychotic medications for the treatment of 
schizophrenia. A combination of text and index terms of MEDLINE, EMBASE, 
PsyciNFO, and the Cochrane Library were used to locate relevant articles. English 
language references published between 1990 and 2002 were selected for review. 
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The titles and abstracts were screened and articles were included if costs or cost 
analysis or cost evaluation were apparent in the title or abstract. Review articles were 
excluded if they did not discuss costing or economic analyses. If the primary focus of the 
paper could not be clearly identified by reviewing the title or abstract, the article was 
obtained for further review. All selected studies were reviewed and categorized into two 
groups based on the types of economic evaluation used in the analysis: i) full economic 
evaluation; and ii) partial economic evaluations. A full economic evaluation is the 
comparative analysis of alternative courses of action in terms of both costs and 
consequences. Therefore, the economic evaluations which identify, measure, value, and 
compare the costs and consequences of the alternative being considered were further 
classified into one of the five categories: 1) cost-minimization analysis (CMA); 2) cost-
effectiveness analysis (CEA); 3) cost-utility analysis (CUA); 4) cost-benefit analysis 
(CBA); and 5) cost-consequence analysis (CCA). 86 The label partial economic 
evaluation indicates that the studies do not entirely fulfill both of the necessary conditions 
for economic evaluation (costs and consequences). However, cost analysis (CA), can 
provide useful information on 'upfront' costs compared to 'downstream' cost avoidance. 
For this reason, both full economic evaluations and cost analyses were included in this 
review. 
Descriptive information on the populations, interventions evaluated, the study 
year, perspective, and country of study were extracted for each study. Data specific to 
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the costs and effectiveness of each cost comparison were also extracted and summarized 
in appendix G. 
Full economic evaluations 
The following section reports the findings of ten full economic evaluations 
dealing with the use of atypical antipsychotic medications for the treatment of 
schizophrenia. 
A group of Canadian researchers87 reported a cost-utility analysis of data 
collected during an 8-week, clinical dose finding trial comparing four fixed doses of 
risperidone (2, 6, 10 or 16 mg/day) with haloperidol 20 mg/day or placebo in the 
treatment of schizophrenia. Risperidone 6 mg/day was found to be the most efficacious 
dose, so data from these patients and the data from patients receiving haloperidol or 
placebo were used in the cost-utility analysis. The model estimated the cost of 
substituting risperidone for haloperidol. The value (utility) of changes in psychological, 
physical, and social functioning; current treatment; and drug-induced adverse effects with 
the switch were estimated by 100 psychiatric nurses assigning preference ratings. 
Utilities were assigned by using linear analog and standard gamble techniques to rate 
health status profiles designed to represent mild, moderate and severe symptoms of 
schizophrenia. Cost estimates were based on medication acquisition costs. Lifetime 
quality adjusted life years (QALYs) were calculated by subtracting the baseline utility 
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from the 8-week follow-up utility and then multiplying by the estimated number of 
remaining life years. The incremental QAL Y for risperidone over haloperidol was 
calculated to be 0.075/patient, about a threefold greater improvement in quality of life. 
The annual incremental treatment cost of risperidone over haloperidol was 
$1 ,600/patient, resulting in an incremental cost-utility figure of $24,259/QAL Y for 
risperidone compared to haloperidol. 
Another group of Canadian researchers conducted two separate economic 
evaluations: clozapine in treatment-resistant schizophrenia and risperidone in chronic 
schizophrenia.7 Specifically, the report looked at two cost-utility analyses using meta-
analysis techniques: 1) clozapine compared to chlorpromazine and haloperidol in 
hospitalized patients with treatment-resistant schizophrenia; and, 2) risperidone compared 
with haloperidol, haloperidol decanoate and fluphenazine decanoate in the treatment of 
hospitalized patients with chronic schizophrenia who had experienced an exacerbation in 
symptoms. 
In the first evaluation, a cost utility analysis, using the results of 3 studies with a 
total of 157 patients, was performed to compare the costs and quality-adjusted outcomes 
treated with one of the agents. A decision analytic model was constructed to evaluate 
treatment sequences with the probabilities of each event derived from the literature and 
expert opinion. Health state utilities were obtained through interviews with 7 patients 
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with schizophrenia using standard gamble techniques and a rating scale. The direct 
health costs of treatment were included in the analysis and the authors found that 
compared to chlorpromazine, clozapine might save $38,879 per year while producing 
0.04 more QALYs. Over a lifetime of 37 years, this could project to a savings of 
$682,204 and a gain of 0.07 QAL Y s per patient. This may be associated with $389 
million in annual cost savings in direct health care expenditures and slightly higher utility 
compared with chlorpromazine or haloperidol. 
The second economic evaluation by Oh and colleagues used the same 
methodology as above to compare risperidone with haloperidol, haloperidol decanoate, 
and fluphenazine decanoate.7 The meta-analysis of 8, short term (4-12 weeks), studies of 
645 patients revealed that risperidone had the highest efficacy rate ( 67%) compared to 
haloperidol (50%), haloperidol decanoate (46%) and fluphenazine decanoate (39%). The 
expected costs and utilities were calculated and it was determined that risperidone was 
the dominant therapy compared to haloperidol, haloperidol decanoate or fluphenazine 
decanoate since it was associated with the lowest overall cost and highest number of 
QALYs. The authors concluded that compared with haloperidol, the use ofrisperidone in 
schizophrenic patients with moderate symptomatology in a hospital setting will lead to 
lower management costs (savings of $6,510 per year) and higher utility (0.04 QALYs). 
This could translate into a savings of $114,230 over a lifetime. 
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Davies et al. 88 also developed a decision analytic model in Australia to estimate 
the comparative effectiveness and direct costs of risperidone and haloperidol for 
treatment of patients with chronic schizophrenia. The parameters in the model were 
based on the results of a meta-analysis of the efficacy and tolerability of risperidone and 
an expert panel. 89 A favorable outcome was defined as being in a clinical response phase 
at the end of the 2-year model period. The probability of a patient experiencing a 
favorable outcome at the end of 2 years was 78.9% for risperidone versus 58.9% for 
haloperidol. In this model, the total cost of treatment for 2 years was $15,549 for 
risperidone versus $18,332 for haloperidol. The expected cost per favorable outcome 
was $19,709 for risperidone versus $31,104 for haloperidol. The authors concluded that 
risperidone was more cost-effective than haloperidol for chronic schizophrenia and 
therefore was "dominant" because it produced a higher proportion of favorable outcomes 
at lower cost. However, sensitivity analysis showed that the difference in clinical 
response rate was a key determinant of cost-effectiveness. 
Tunis et al.90 utilized data from a multicentre double-blind randomized clinical 
trial of 1,996 schizophrenic patients60 to compare the total cost of care between 
olanzapine and haloperidol over 1 year and combine cost and functional outcomes 
information to estimate the incremental cost-effectiveness ratio of the two therapies in 
this sample. Using the Medical Outcome Study Short Form (SF-36), the functional status 
of 812 patients from the United States was collected. The analysis included both 
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responders and non-responders and represented changes in SF-36 and hospital costs over 
a 1-year study period. Medical services were assigned an estimated cost in 1995 US 
dollars based on a standardized list of prices for services. The difference in hospital costs 
between olanzapine-treated and haloperidol-treated patients during the 52-week treatment 
period was $9,386.87. The authors suggest that large savings in hospital costs were 
experienced by olanzapine-treated patients, representing more than 15 days in hospital 
annually. Patients treated with olanzapine scored 5.75 units better on the physical heath 
and functioning composite score of the SF-36 and 1.66 units greater on the mental health 
and functioning composite than haloperidol-treated patients. This combination of greater 
effectiveness and lower cost produces an annual cost-effectiveness ratio, where improved 
effect is associated with extra savings rather than extra cost. Using these data, the 
incremental cost effectiveness ratios (ICER) were calculated as $1,632.50 for each point 
of change in the SF-36 physical health and functioning score and $5,654.74 per point of 
change on the mental health and functioning composite score. Statistical significance of 
these differences was not reported. 
The cost-effectiveness of clozapine was compared with conventional 
antipsychotic medication alternatives typically used for patients with treatment-refractory 
schizophrenia in state hospitals.91 227 patients were randomly assigned to begin open-
label clozapine treatment (n=l38) or to continue receiving conventional antipsychotic 
medications (n=89). Measures of prescribed medications, service utilization, and other 
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costs were combined with a number of effectiveness measures (BPRS, quality of life, 
BPS, hours in special observation, occurrence of problematic behaviour) to estimate 
incremental cost-effectiveness ratios. The authors found that patients assigned to 
clozapine accrued, on average, $1,112 more cost in year 1 but $7,149 less cost in year 2 
than did patients assigned to usual care. Clozapine was found to be more effective on 
some but not all effectiveness measures but fairly similar on cost, when the alternative 
was a range of conventional antipsychotic medications. The authors estimated 
incremental cost-effectiveness ratios for the 4 effectiveness measures where clozapine 
was more effective than usual care: BPS-free months, disruptiveness, psychiatric 
symptomatology, and weight gain. However, the actual ICBR values were not reported 
in the paper but the probability of an ICER estimate for clozapine falling into the 
dominant strategy on the cost-effectiveness plane was provided. For example, the ICBRs 
for number of BPS-free months indicated that there is 0.80 probability that clozapine was 
cost-effective. 
Schiller et a1. 92 utilized a pre-post design to retrospectively evaluate risperidone's 
effectiveness in reducing symptoms and its cost when compared with the effectiveness 
and cost of standard antipsychotic medication based on an intention-to-treat model. The 
authors identified 112 adults (56 were receiving risperidone, and 56 were receiving 
traditional antipsychotics) with schizophrenia or schizoaffective disorder receiving care 
in a public mental health system for which prescription and medical records data were 
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available for the 12 months before and after initiation of risperidone. Patients receiving 
conventional agents were matched to those in the risperidone group based on age, sex, 
ethnicity, marital status, medication clinic site, diagnosis and number of psychiatric 
emergency room visits in the previous year. Global Assessment Functions (GAF) scores 
were used to assess effectiveness while service utilization and medication data were 
extracted from subjects' outpatient charts to calculate the cost of treatment. The authors 
found the mean monthly total treatment costs were $370.18 higher in the risperidone 
group, however the difference was not statistically significant (P=0.08). Monthly GAF 
scores revealed no group differences in the effectiveness of the medications. The study 
showed that no significant change in health service utilization occurred. Controlling for 
differences in baseline GAF scores, the authors reported no significant differences in cost 
or effectiveness between the risperidone and comparison groups. 
Guest et al. 93 used resource utilization data from a Swedish trial94 in chronic 
schizophrenia to model the economic effect of treating patients with risperidone in the 
United Kingdom. Data on 31 patients originally enrolled in a short-term multicentre 
clinical trial comparing efficacy of risperidone and haloperidol were included. All 
patients received risperidone for 1 or 2 years regardless of the original study medications. 
Clinical data, based on scores from the P ANSS, the CGI and the Extrapyramidal 
Symptom Rating Scale (ESRS), were reported for 31 subjects for 1 year, and 18 subjects 
for 2 years. Economic data were collected retrospectively and compared with data from 
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the year before risperidone was started. At the end of 1 year of treatment, the mean 
PANSS, CGI, and ESRS scores had fallen significantly (P<0.0001, P<0.0005 and 
P<0.0002, respectively). Clinical improvement was maintained during the second year of 
treatment for the 18 patients followed for 2 years. During year 1, inpatient days 
decreased significantly (P<0.02) while use of residential accommodations increased 
significantly (P<0.03) as did medication costs (not significant). During the second year, 
both inpatient days and use of residential accommodations declined slightly but remained 
fairly constant during year 2. Total costs of care decreased during both years compared 
to the year prior to risperidone. In this study, the decrease in total costs was due 
primarily to the decrease in days of inpatient care. The authors did a sensitivity analysis 
to look at changes in cost over a range of costs for inpatient bed days. For the patients 
followed for 2 years, a net cost reduction was demonstrated even if bed prices were 
reduced. The authors concluded that switching patients suffering from chronic 
schizophrenia to treatment with risperidone results in clinical improvements which 
potentially reduce costs. No statistical data for the cost analysis was reported in this 
study. The authors concluded that when a cohort of patients with chronic schizophrenia 
was treated with risperidone there were potential savings to the National Health Service 
(NHS) of £4200 per patient in the first year. 
Another pre-post study by Galvin et al. 95 was conducted to compare both the 
clinical effectiveness and the treatment costs of atypical antipsychotic medications 
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( clozapine and risperidone) with those of older neuroleptic medications (chlorpromazine 
and haloperidol) for psychosis in a community mental health care setting. Participants 
received older medications for 1 year and newer medications for an additional year. The 
study used a retrospective, uncontrolled, open, nonrandomized, within-subject design and 
relied on medical records as a data source for 3 7 patients (23 on clozapine and 14 on 
risperidone ). Effectiveness data were extracted from the medical record using a study 
specific scale. Use of either risperidone or clozapine was associated with a statistically 
significant reduction of clinical symptoms and tardive dyskinesia compared to traditional 
antipsychotic medications. Newer antipsychotics were associated with significantly 
higher medication costs (?<0.0001), but total cost of care was $3,000 less per patient per 
year with the newer medications. It was not clear whether drug costs were included in 
this calculation or not. Additionally, statistical tests were not reported for total costs. 
Almond et al.96 conducted a cost analysis using Markov modeling techniques to 
compare the costs of two atypical drug therapies ( olanzapine and risperidone) with one 
another and with a conventional antipsychotic (haloperidol) in the treatment of 
schizophrenia. The analysis was based on a simulation model with BPRS scores, 
probabilities of suicide, relapse, rehospitalization, switching to another antipsychotic or 
dropping out of care. The data used to fill the model were based on results of a clinical 
triaC3, other published literature, and expert advice. The researchers found that the 3 
therapies were approximately cost neutral over a 5-year period (olanzapine £35,701, 
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risperidone £36,590, haloperidol £36,653). This shows that the pnce advantage to 
haloperidol relative to the atypical therapies is lost because lower efficacy results in 
greater utilization of health services and a higher probability of switching to the more 
expensive drugs. There was evidence of greater efficacy with the atypical drugs (average 
percentage of 5 years with Brief Psychiatric Rating Scale (BPRS) scores < 18: olanzapine 
63.6%, risperidone 63.0% and haloperidol 52.2%). The cost neutrality, together with the 
greater efficacy of olanzapine and risperidone compared with haloperidol in terms of 
reduced BPRS scores and relapse rates, suggests the former 2 drugs represent cost-
effective treatment options. 
Partial economic evaluations 
Hamilton et al. 97 conducted a cost analysis of 817 subjects from the original 1 ,996 
enrolled in the Tollefson's study60 comparing olanzapine with haloperidol. Subjects who 
demonstrated symptom response and tolerated the study medication during the acute 
phase (first 6 weeks of the trial) were eligible for the second phase of the trial (46 
additional weeks). Thus, cost comparisons for maintenance therapy were limited to the 
sub-sample of responders. Direct health care resource utilization (inpatient, outpatient, 
and medication use) by the study participants was quantified and assigned prices from a 
standard list. Costs were compared between treatment groups separately for the 6-week 
acute phase and the 46-week maintenance phase. In the acute phase, mean total medical 
costs were statistically significantly lower for patients receiving olanzapine ($6,114) than 
54 
for those receiving haloperidol ($6,502) even when the cost of medication was included 
in the analysis (P=0.033). This difference was mainly due to the decrease in hospital 
utilization in the olanzapine group. Analysis of costs during the 46-week extension phase 
revealed that mean total medical costs, including medication costs, were also lower for 
patients receiving olanzapine ($15,594) than for those receiving haloperidol ($16,230) 
but the difference was not statistically significant (P=0.128). 
Albright et al.98 linked five computerized databases to assess the change in 
healthcare resource utilisation and costs related to the initiation of risperidone therapy in 
146 patients with chronic schizophrenia in Saskatchewan, Canada. This retrospective 
cohort study measured and compared resource utilization for the 10 months before and 
after initiation of risperidone. Resource utilization included hospital services, physician 
services, mental health services, and drug services. During the period of risperidone use, 
total hospital admissions declined from 180 to 73 (a decrease of 59%, P<O.OOl), their 
total hospital length of stay decreased from 3888 days to 1624 days (a decrease of 58%, 
P<0.001), and their total physician visits decreased from 3963 and 2881 (a decrease of 
27%, P<0.001). Only small decreases in community health service use were observed. 
When services were assigned costs, the use of risperidone resulted in a net savings of 
approximately $8000 per patient per year, despite the statistically significant increase in 
the cost for medication (P<O.OOl). The incremental cost of risperidone therapy was 
offset almost 8-fold by these savings. 
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Glazer and Ereshefsky99 developed a clinical decision analytic model for 
examining the medical costs of treating the "revolving door" schizophrenia patient with 
either haloperidol, haloperidol decanoate, or risperidone over 1 year. Under the baseline 
set of assumptions, the use of a depot neuroleptic in the year following hospital discharge 
was the least costly strategy. The cost of continuing a traditional oral neuroleptic was 
estimated to be $5,752, switching to a depot neuroleptic was estimated to be $4,595 and 
switching to an atypical oral antipsychotic was estimated to be $7, 162 during the first 
post-discharge year. The authors varied the assumptions by increasing rates of adherence 
and by decreasing costs of medications and hospitalizations. Use of a novel antipsychotic 
was the least costly alternative only when the rate of adherence for the novel 
antipsychotic was considered to be equal to that of a depot antipsychotic. The authors 
concluded that for patients with a strong history of relapse and rehospitalization, use of 
traditional depot antipsychotic medications would result in the lowest direct treatment 
costs in the first year following hospital discharge. However, it was acknowledged that 
the application of this model in different clinical scenarios associated with different 
outcome probabilities and treatment costs may well provide different results. 
Finley et a1. 100 used a retrospective cohort, intention-to-treat analysis of all 
patients initiated on risperidone therapy at an inpatient veteran's psychiatric facility to 
analyze the financial impact of risperidone on the treatment of psychotic symptoms. This 
study included patients with treatment resistant and treatment intolerant schizophrenia 
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(n=49), bipolar affective disorder (n=5), and depression with psychotic features (n=3). 
Of the patients initiated on risperidone, 50 received a minimum trial of 14 days of 
continuous treatment and had complete medical record data permitting study inclusion 
and only 27 of these continued to receive risperidone for the entire 12-month post-
treatment period and were therefore considered therapeutic responders. The total number 
of inpatient days decreased from 2,54 7 before risperidone to 2,021 days after, a decline of 
526 inpatient days overall. Therefore the total decline in direct hospitalization costs 
yielded a savings of $203,036. Given that the total annual acquisition cost of risperidone 
in this analysis was $55,074, resulting in a net savings of$149,962 for the institution. Of 
note, the acquisition cost of other psychotropic medications received prior to the 
initiation of risperidone or for non-responders was not accounted for in the analysis. 
Edgell et al. 101 used data from a multicentre, double-blind, prospective study of 
olanzapine (n=75) and risperidone (n=75)73 to measure health service use of enrolled 
patients at baseline and prospectively, at 8-week intervals and at study completion (28 
weeks). Median total, inpatient/outpatient service and medication acquisition costs were 
compared between treatment groups. The authors found that total per patient medical 
costs over the study interval were $2,843 (36%) lower in the olanzapine treatment group 
than in the risperidone treatment group (P=0.342). Medication costs were significantly 
higher for olanzapine-treated patients ($2,513 vs. $1,581; P<0.001), but this difference 
was offset by a reduction of $3,774 (52%) in inpatient/outpatient service costs for 
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olanzapine-treated patients in comparison with risperidone-treated patients ($3,516 vs. 
$7,291, P=0.083). 
Health care utilization and health status for hospitalized patients with 
schizophrenia was measured following the commencement of clozapine treatment in a 
US study.102 The mean total direct Medicaid costs for all subjects was $48,114 per 
person for the six months preceding clozapine treatment and $44,847 per person for the 
six months after for the 33 subjects recruited into the study. Of those who stayed on 
clozapine treatment (52%, n=l7), the health care costs showed a savings of $11,464 per 
person. The main findings were that continued clozapine treatment was associated with 
reduced days of psychiatric hospital care, reduced costs even after including increased 
costs for outpatient care and residential costs for a period as brief as six months. 
An Australian study on the long-term use of clozapine examined the clinical and 
economic outcomes 3 years after the prescription of clozapine to a cohort of 37 
patients. 103 Experience during the 2 years before clozapine was compared with 
experience in the following 3 years on the basis of a retrospective review of health care 
records. Compared with the pre-clozapine period, there were significant reductions post-
clozapine in hospital admissions (year 3) and hospital bed-days (year 2) by the total 
cohort and in hospital bed-days and hospital expenditure for those patients (n=25) who 
remain on clozapine (years 2 and 3). There was no significant increase or decrease post-
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clozapine in the estimated combined cost of treatment attributable to bed use, clozapine 
tablets, and blood monitoring before and after the initiation of clozapine. For example, 
compared with 1 year pre-clozapine, the difference in cost for the cohort in year 3 post-
clozapine was a reduction in $470 per patient per year. 
2.2.2.1 Quality of the Studies Reviewed 
It is important to note from the outset that most of the economic evaluations 
conducted to date in schizophrenia are not technically "cost-effectiveness" studies that 
measure cost per successful patient outcome over time, but cost-minimization analyses 
that measure total cost savings per patient over time. An ideal study would explicitly 
measure direct and indirect medical costs associated with the use of newer antipsychotic 
medications. Most published studies have used only a proxy for these costs (such as 
reduction in hospital days) to estimate cost-effectiveness. This proxy is useful because 
traditionally a majority of medical costs incurred in treating patients with schizophrenia 
are due to hospital costs. However, full enumeration oftotal costs is desirable. 104 
Many of the studies evaluated patients who were treatment-resistant or treatment 
intolerant and thus the generalizability of the results is decreased. The failure to include 
the costs of treatment dropouts may introduce bias since patients discontinuing treatment 
because of side effects or lack of efficacy are likely to be high users of heatlh care 
resources and therefore incur higher costs. Furthermore, many other aspects of care can 
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affect costs of care after a patient switches to an atypical agent. For example, hospital 
policies regarding decreasing length of inpatient stay for schizophrenia would affect this 
outcome. Given that this has been a growing trend in recent years, it is difficult to 
determine if decreases in hospitalization rates and costs are due to use of second-
generation anti psychotics or to changes in healthcare policy. The question of whether the 
change in inpatient care is due to initiation of a new medication or a change in policy is 
very important since most cost savings with second-generation antipsychotics appear to 
be due primarily to decreased use of inpatient care. Additionally, any cost savings seen 
due to reductions in hospital utilization will be conditional upon the presence of adequate 
services to support the care of these patients in the community. 
Schizophrenia is characterized by exacerbation and remission. However, the 
results of the studies were based on short-term follow-up and as a result there was 
insufficient data to confirm that any health status difference between patients treated with 
different classes of medications will remain stable over the patients' remaining lifetime. 
Studies without randomization or appropriate controls are likely to be biased in favour of 
the intervention, because the physician may provide better care, or there may be a 
placebo effect, or because something else changes in the health care system. 
Additionally, the evaluations did not take account of factors such as adherence rates that 
might modify the impact of these drugs in the "real world". 
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2.2.2.2 Summary of the Studies Reviewed 
The majority of studies reviewed found that novel antipsychotics are at least cost-
neutral and may offer cost advantages compared to traditional agents despite the 
increased acquisition costs of the former. Some studies also reported greater 
improvement in effectiveness and quality of life when novel antipsychotics were 
compared to traditional antipsychotic medications. However, given the uncertainty that 
surrounds the clinical data, and the uncertainty regarding the cost and outcomes data, 
small sample sizes and limited study designs available in the literature, it is difficult to 
reach any definitive conclusion as to whether the additional costs and benefits represent 
value for money. 105-107 It is necessary that sophisticated concurrent prospective economic 
evaluations be conducted in the real world to address whether novel antipsychotics are 
actually cost-effective. 
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2.3 Access to and Utilization of Pharmacotherapies 
The increase in both pharmaceutical prices and drug benefit expenditures has 
prompted many payers to implement various policies as means to control costs and 
discourage inappropriate utilization. The two separate mechanisms that affect the extent 
to which people receive pharmacotherapies may be described as access and utilization. 
They work together to determine whether a particular drug is used widely in the health 
care system. Access is a complex concept and often refers to structural issues (e.g. 
coverage and benefit) within the health care benefit system that determine whether a 
health care service is available for use. Utilization is a more subjective concept and 
reflects the degree to which services that are available are actually used by the consumer 
or the extent to which a population 'gains access'. In tum, each of these components is 
influenced by several factors. 108 
2.3.1 Defining Access 
Access to a particular health care service may be defined as the set of factors that 
affect the potential ability of an individual or a group to acquire timely and appropriate 
use of that service. 108 Health care payers have direct control over access via the design of 
their benefit programs. Among these, there are a number of factors that affect access to 
pharmaceuticals: patient-level restrictions on access, such as cost-sharing (co-payments) 
or drug prescription limits or caps (number), as well as efforts to improve patient 
adherence; and administrative restrictions that limit clinicians' ability to prescribe 
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particular medications, such as the imposition of a limited list of drugs eligible for 
reimbursement (formularies), category exclusions, or prior authorization requirements. 109-
112 It is the sum of these interacting policies that defines drug policy and it is the global 
impact of these drug policies that is of importance to policy makers. 
2.3.1.1 Patient-Level Restrictions: Cost-sharing and Prescription Limits 
Benefit design is the primary mechanism that influences access to newer 
pharmaceuticals. Some health plans place restrictions on the number of prescriptions a 
given beneficiary may receive each month while others require program beneficiaries to 
pay a fixed amount toward the cost of each prescription in the form of co-payments or 
coinsurance. There are a number of objectives often cited for cost-sharing requirements, 
such as: deterring consumption of "unnecessary" drugs; making patients aware of the 
costs of medicines; helping to contain rising drug costs. 113 Contributions by patients, 
whether as a co-payment or a coinsurance, provide additional money to support the 
purchase of prescription drugs. Evidence from the literature consistently shows cost-
sharing to be an effective source of additional funding for medicines. At the same time, 
patients reduce their consumption of prescription drugs as their out-of-pocket costs 
increase. 114-117 However, subtle changes in prescription drug consumption can have large 
health consequences. Ideally, changes in drug consumption would be limited only to 
"unnecessary" drug consumption. By definition, "unnecessary" implies there is little or 
no negative impact on health. On the other hand, to the extent that "essential" 
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medications are also affected, negative health impacts are expected. 113 Cost-sharing 
could actually inhibit the efficient use of scarce resources, e.g., reductions in the use of 
necessary medications thereby requiring treatments of increased frequency or intensity. 
Additionally, this approach places the burden on patients to identify which medications 
are necessary, and to select some drugs while rejecting others. However, it is unlikely 
that most chronically ill, elderly patients are adequately informed about the efficacy of 
their medications and, in many cases, may not be able to distinguish essential from less 
effective medications. 118 Thus, for poor and chronically ill individuals who have few 
financial resources and often multiple medical needs, there is a risk that high levels of 
cost-sharing will also reduce the use of effective and essential therapies. 109 From a policy 
perspective, the correct question to ask is whether the positive impact of imposing cost-
sharing as a means to deter inappropriate use of prescriptions and providing additional 
funding is worth the health risks and costs observed when prescription drugs are used 
inappropriately. Adverse effects on people's health may lead to higher overall healthcare 
costs.112 113119 
Evidence of the deleterious effects of the introduction of a cost-sharing policy for 
drugs emerges from studies of changes to the Quebec public drug plan in the mid 
1990s.120 Quebec imposed user fees for the elderly and poor who had previously been 
exempt from these charges. The authors found that drug use decreased by 14.7% among 
welfare recipients and 7. 7% among the elderly following the implementation of the 
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policy. Emergency room visits increased 71% and visits to doctors' offices increased by 
17%. Emergency room visits by the mentally ill grew by 558%. The policy was 
estimated to have caused an extra 2,000 hospital admissions. The authors concluded that 
increased cost-sharing reduced the use of less essential drugs but also had the unintended 
effect of reducing the use of drugs that were essential for disease management and 
prevention. As a result, there was an increase in the rate of adverse events and 
emergency department visits in the post-policy period. 
Cost-sharing arrangements influence the consumption of medications, the health 
of patients, and the cost of health care more broadly. Additionally, the injection of more 
private funding would take Canada further away from the model of largely public 
financing of pharmaceuticals that exists in most developed countries (generally less 
expensive and more equitable) and closer to the US model (more expensive and less 
equitable). 
2.3.1.2 Administrative Restrictions on Prescribing 
Administrative restrictions on specific drugs have been used increasingly as a 
cost-containment tool around the world. Most drug programs have adopted the use of 
formularies as a method for containing costs by limiting the availability of agents, namely 
by restricting access to expensive medications. 
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Special Authorization 
Special authorization, a form of restriction on benefits, is used in many drug 
benefit programs under various designations (e.g., special authority, exception drug 
status). This policy requires pre-approval for reimbursement for particular drugs or drug 
categories and is intended to ensure optimal, cost-effective, evidence-based prescribing. 
In this situation, a physician is required to submit a specific request for each patient 
indicating why a non-benefit product is required and seeking approval for benefit 
coverage of the product. The process requires forms to be completed and reasons given 
for use of the drug. The health care payer organization approves or denies a particular 
prescription request based on a defined set of criteria. In theory, special authorization 
provides a method to target costly, newly introduced, and/or potentially toxic drugs only 
to recipients who truly need them, while eliminating their use in cases where less 
expensive or safer alternatives could be used. The rationale for using special 
authorization is based on several assumptions. These may include: 
o No clinically important efficacy or effectiveness differences exist between two 
agents of a given class. Therefore, it is only necessary to reimburse one of these 
agents on a routine basis. 
o The agents designated for special authorization have the potential for abuse by 
either providers or patients. Therefore it is necessary to restrict access to these 
agents and document clinical necessity prior to dispensing. 
o The agents designated for special authorization are more expensive than other 
alternatives, while their increased benefit is less clear. Because lowering 
pharmaceutical expenditures is a valid endpoint in its own right or directly 
correlates with overall medical cost savings, dispensing of the more expensive 
h ld . . 1 . . 111 121 agent s ou reqmre spec1a permissiOn. 
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Interchangeability 
Some drug benefit programs have implemented interchangeability policies in their 
drug formularies. Interchangeability can be determined on the grounds of bio-
equivalence or therapeutic equivalence. A bio-equivalent category is one in which all the 
products have the same chemical active ingredient which has been shown to be 
biologically equivalent in its absorption. Therapeutic equivalence is used for a 
therapeutic subclass of drugs. It is a broader concept and includes all listed drugs that are 
used to treat a specified diagnostic class of patients. 121 For example, all listed drugs 
which are used as antihistamines are considered to be in the same therapeutic class and 
identical for therapeutic purposes. From the point of view of drug benefit programs, 
interchangeability is a concept that allows drugs within a class to be identical for 
reimbursement purposes. 
British Columbia introduced this type of policy within some therapeutic classes of 
drugs (H2 antagonists, vasodilating nitrates, non-steroidal anti-inflammatory drugs, and 
two classes of anti-hypertensives: ACE inhibitors and calcium channel blockers). This 
concept is also referred to as Reference Based Pricing, whereby only the cost of the 
lowest price drug in a therapeutic group is covered by drug benefit plans. The 
reimbursement price is set irrespective of the drug or brand prescribed. If patients wish 
to have a drug prescribed other than the reference product they must pay the difference 
out of their own pocket. 121 122 This policy functions like an ideal, fully informed market, 
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reducing the sale of products whose higher price is not matched by increased value. 123 It 
is a logical extension of policies to encourage the substitution of lower-cost generic drugs 
for high-priced branded equivalents, policies that will become less effective as Bill C-91 
reduces the availability of generic substitutes. 119 121 124 This approach is designed to 
provide complete coverage for prescription drugs, reduce the amount paid out by drug-
benefit plans and provide an incentive for pharmaceutical manufacturers to lower their 
prices. 125 
Restrictive formularies and other limitations may lower drug quantities and 
reduce expenditures. 126-129 But the direct effects are not necessarily a good indication of 
the total effects of these policies on overall health care costs and quality of care. Costs 
are often shifted to other areas, resulting in an increase in the use of other health services 
or a shift of the burden to patients or caregivers. There are numerous studies109 130 127 121 
129 131 that have found that while implementation of a restrictive formulary could reduce 
drug expenditures, these savings are more than offset by spending increases caused by 
. b . . 1 h . h F 1 H d k 132 133 service su stltutwn e sew ere m t e system. or examp e, om an co-wor ers 
found that restrictive formularies tended to mcrease utilization of other health care 
resources for patients with diagnoses of arthritis, asthma, epigastric pain/ulcer, 
hypertension, and otitis media. 
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Administrative restrictions have become increasingly controversial for a number of 
reasons: they frequently deny beneficiaries access to newer, more expensive, and 
possibly more effective agents; 134 physicians are often concerned about the infringement 
of their ability to select whichever drug they feel is most appropriate; they create a 
physician "hassle factor," that is to say, the documentation required to get a prior 
authorization drug approved is too burdensome for most physicians to be willing to 
pursue; 111 and finally, the Pharmaceutical Industry argue that reduced manufacturer 
income might reduce their spending on research and development. 
Global Budgets 
In Germany, New Zealand, Northern Ireland and the United Kingdom, and other 
countries, drug and physician remuneration budgets have been integrated to make 
physician incomes or practice revenues partly dependent (negatively) on prescribing 
volume. Such integration, which recognizes the obvious fact that the prescribing 
physician is the critical actor in the chain of drug use, has had some success in cost 
reduction.112 135 136 137 138 This type of system forces physicians to improve the 
management of pharmaceuticals as a component of their practice. They are encouraged 
to more closely monitor their patients' utilization of drugs and adherence with prescribed 
regimes.\39 119 
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Fundholding 
In the early 1990s, the National Health Service (NHS) in Britain introduced a 
general practice fundholding mechanism. Fundholding was an attempt to introduce a 
positive incentive for doctors to think carefully about their prescribing. In this 
arrangement, volunteer practices were responsible for managing their own prescribing 
budgets and purchasing a limited range of community health services and elective 
hospital procedures on behalf of their patients. Fundholders were able to make savings 
from their budgets, and invest these savings in additional services or improving facilities 
in their practices. It could not be used to increase the doctors' income or to benefit the 
practice generally. If fundholders made savings they could use these on other parts of the 
fund or they could use the fund to pay for any drug overspending.*140 The desired effect 
of this funding arrangement was to decrease drug expenditure. 
New Zealand has also implemented a similar system where independent 
practitioner associations (IP As) were developed as a strategy for containing their 
expenditure growth on pharmaceutical and laboratory services through budget holding. 
One of these IP As, Pegasus Medical Group, began a pharmaceutical budget holding in 
December 1994. The strategy focused on a broad range of activities: the development of 
guidelines by those involved; personalised feedback of prescribing costs; peer group 
'fundholding has been replaced with a recognizable similar strategy of primary care groups (PCGs) when 
the New Labour government assumed power in the late 1990s. 
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discussions and sharing of information; providing information on the costs of 
pharmaceuticals; and professional incentives enabling the use of savings for alternative 
services. 136 Despite successfully reducing laboratory test behaviour, the arrangement was 
less successful in reducing prescribing costs. What is important to note here is the 
policy's success in establishing professional accountability for both cost and quality. 
Supply-side initiatives such as fundholding affect prescription drug utilization 
and the cost of a drug benefit program. These initiatives aim to influence behaviour of 
prescribing physicians, encouraging them to consider costs as well as benefits in their 
prescribing decisions. These types of incentives can be successful in reducing costs by 
encouraging fundholders to search for more effective and cost-effective ways of 
delivering care. 141 
A concern with this arrangement is that many would over spend their budget and 
then be unable to treat patients at the end of the financial year. A second fear is related to 
the calculation of the budget. In Britain, the Department of Health decided to base the 
budgets on an historic cost basis. Practices would be given a budget based on last year's 
spending plus an 'uplift' factor. However, this way of setting the budgets created a 
perverse incentive. It was in the interest of practices to bid up their referrals and their 
drug spending in the year before they became fundholders and to sustain or increase it 
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thereafter. In response, the Department returned to the task of calculating a capitation 
formula. 140 
Outcomes Guarantee 
A novel approach to ensuring maximum health benefits from a drug has been 
developed and piloted in the UK. This new method of risk sharing is referred to as an 
"outcomes guarantee," in which a pharmaceutical company and prescribing stakeholders 
agree on the outcomes that they would expect from a drug for a given indication. 142 If the 
drug fails to fulfil expectations, the pharmaceutical company refunds the cost of the drug. 
This encourages the pharmaceutical company to promote responsible prescribing for their 
drugs and ensures that healthcare resources are not wasted on ineffective treatments. The 
results of this pilot project have not yet been published but the researchers believe that 
the ultimate goal of refinement of clinical behaviour is achievable through the outcomes 
guarantee project. 
2.3.1.3 Differential Access to Prescription Medicines in Canada 
When Medicare was first introduced in Canada, prescription drugs played a 
limited role in the health care system and in the day-to-day lives of the vast majority of 
Canadians. Today, they are a fact of life for many Canadians. In fact, they have 
fundamentally changed the face of health care as is evident by the fact that 300 million 
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prescriptions are filled in Canada each year, amounting to about 10 prescriptions per 
person. 1 
The cost of medications in Canada while in hospital is covered but, like home 
care, there is no requirement under the Canada Health Act of 1984 for provinces to cover 
the costs of drugs prescribed outside of hospital. As a result, coverage across the country 
is variable with some provinces providing nominally universal programs (with high 
levels of co-payment), and others covering certain diseases (e.g. cancer). In all Canadian 
programs, eligibility for public drug insurance coverage tends to be based on age or 
socioeconomic circumstances while private drug insurance coverage largely depends 
upon employment status. There is considerable disparity among provincial plans in terms 
of who is covered, for what drugs, and what kinds of co-payments or deductibles are 
required. For example, British Columbia, Alberta, Quebec, Saskatchewan and Manitoba, 
have plans that offer coverage to all residents (universal). However none provide first 
dollar coverage, and the deductibles and co-payments are set sufficiently high to limit the 
number of residents receiving reimbursement and ultimately to limit the accessibility of 
prescription medicines. In Atlantic Canada, relatively fewer residents are eligible for 
plan coverage than other regions. As a result, Canadians with similar income and 
medical needs will receive widely varying levels of government plan benefits depending 
h . h 1' . 143 on t e provmce t ey 1ve m. 
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There are few mechanisms in place to ensure continuity of coverage as changes in 
individuals' circumstances affect their plan eligibility, especially for those individuals 
who rely on employer-sponsored programs, or who move between provinces. While the 
size of the uninsured or underinsured population varies depending on what is considered 
adequate insurance, several groups appear less likely to have adequate coverage: 1) 
residents of the Atlantic provinces (other than those in targeted government programs 
[seniors, social assistance] and those in employer sponsored group programs) have no 
protection against catastrophic levels of drug expense; 2) in all provinces, other than 
Quebec, those working part time or in low wage occupations (less than $10,000 per year) 
are more likely to be uninsured or underinsured for routine drug expense compared to the 
general population under age 65, due to their lower coverage rates under employer 
sponsored group plans; and 3) in most provinces there is a clear reduction in coverage in 
the age 55 to 64 groups as adults start to withdraw from the labor force and are less likely 
to have an employer-sponsored group plan and do not yet qualify for seniors' programs. 
Overall, approximately 90% of Canadians have some coverage for routine drug 
expenses. 11% can expect to obtain routine drug prescriptions without out-of-pocket 
costs. This full reimbursement coverage is normally provided either by social assistance 
or by employer sponsored group programs. An additional 69% of Canadians have drug 
plan coverage with relatively modest deductibles and co-payments. 10% are covered but 
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could be considered underinsured since their plan would pay less than 35% of a $1,000 
annual expense. 143 Approximately 10%, or 3 million people, are considered uninsured 
for routine drug expenses having no plan coverage or having a plan that would only cover 
annual expenses higher than $1,000. 143 
2.3.2 Defining Utilization 
Utilization is defined as the use of a health care serv1ce, procedure, device, or 
pharmaceutical. Utilization is influenced by access, although the actual utilization of a 
given pharmaceutical may not reach the maximum level expected given a specified level 
of access or availability. Utilization of health care services can be recorded in a number 
of ways (e.g. per capita, hospital admissions and length of stay, physician office visits, or 
number of prescriptions). With respect to pharmaceuticals, there are a number of factors 
that affect utilization such as physician prescribing behavior and patient adherence to 
prescribed medications. 
2.3.2.1 Physician Prescribing Behaviour 
Ultimately, a prescription drug can only be used as often as physicians prescribe 
it. It is therefore little wonder that patients, academics, policy makers, third-party 
msurers, and pharmaceutical manufacturers are interested m influencing physician 
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behaviour. Educational strategies have relied on passive strategies such as continuing 
medical education (CME), which generally includes lectures and other passive means of 
education. The ability of this method of affecting behaviour has been disappointing. 144 
The dissemination of printed materials containing useful information such as practice 
guidelines by professional organizations has also been evaluated and the results have 
shown that this method may be insufficient to provoke a change in physician 
behaviour. 145-148 However, academic detailing (i.e., one-on-one education) has been 
shown to be an effective educational intervention in promoting optimal drug 
prescribing. 149-152 
Education alone may fail to change physician behaviour, and as a result various 
motivational interventions have been studied. Physicians may be motivated by their 
desire to be perceived as good doctors by their patients and colleagues. Feedback, also 
know as profiling, has been moderately successful in improving physician motivation. 
The goal is to show a physician how his or her practice patterns compares with that of 
his/her peers. The expectation is that people will try to fit their behaviour to the norm. 
For example, feedback on the use of antibiotic prescriptions has resulted in the use of less 
expensive agents in some settings. 153 A randomized trial with feedback to 97 physicians 
showed that diabetes care was improved with feedback. 154 However, feedback is not 
always successful and the success depends on things such as the timing of the feedback 
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and physician buy-in which can be assisted via enlistment of local opinion leaders. 155-157 
Additionally, reminders and clinical decision support systems, which can also provide 
relevant and patient-specific information in a well-timed fashion, have the potential to 
facilitate improved clinical decisions. 158 159 
Despite the development of various methods of influencing prescribing practices, 
over-prescribing persists. A number of other factors within the health care system have 
been identified as contributing to this behaviour. The cost structure of the pharmaceutical 
industry creates very powerful economic incentives forcing manufacturers constantly to 
expand their sales. Massive resources are thus put into highly sophisticated marketing 
campaigns, and successful marketing means more drugs sold-more utilization. 119 Each 
year, more than $11 billion US is spent by pharmaceutical companies in promotion and 
marketing, $5 billion of which goes to sales representatives. 160 The time constraints 
imposed on physicians by the very nature of their occupation, make it difficult for 
physicians to keep up with clinical evidence on the appropriate use of new drugs. 
Doctors, therefore, may rely on pharmaceutical companies, whose primary interest is to 
sell their products, as sources of information. Thus, marketing-not science-could be 
playing a role in influencing prescribing pattems. 112 In addition, the industry sponsors 
numerous physician education symposia and programs that qualify for continuing 
medical education (CME) credit either at a local level or at national meetings. It can be 
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expected then, that there will be a steady rise in drug expenditures. The surging cost of 
prescription drugs is a concern, and the 20-year patent protection implemented by the 
introduction of Bill C-91 is a source of high prices. 119 
Over-prescribing may also result from the pressures of fee-for-service medical 
practice which make the prescription a critical stage in closing off a patient visit, 
symbolizing that the problem has been understood and the therapy chosen. 161 A study of 
Newfoundland GPs found that fee-for-service physicians gave antibiotic prescriptions to 
more patients than did salaried physicians. 162 Also, physician incomes are directly linked 
with a high throughput fee for service practice style. 163 
The basic structure and organization of our health care system potentially 
contributes to inappropriate prescribing by physicians. In our system, control over 
resource deployment is separated from accountability for efficient resource use. 
Clinicians are responsible for many resource allocation issues, but they do not have 
budgets for which they have to account. Clinicians do not deliberately go out of their 
way to be inefficient, but incentive mechanisms and constraints are not there to channel 
them into more efficient behaviour. 164 It may be argued that the central problem does not 
lie with clinicians as such but with the organizational system within which they operate. 
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2.3.2.2 Patient Adherence 
An estimated 350 million prescriptions were dispensed in Canada in 2002. 165 
Unfortunately, prescriptions filled does not indicate adherence with treatment. It has 
been consistently found that between one third and one half of patients fail to comply 
with medical advice and prescriptions. 166 As a result, the effectiveness of drug treatment 
in clinical practice is considerably lower than the efficacy shown in controlled studies. 
Discontinuing beneficial medication can cause preventable morbidity, and contribute to 
the burden of disease, at an estimated annual cost of $7 to $9 billion. 167 Included in this 
economic burden are the direct costs such as institutionalization and ambulatory care 
services (physician visits, laboratory tests, treatments), as well as the indirect costs 
associated with lost productivity and/or premature death. Likely consequences of 
medication non-adherence on health status include delayed recovery from acute illness, 
disease progression in chronic illness, and the subsequent need for more aggressive 
treatments. 168 
Medication adherence can be defined as the degree to which the patient follows a 
prescribed drug regimen. Three common forms of drug treatment non-adherence are: 
overuse and abuse, unintentional non-adherence (forgetting), and alteration of schedules 
and doses (intentional non-adherence ). 169 Within these categories, non-adherence occurs 
to different degrees. For example, overuse can range from taking one extra tablet to 
taking many times the prescribed amount. Overuse of a prescribed medication may arise 
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from a belief that taking more of the drug will result in more health-related benefits, such 
as less pain or lower blood pressure. Conversely, patients may forget the occasional dose 
or they may forget many doses on a regular basis. Patients may intentionally lengthen the 
duration of time between doses, or they may take drug holidays of weeks or months 
during their treatment regimens. 169 
Some suggest that adherence is not an issue: patients do not perceive taking drugs 
entirely in terms of obeying the doctor's orders. 166 Instead, they weigh up the costs and 
benefits of taking particular medications as they perceive them within the contexts and 
constraints of their everyday lives and needs. For example, a common reason given for 
intentional discontinuation is that patients are often unconvinced of the need for 
treatment. 170 171 Fear of side effects and fear of dependency are common reasons for 
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2.3.2.3 Summary 
The various policies and interventions implemented to influence drug access and 
utilization should be assessed based on economic efficiency. Economic efficiency means 
that maximum benefits to society are derived from the available resources. That 
definition requires evaluating both the costs of providing the prescription drug coverage 
and the benefits derived. Importantly, because government funds the public provision of 
the majority of health care in Canada, the provincial prescription drug programs must be 
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evaluated within the context of that broader health care system. Unfortunately, policy 
decisions are often made in isolation from the broader context, resulting in a focus on the 
cost of the drug program and drug utilization, without considering the benefits or impact 
on other parts of the health care system. In tum, this makes it difficult, if not impossible, 
to assess, unambiguously, the economic efficiency of the various initiatives being 
evaluated. To do so correctly requires consideration of the cost of the drug program, 
equity, drug utilization, appropriateness of prescribing, patient health effects, and effects 
on the cost of health care more broadly. 
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CHAPTER III- DESIGN AND METHODS 
3.1 Introduction 
The decision to allow for unrestricted access to a class of prescription medications 
by a provincial drug formulary provided a unique opportunity to conduct an observational 
evaluation of some of the clinical and economic consequences of such a decision. This 
research project was designed to evaluate two separate but related issues surrounding the 
unrestricted access to atypical antipsychotic medications: 1) hospital utilization by 
persons suffering from schizophrenia; and 2) the utilization of and expenditure for these 
new agents by the Newfoundland and Labrador Prescription Drug Program (NLPDP). 
This study consisted of 3 phases of data collection: 1) 12 months (1995/96) near the 
beginning of restricted access; 2) the last year of restricted access (1998); and 3) the 
second year of unrestricted access (2000). 
The hospital utilization portion of the study measured the total number of 
admissions, the length of stay, the total number of hospital days, and the time to 
readmission for those individuals who had a diagnosis of, were treated for, and 
discharged from acute care psychiatry with schizophrenia. Patient demographic, clinical 
and treatment information was collected for each of the study years so that account could 
be taken of differences in variables which could influence length of stay and readmission. 
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The ultimate goal was to determine whether hospital utilization decreased as the use of 
atypical agents increased over time. 
The utilization and expenditures for atypical antipsychotic medications were 
identified using the NLPDP prescription claims database. 
3.2 Ethical Considerations 
This study was approved by the Human Investigation Committee of Memorial 
University of Newfoundland. Informed consent of patients was not required because 
their information was obtained through chart abstraction without patient participation. 
The hospital study can be viewed as an audit of patient care, which traditionally does not 
require patient consent. We did not interview individual patients nor did we use their 
identity in data analysis. 
The measurement of the number of claims reimbursed and amount of money 
spent for antipsychotic medications by the Newfoundland and Labrador Prescription 
Drug Program over time did not require beneficiary consent. 
Physicians identified as initiating atypical antipsychotic therapy for their patients 
during the study period were asked to participate in the study. A letter of intent 
describing the study and its purpose (appendix H) and a consent form (appendix I) were 
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mailed to each physician. Individual consent was obtained despite having received 
formal written support from both the Newfoundland Psychiatric Association and the 
Newfoundland and Labrador Medical Association. Participation was entirely voluntary 
and volunteers were to be reimbursed for their time. Participants were informed that all 
information collected was to be described in a manner that prevented identification of any 
individual. Confidentiality of information concerning physicians and patients was 
maintained by the investigator. 
3.3 Hospital Utilization in Newfoundland 
3.3.1 Data Source and Study Population 
The study population comprised all patients, age greater than 18 years, discharged 
from all general and psychiatric hospitals in Newfoundland and Labrador with a 
diagnosis of schizophrenia during the three 12-month periods. The medical records 
departments of all hospitals in the province that admit psychiatric patients were contacted 
by letter to enlist their participation in the study. Each department was asked to provide 
the research team with a list of patients with both primary and secondary discharge 
International Classification of Diseases, 9th Revision (ICD-9) 174 diagnosis codes of295.0-
295.9 (schizophrenic psychoses) during 3 time periods: 1) at the beginning of restricted 
access (April 1, 1995 through March 31, 1996), 2) at the end of restricted access (January 
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1, 1998 through December 31, 1998), and 3) in the second year of open access (January 
1, 2000 through December 31, 2000). 
3.3.2 Data Collection 
In order to collect relevant information from patient's charts, a team was 
assembled to create a data collection form. The team consisted of a psychiatrist, a 
clinical pharmacist who specializes in psychiatry, a clinical epidemiologist, a health 
policy analyst, and a member of the Mental Health Program with the Health Care 
Corporation of St. John's. The information to be included on the form was based on 
published clinical practice guidelines, 175 176 published psychopharmacological screening 
criteria, 177 quality of care indicators important to the Mental Health Program, and expert 
opmwn. Data to be collected included demographic information, psychiatric status, 
management with pharmacotherapy and electroconvulsive therapy (ECT), utilization of 
various mental health programs, attempted suicide, use of seclusion, drug side effects, 
length of stay, previous admissions and readmission rates. This form was used to review 
ten hospital psychiatric charts and it was determined that the following data was not 
readily available in the chart: assessment and/or treatment by interdisciplinary care; 
referrals to services within the Mental Health Program; case management; ongoing 
counselling/therapy; drug side effects; and specific follow-up treatment plans. A revised 
version of the abstraction form was utilized to collect data.(Appendix J) Two research 
personnel reviewed the same five patients' charts independently to ensure consistency 
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between the abstracters. The researchers were satisfied that the same data was being 
collected, and independent abstraction was undertaken. 
Each hospital medical records department in the province with patients admitted 
for the treatment of schizophrenia assigned staff to pull all of the patient charts. A 
member of the research team travelled to each site to conduct the chart abstraction 
process. While on site, each patient's hospital chart on the list was reviewed and all 
admissions to hospital during each study period were screened to determine whether they 
were related to the patient's psychiatric illness. This allowed the research team to capture 
all hospitalizations resulting from an exacerbation of schizophrenia (e.g. suicide 
attempts). Any admission not related to a patient's psychiatric diagnosis (e.g. patients 
admitted for the treatment pneumonia with a secondary diagnosis of schizophrenia) was 
excluded from the study. Lengths of stay that exceeded 365 days were also excluded. 
Transfers between hospitals were treated as a single episode of care. The first 
episode of care identified in each study year was considered the index admission for that 
year and the first admission identified for the 3 study years was referred to as the study 
index admission. Patients were followed after each discharge in each 12 month interval 
and were censored at death or last follow-up. 
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All data collected were subsequently entered into Paradox® (version 7) for ease of 
data entry. After all data were checked and cleaned, the database was transferred to the 
Statistical Package for the Social Sciences (SPSS~ version 9.0 for Windows for analysis. 
3.3.3 Outcome Measures 
The primary outcome of interest was total days in hospital for schizophrenia per 
year. The number of admissions per year, length of stay in hospital, and the number of 
days from index discharge to re-hospitalization were secondary outcomes. 
3.3.4 Demographic Characteristics 
Demographic characteristics such as age, gender, region of domicile, education, 
income source, and occupation were obtained from the hospital chart. Region of 
domicile was categorized by placing the community where the patient lived from the 
home address provided in the chart and its location identified within one of the 
boundaries of the Regional Institutional Boards. Income source was defined as receiving 
social assistance, and other (employment, disability insurance, unemployment insurance, 
old age security, financial support from spouse, family, or children). 
3.3.5 Psychiatric Symptoms and Clinical Presentation 
Each study patient had their first psychiatric admission chart reviewed. This 
review enabled the researchers to determine the date of first psychiatric admission as well 
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as the calculation of duration of disease. The medical records departments of all of the 
institutions that admitted patients for the treatment of schizophrenia provided the 
researchers with a computerized printout of all previous admissions to that hospital, from 
which the total number of previous psychiatric hospitalizations were calculated. 
In many cases, a brief examination of mental status is conducted on a psychiatric 
patient upon admission to hospital. These examinations identify patients as having any or 
all of the following characteristics: thought disorder (e.g. disorganized speech and 
delusions); perceptual disorder (e.g. auditory hallucinations); affect disorder (e.g., 
euphoric mood); and disordered behaviour (e.g. catatonic motor behaviour). Substance 
abuse (e.g. alcohol and/or drugs), non-adherence with prescribed pharmacotherapy prior 
to admission, discharged against medical advice, first psychotic admission and suicidal 
ideation on admission were all considered symptoms of disease. All of the 
aforementioned information was collected when the data was available in the chart. 
The need for seclusion due to uncontrollable and/or violent behaviour and 
electroconvulsive therapy (ECT) while in hospital were also abstracted. 
3.3.6 Pharmacotherapy 
All of the medications ordered by the treating physicians and administered to 
patients while in hospital were documented in the clinical records. Dosage, route, date 
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started, and date discontinued for all antipsychotic medications were subsequently 
abstracted by the researchers for each patient. The antipsychotic medications were 
classified as being either an atypical antipsychotic ( olanzapine, risperidone, quetiapine, 
clozapine) or a conventional antipsychotic agent (oral, injectable short acting and depot). 
The antipsychotic therapy prescribed on discharge was also abstracted from the chart. 
3.3.7 Analytic Approach 
Data was tabulated for each of the 3 phases of the study. Continuous variables 
were analyzed using one-way analysis of variance (ANOV A) or the Student's t-test, 
where appropriate. Approximately normal distributions of continuous variables were 
described with the mean and standard deviation; other distributions were transformed 
using logarithmic transformation and presented as medians. When continuous variables 
were found to be significantly different between the three years, post hoc analyses were 
conducted to determine which years were significantly different using Tukey' s test of 
significance. 
The length of stay in hospital was calculated by subtracting the admission date 
from the discharge date. All analyses of length of stay excluded patients who died in 
hospital since the length of stay was intended to be an indicator of improvement in 
psychiatric status. A Kaplan-Meier curve of the time to discharge was used to compare 
the length of stay for each study year. Lengths of stay were compared using the log rank 
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test statistic. Multivariable Cox proportional hazards regression analysis using a block 
entry of variables was used to determine significant independent predictors of both time 
to discharge (length of stay) and time to readmission. Block entry of variables is a 
procedure for variable selection in which the named variables are entered in a single step 
without checking any of the entry criteria. The analysis determined whether a hospital 
admission during one of the three phases of the study influenced time to discharge or 
time to readmission independent of demographic factors, psychiatric symptoms, and 
pharmacotherapy (switching from conventional to atypical agent). Given that the Cox 
proportional hazards model provides the risk of discharge from hospital, the hazard ratios 
and 95% confidence intervals were inverted so as to present the results as the risk of an 
increased length of stay. 
When a patient was identified in more than one study year, only their first 
admission to hospital for the entire study period was included in the multivariable model 
in order to avoid multiple contributions and thus bias the results. These multiple 
admitters were separated and compared to those patients who did not appear in more than 
one study year using both Student's t-test and chi-square statistics where appropriate. 
All categorical variables were recoded for computer analysis. Comparisons of 
categorical variables were done using cross-tabulations and chi-square statistics to 
evaluate significance. The results were presented as percentages. 
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The time to readmission was calculated by subtracting the date of discharge from 
the date of next admission. The variable, time to readmission, was recoded into a 
dichotomous outcome variable with two groups: those readmitted to hospital within 365 
days of discharge and those who were not readmitted to hospital within 365 days of 
discharge. Bivariate statistical comparisons were made between the two groups using the 
two-tailed Student's t-test for continuous variables and chi-square statistics for 
categorical variables, with the level of significance set at 0.05. 
Multivariable logistic regression was used to determine significant predictors of 
the probability of being readmitted within one year of discharge relative to not being 
readmitted within 1 year of discharge. Patients who either died or were confirmed to 
have left the province within 365 days of discharge were removed from the analysis, as 
they were not available for readmission. All independent variables were entered into the 
model using a standard method where all variables are entered at once. All variables 
were evaluated in relation to the dependent variable through use of partial correlation 
coefficients. This method was chosen based on theoretical relationship with the response 
variable. Again, demographic factors, psychiatric symptoms, and pharmacotherapy 
(atypical or conventional antipsychotic prescribed on discharge) were included in the 
multivariable analysis. The length of stay was included as an independent predictor in 
the multi variable analysis for readmission. 
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3.4 Patterns of Antipsychotic Medication Utilization and Expenditure in the 
Province of Newfoundland (NLPDP), 1995-2003 
3.4.1 Utilization and Expenditure 
Newfoundland and Labrador Prescription Drug Program (NLPDP) claims data 
were received biannually from the Department of Health and Community Services. The 
database includes all prescriptions (i.e., from all therapeutic categories) reimbursed by the 
program and uses the American Hospital Formulary System (AHFS), a therapeutic 
classification system, to group drugs. The AHFS groups drug products according to their 
therapeutic use. The therapeutic category corresponding to the relevant products 
(28:16.08) was used to extract the antipsychotics for the fiscal years 1994/1995 to 
2002/2003, inclusive and was entered into an Excel database. These data allowed for the 
analysis of the utilization of individual pharmaceutical agents covered by the provincial 
drug plan as well as the amount paid by the program. Utilization was defined as the 
volume of prescriptions and type of antipsychotic medication reimbursed by the NLPDP. 
The database does not accurately record the number of pills dispensed per prescription 
and thus it was not possible to determine the duration of treatment. All antipsychotic 
agents were grouped into one of two categories: atypical and conventional. The atypical 
antipsychotic agents considered in this study include: clozapine, risperidone, olanzapine, 
and quetiapine. 
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3.4.2 Indication for Use of Atypical Antipsychotic Medications for Claims 
Reimbursed by the NLPDP 
3.4.2.1 Identification of Prescribing Physicians 
The implementation of an umestricted reimbursement policy opens up the 
possibility that over-utilization of atypical antipsychotic medications could occur through 
prescription for disorders other than schizophrenia. The current study proposed to 
measure the appropriateness of initiating atypical antipsychotic medication therapy in 
patients covered by the NLPDP. 
All patients prescribed an atypical antipsychotic medication for the first time were 
identified by manually reviewing all formal written requests for approval in the pre 
policy period. Each new patient started on an atypical antipsychotic was documented and 
assigned a date of first prescription. The information collected from this process was 
subsequently entered into an Excel spreadsheet so that the NLPDP claims databases 
received each year could be cross-referenced so that only new patients in each study year 
were included. 
The information contained in the NLPDP database was deficient for our purposes 
because the database was created solely to reimburse claims submitted by the pharmacy 
where a prescription was filled. Therefore the only information a pharmacy was required 
to submit was for reimbursement: the beneficiaries' drug card number, name, prescribing 
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physician's name, drug description, cost of the prescription and date the prescription was 
filled. There was no patient specific information (e.g. age, gender, diagnosis) in the 
database and it was not possible to link the database with any other information to 
determine the indication for the use of atypical antipsychotic medications. It was decided 
to use information gathered from the prescribing physician to determine diagnosis and 
indication for atypical antipsychotic use. 
All physicians in the province initiating therapy with an atypical antipsychotic 
medication were identified. Each physician was mailed a letter requesting their 
assistance in identifying the indication for use for each patient receiving an atypical 
antipsychotic through the NLPDP. The envelope contained a letter which outlined the 
intent of the study and its purpose (Appendix H) as well as a consent form (Appendix I). 
Prescribing physicians were to be interviewed to confirm diagnosis and indication for 
treatment. Participation was entirely voluntary. 
The therapeutic decision to prescribe atypical antipsychotic agents was to be 
compared to practice guidelines applied by an expert panel. This panel of experts were to 
use the practice guidelines recommended by the American Psychiatric Association, 176 
and the Canadian Psychiatric Association, 175 as well as other published literature on 
efficacy of antipsychotic medications, to complete its evaluation of appropriateness, 
inappropriateness, and uncertain appropriateness of pharmacotherapy. The academic 
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panel was to consist of a clinical epidemiologist, a professor of clinical psychiatric 
pharmacy, and a psychiatrist. Classification of the panel's decisions on the appropriate or 
inappropriate use of atypical antipsychotic medications was to be developed post-hoc. 
3.4.2.2 Method of Data Collection 
Visits to the participating physicians were arranged and interviews were 
conducted. Information collected during each visit included patient demographics, 
presenting complaints, symptoms, relevant past psychiatric history, diagnoses and types 
and quantities of antipsychotic medications prescribed, as well as factors influencing 
atypical antipsychotic prescription decision (Appendix K). The physician interviews 
took approximately 3-4 minutes per case and volunteers were paid $15.00 per interview. 
Participants were informed that all information collected was to be described in a manner 
that would prevent identification. Confidentiality of information concerning physicians 
and patients were maintained by the investigators. 
The response from this request for participation was very poor and thus no useful 
data on the indication for use was obtained through this process. As a result, it was 
decided to assign each new prescription for an atypical antipsychotic in the years 
1995/96, 1998 and 2000 to the prescribing physician and look at the specialty of the 
prescriber. This did not enable us to make any conclusions but would give an idea as to 
who was prescribing these medications (e.g. psychiatrists vs. other specialties). Using the 
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Newfoundland and Labrador Medical Association, Directory of Physicians, the speciality 
of each prescriber for each claim was assigned to each record in the database. 
3.4.3 Atypical Antipsychotic Utilization in Canada 
Data on estimated national totals of atypical antipsychotics prescriptions in the 
years 2000 to 2003 were obtained from Brogan Inc., a market research company that 
collects provincial and private drug program data from 8 of the 10 Canadian provinces 
and a number of major private insurers. This represents over 65% of all retail 
prescription drug sales in Canada. The National Brogan data used in this study is 
projected based on the Ontario Drug Benefits (ODB) Program and Private Payer data and 
was extrapolated to the entire country. 
The ODB program covers approximately 2.2 million active claimants and pays for 
68 million prescriptions annually. The ODB claimant population is approximately 66% 
seniors (over age 65). About 33% claimants receive benefits through social assistance, 
disability or catastrophic illness programs. All of these claims were adjudicated online 
and transmitted monthly to Brogan Inc, under a data services agreement with the Ontario 
government. The Brogan Inc. Private Payer database is comprised of drug benefits 
claims paid by a host of private insurers. The database in total collects information on 
over 10 million Canadians with 83 million prescriptions annually. Thirty-four percent of 
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records come from Ontario, 28% from Quebec, 29% from Western Canada and 9% from 
Atlantic Canada. 
The database provided the number of prescriptions, as well as cost for each 
atypical antipsychotic (with the exception of clozapine), grouped according to diagnosis. 
Brogan uses various algorithms to determine the indication for use (Appendix L). 
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CHAPTER IV -RESULTS 
4.1 Acute Care Hospital Utilization Over Time in Newfoundland 
4.1.1 Summary of the Three Study Years 
There were 314 patients admitted to hospital for the treatment of schizophrenia in 
Newfoundland and Labrador in 1995/96. The number decreased by 9.4% (n=287) and 
22.2% (n=257) in 1998 and 2000 respectively. The total number of unique patients was 
645 where 74.0% (n=477) appeared in one study year, 19.1% (n=123) were admitted to 
hospital in two of the years and a small proportion (7 .0%, n=45) were admitted to 
hospital in all three years (Table 1 ). These 645 patients had 1,625 episodes of care 
resulting in a total of 47,098 hospital days. The mean number of episodes per patient per 
year was 1.9 in all study periods (Table 1). 
There were 586 episodes of care evaluated in 1995/96,551 (6.4% decrease) in 
1998 and 488 (20.1% decrease) during the 12-month period of open access to atypical 
antipsychotic medications. However, the number of hospital days increased over the 
same time period (Table 1 ). 
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Table 1. Summary of the three study years 
1995/96 1998 2000 Total 
Number of patients 314 287 257 645 unique patients 
(-8.6%) (-18.2%) 477 (74.0%) in 1 year 
123 (19.1 %) in 2 years 
45 (7.0%) in 3 years 
Episodes of care 586 551 488 1,625 
(-6.0%) (-16.7%) 
Hospital bed days 15,089 16,318 15,691 47,098 
(+8.2%) (+4.0%) 
Mean # episodes per 1.9 1.9 1.9 P=0.892 
patient per year (SD) (1.4) (1.5) (1.4) 
4.1.2 Sociodemographic Characteristics 
Table 2 illustrates the sociodemographic characteristics of the patients admitted in 
each of the study years. Approximately two thirds of the study population in each study 
year were male. The patients admitted in 2000 were older than those admitted in 1995/96 
(median=41.0 vs. 37.0). This may partly be explained by the fact that patients appearing 
in more than one study year were included and thus are increasing in age. Approximately 
72 percent of each group were receiving social assistance and close to half of the 
populations had less than a grade 10 education. 
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Table 2. Characteristics of patients admitted to hospital during each study year 
(percentages (numerator/denominator) of patients unless otherwise indicated) 
Characteristic 1995/96 1998 2000 
n=314 n=287 n=257 
Sociodemographic 
Male 66.6 69.3 70.8 
(209/314) (199/287) (182/257) 
Median age in years 37.0 (17, 85) 39.0 (16, 88) 41.0 (18, 83) 
(min, max) n=314 n=287 n=257 
St. John's Region 61.8 59.9 62.6 
( 194/314) (172/287) (161/257) 
<grade 10 education 47.9 49.3 47.5 
(146/305) (135/274) (115/242) 
Social Assistance 73.6 71.6 72.7 
(226/307) (204/285) (184/253) 
Psychiatric status 
First psychotic episode 5.1 5.9 1.6 
(16/314) (17/287) ( 4/257) 
Substance abuse 32.3 29.6 30.0 
(98/303) (85/287) (77/257) 
Suicidal ideation on admission 30.9 36.9 30.4 
(97/314) (106/287) (78/257) 
Thought disorder 78.0 83.3 79.4 
(245/314) (239/287) (204/257) 
Perceptual disorder 62.7 55.1 68.9 
( 197 /314) (158/287) (177/257) 
Affect disorder 83.1 86.8 91.4 
(2611314) (249/287) (235/257) 
Disordered behavior 2.9 4.2 1.2 
(9/314) (12/287) (3/257) 
Discharged AMA 12.4 9.1 7.4 
(39/314) (26/287) ( 19/257) 
Non-adherent with medication 54.0 49.1 52.8 
(157/291) (141/287) (131/248) 
Median # of previous admissions 7.0 (1, 85) 8.0(1,91) 10.0 (1, 94) 
(min, max) n=314 n=287 n=257 
Median # years of disease 12 (0, 52) 13.5 (0, 53) 14.5 (0, 59) 
suffering (min, max) n=307 n=284 n=251 
Level of Care 
Recommended for ECT 5.7 7.7 9.0 
(18/314) (22/287) (23/257) 
Seclusion 12.7 13.2 9.3 
( 40/314) (38/287) (24/257) 
Pharmacotherapy 
Atypical agent prescribed on 16.0 50.8 77.5 
100 
discharge (47/293) (136/268) (183/236) 
4.1.3 Psychiatric Status 
The inpatient chart review revealed that about half of patients admitted to hospital 
were non-adherent with prescribed medications on admission in each year (Table 2). One 
third of the population expressed suicidal ideation and approximately 30% were 
substance abusers. The number of previous psychiatric admissions to hospital was shown 
to be higher in the final study year as compared to baseline (1995/96), but again the 
multiple contributions of readmitters would help explain this. Sixteen ( 5.1%) and 
seventeen (5.9%) patients experienced their first psychiatric admission to hospital during 
1995/96 and 1998 study years. However, the number of first psychotic episodes in 2000 
was significantly lower with only 4 patients (1.6%). This may partly explain the increase 
in average number of previous admissions in this same year. The number of patients 
admitted with perceptual disorder was higher in 2000 than in 1998 and there was a 
greater number of patients admitted with affect disorder in 2000 than in the baseline year. 
The percentage of patients discharging against medical advice (AMA) was 12.4, 9.1 and 
7.4 in 1995/96, 1998, and 2000, respectively. This change may be clinically significant 
since it may indicate that patients are remaining in hospital longer to receive treatment. 
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4.1.4 Level of Care Required During Admission 
Table 2 illustrates the level of care required while a patient was in hospital for the 
exacerbation of schizophrenia. The proportion of patients recommended for 
electroconvulsive therapy (ECT) during their hospital admission increased from 5.7% to 
9.0% over the study period. At the same time, the percentage of patients requiring 
seclusion for uncontrollable behaviour was 12.7% (n=40), 13.2% (n=38) and 9.3% 
(n=24) in 1995/96, 1998 and 2000, respectively. 
4.1.5 Pharmacotherapy Prescribed on Hospital Discharge 
Forty-seven patients (16.0%) in the baseline population were discharged on an 
atypical antipsychotic medication following an index admission. The corresponding 
numbers were 136 (50.8%) and 183 (77.5%) in 1998 and 2000, respectively. This 
increase in atypical use corresponds to both the introduction of two more atypical agents 
( olanzapine in October, 1996 and quetiapine in December, 1997) and the introduction of 
the unrestricted access policy implemented in December 1998. 
10.9% (n=31) of the patients receiVmg an atypical antipsychotic agent on 
admission in 1995/96 were also discharged on an atypical agent, compared with 38.3% 
(n=l01) in 1998 and 65.2% (n=148) in 2000 (Table 3). 82.0% (n=233) of the baseline 
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study population were admitted and discharged on a conventional agent vs. 45.1% 
(n=119) and 18.9% (n=43) in the next 2 years. 14 (4.9%), 33 (12.5%) and 28 (12.3%) of 
hospitalized schizophrenia sufferers were switched from a conventional antipsychotic to 
an atypical antipsychotic during the index admission in the three study years (Table 3). 
Table 3 Pharmacotherapy prescribed during annual index admission (number 
(percentages) of patients unless otherwise indicated) 
Admission/discharge drugs 1995/96 
(n=284) 
Atypical to atypical 31(10.9) 
Conventional to conventional 233 (82.0) 
Atypical to conventional 6 (2.1) 
Conventional to atypical 14 (4.9) 
4.1.6 Length of Stay in Hospital 
1998 
(n=264) 
101 (38.3) 
119 (45.1) 
11 (4.2) 
33 (12.5) 
2000 
(n=227) 
148 (65.2) 
43 (18.9) 
8 (3.5) 
28 (12.3) 
The length of stay per episode of care in 2000 was longer than the length of stay 
per episode in 1995/96 and based on the log transformation of the length of stay, this 
difference was statistically significant (P<0.001)(Table 4). The post hoc analysis showed 
that both 1998 and 2000 were significantly longer than 1995/96. There was a significant 
difference between the numbers of hospital days per patient in each year as well. The 
post hoc analysis revealed that 2000 was significantly longer than 1995/96 (Table 4). 
There were instances where the maximum value of the total number of days per patient 
per year exceeds 365 days. This is explained by the fact that a few patients were 
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admitted to hospital prior to the study year but discharged in the year of interest and 
subsequently having hospital days outside of the 365 days of the study year. 
Table 4. Time spent in hospital in each study year 
Median LOS per episode 
(min, max) 
Median days per patient 
per year (min, max) 
* -Significant at P-value < 0.05 
t = based on log transformation 
1995/96 1998 
15.0 
(1, 319) 
32.0 
(1, 369) 
19.0 
(1, 336) 
40.0 
(1' 336) 
2000 
22.0 
(1, 296) 
40.5 
(1, 372) 
P-value 
<0.001 *t 
0.006*t 
Kaplan Meier survival curves were created for each year of the study for the 
length of stay of the annual index admission (Figure 1 ). A comparison of these three 
curves using the log-rank test revealed a statistically significant difference between the 
curves (P=0.0192). The average length of stay during the annual index admission during 
2000 was just over a week longer than the annual index admission during the baseline 
period ofrestricted access (39.2 days vs. 31.7 days). Pairwise comparisons using the log 
transformation of length of stay for the index admission revealed that this difference was 
significant (P=0.006). 
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Figure 1. Length of stay for the annual index admission for each study year 
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4.1.6.1 Comparison of Patients Admitted in Multiple Years vs. Patients Admitted in 
One Year 
477 (74.0%) patients appeared in one study year and experienced 732 episodes of 
care over the course of the study and 22,660 hospital days while 168 (26.1 %) 
schizophrenia sufferers appeared in at least 2 of the selected time periods and incurred 
863 episodes of care and 24,438 hospital days (Table 5). The demographic information, 
psychiatric status, and level of care required in hospital for each population was 
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compared to see if they differed and thus bias the results of the multivariable analyses. 
The results revealed that the readmitters were younger (P=0.046) and were more likely to 
be on social assistance (P<0.001) than those patients who were admitted in only one 
study year (Table 6). Patients who were admitted to hospital in multiple study years were 
more likely to be non-adherent with prescribed medications on admission (P<O.OOl), 
more likely to discharge themselves from hospital against medical advice (P<O.OOl) and 
had significantly more previous psychiatric admissions (P=0.002) than those found in 
only one study period. In addition, multiple admitters were more likely to require 
seclusion for uncontrollable behaviour (P=0.008) (Table 6). Given these results the 
multivariable analyses included each patient once. 
Table 5. Patients admitted in one study period compared to patients admitted in more 
than one study period 
# of patients (%) 
Episodes of care 
Hospital bed days 
1 Year 
477 (74.0) 
762 
22,660 
>1 Year 
168 (26.1) 
863 
24,438 
Total 
645 
1,625 
47,098 
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Table 6. Comparison of patients admitted in multiple years with patients admitted in one 
study year (percentages (numerator/denominator) of patients unless otherwise indicated) 
Characteristic 1 Year >1 Year P-value 
(n=477) (n=168) 
Sociodemographic 
Male 70.2 67.3 0.472 
(335/477) (113/168) 
Median age in years (min, max) 39.0 (16, 88) 36.5 (17, 68) 0.046*t 
<grade 10 education 46.4 50.3 0.393 
(207/446) (831165) 
Social Assistance 65.0 81.2 <0.001 * 
(305/469) (134/165) 
Psychiatric status 
First psychotic episode 6.1 4.8 0.528 
(29/477) (8/168) 
Substance abuse 31.6 39.3 0.076 
(149/471) (64/163) 
Suicidal ideation on admission 30.4 37.5 0.090 
(145/477) (631168) 
Thought disorder 80.9 79.2 0.622 
(386/477) (133/168) 
Perceptual disorder 62.9 61.3 0.715 
(300/477) (1 03/168) 
Affect disorder 84.5 86.9 0.449 
(403/477) (146/168) 
Disordered behaviour 2.9 2.4 0.708 
(14/477) ( 4/168) 
Discharged AMA 6.5 16.7 <0.001 * 
(311477) (28/168) 
Non-adherent with medication 45.7 63.0 <0.001* 
(208/455) (1 02/162) 
Median # previous admissions 6.0 (1, 71) 7.5 (1, 85) 0.002*t 
(min, max) 
Median # years of disease suffering 12.0 (0, 59) 13.0 (0, 41) 0.306t 
(min, max) 
Level of care 
Recommended for ECT 6.7 3.0 0.074 
(32/477) (5/168) 
Seclusion 9.2 16.7 0.008* 
(44/477) (28/168) 
Pharmacotherapy 
Atypical agent prescribed on 45.4 23.0 <0.001 * 
discharge (199/438) (371161) 
*=Significant at ?-value< 0.05 
t = based on log transformation 
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4.1.6.2 Significant Factors Influencing Length of Stay 
The multivariable Cox proportional hazards model to determine the independent 
predictors of time spent in hospital included 78.9% (509/645) of the original population 
due to missing information for some variables for the 136 excluded patients. Of the 18 
variables that were entered in the model, six were found to significantly influence the 
amount of time a patient admitted for the treatment of schizophrenia remained in hospital 
(Table 7). 
Given the change in access to atypical antipsychotic agents over the course of the 
study, an interaction term was created to measure the effect of switching from a 
conventional antipsychotic to an atypical agent on length of stay in each year. The effect 
of switching in 1995/96 was shown to significantly increase length of stay when 
compared to the effect of switching in 2000 (hazard ratio 2.61, 95% CI = 1.12-6.11, 
P=0.027). Independent of age and gender, requiring ECT, seclusion and having thought 
disorder significantly increased a patient's time in hospital (hazard ratio 1.42, 95% CI = 
1.11-1.82; P=0.006. Suicidal ideation on admission (hazard ratio 0.71, 95% CI = 0.58-
0.87; P=0.0009) and discharging oneself against medical advice (hazard ratio 0.40, 95% 
CI = 0.28-0.56; P<O.OOl) were significant predictors of a reduced length of stay. Factors 
which failed to impact upon length of stay included years since first diagnosis, number of 
previous hospitalizations, the first psychotic episode, substance abuse, presence of 
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perceptual disorder, affect disorder, disordered behaviour, having low education, being 
non-adherent with prescribed medication on admission, and being in receipt of social 
assistance. 
Table 7. Multivariable Cox Proportional Hazards Model of the independent variables 
predicting an increased length of stay by study index admission, for 1995/96, 1998 & 
2000 (n=509/645, 78.9%) 
Characteristic Hazard Ratio 95% CI P-value 
Sociodemographic 
Male 0.82 0.22-1.02 0.074 
Age 1.01 0.99-1.02 0.400 
<grade 10 education 0.90 0.74-1.08 0.258 
Year of admission 
1995 vs. 2000 0.77 0.59-1.01 0.056 
1998 vs. 2000 0.81 0.61-1.07 0.143 
Social Assistance 1.01 0.81-1.25 0.949 
Psychiatric status 
First psychotic episode 1.15 0.74-1.78 0.547 
Substance abuse 0.99 0.80-1.22 0.918 
Suicidal ideation 0.71 0.58-0.87 0.0009* 
Thought disorder 1.42 1.11-1.82 0.006* 
Perceptual disorder 1.00 0.82-1.22 0.995 
Affect disorder 1.16 0.90-1.50 0.260 
Disordered behaviour 1.35 0.78-2.34 0.286 
Discharged AMA 0.40 0.28-0.56 <0.001* 
Non-adherent with medication 1.05 0.86-1.05 0.634 
Mean # previous admissions 1.00 0.98-1.01 0.322 
Mean # years of disease suffering 1.00 0.99-1.02 0.612 
Level of care 
Recommended for ECT 2.58 1.75-3.80 <0.001 * 
Seclusion 1.93 1.45-2.57 <0.001 * 
Pharmacotherapy 
Drug switch (conventional to 
atypical) 1.26 0.74-2.14 0.401 
Year of adrnission*drug switch 
1995 vs. 2000 2.61 1.12-6.11 0.027* 
1998 vs. 2000 1.62 0.81-3.25 0.170 
* =Significant at ?-value< 0.05 
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4.1.6.3 Length of Stay Associated with the Class of Antipsychotic Agent Prescribed 
on Admission and Discharge for Each of the Study Years 
The number of patients admitted and discharged on an atypical antipsychotic 
medication increased by more than 475% from baseline to the final study year (Table 8). 
At the same time, the median length of stay for these patients increased from 13.0 days to 
31.0 days, a difference of 18.0 days. The number ofpatients who were switched from a 
traditional antipsychotic to an atypical antipsychotic medication while in hospital 
remained relatively small in each study year, indicating that most patients were switched 
as outpatients. The median time spent in hospital for these patients was 72.5 days, 40.0 
days, and 29.5 days in 1995/96, 1998, and 2000, respectively (Table 8). 
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Table 8. Length of stay associated with the class of antipsychotic agent prescribed on 
admission and discharge for each study year 
n (%) Median LOS (min, max) 
1995/96 (284/314, 90.4%) 
Atypical-atypical 31(10.9) 13.0 days (3, 137) 
Conventional-conventional 233 (82.0) 17.0 days (1, 314) 
Atypical-conventional 6 (2.1) 41.5 days (3, 66) 
Conventional-atypical 14 (4.9) 72.5 days (30, 319) 
1998 (264/287, 92.0%) 
Atypical-atypical 101 (38.3) 28.0 days (1, 336) 
Conventional-conventional 119 (45.1) 18.0 days (2, 216) 
Atypical-conventional 11 (4.2) 43.0 days (14, 89) 
Conventional-atypical 33 (12.5) 40.0days(12, 180) 
2000 (227/257, 88.3%) 
Atypical-atypical 148 (65.2) 31.0 days (1, 296) 
Conventional-conventional 43 (18.9) 15.0 days (1, 203) 
Atypical-conventional 8 (3.5) 59.0 days (9, 69) 
Conventional-atypical 28 (12.3) 29.5 days (7, 198) 
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4.1.7 Readmission to Hospital 
4.1.7.1 Rates of Readmission to Hospital 
62.4% of the 314 patients admitted to hospital for the treatment of schizophrenia 
during the baseline study period were readmitted within 1 year of discharge. This rate of 
readmission was not significantly different from the other two study years, although the 
trend was lower (?=0.058) (Table 9). 50% of the study population were readmitted in 
215 days in 1995/96, 221 days in 1998, and 223 days in 2000 (P=0.114) (Table 9). 
Table 9. Index admission analysis for readmission to hospital 
1995/96 1998 2000 P-value 
Median time to readmission 215 221 223 0.114t 
(days) 
Readmitted within 1 year of 62.4 59.2 58.6 0.058 
discharge (%) 
t = based on log transformation 
4.1.7.2 Factors Influencing Early Hospital Readmission for all Study Years 
Before conducting the multivariable logistic regression analysis to identify 
predictors of early readmission to hospital, comparisons were made between patients 
readmitted within 1 year versus those who were not. Six patients were removed from this 
analysis because they had either died (n=5) or were confirmed to have left the province 
(n=1) within 365 days of discharge. The results of these analyses demonstrated that 
patients readmitted within 1 year were more likely to be receiving social assistance 
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(P=0.006), to have had significantly more previous psychiatric hospitalizations 
(?<0.001), and to have discharged themselves against medical advice (P=0.006) when 
compared to patients not readmitted within 1 year (Table 1 0). Additionally, it was found 
that patients admitted in 1995/96 were more likely to be readmitted within one year when 
compared to patients admitted in 1998 (P=0.021). However, this may be due to the fact 
that people readmitted from the 1995/96 cohort were removed from the 1998 and 2000 
cohorts in the analyses. There were no significant differences with respect to gender, 
education, or patients who required a period of seclusion, between the two groups. 
Suicidal ideation, thought, perceptual, affect disorders, disordered behaviour, non-
adherence with prescribed medications prior to admission, and the class of antipsychotic 
prescribed on discharge did not significantly affect the probability of readmission within 
one year. The median length of stay for patients readmitted within one year of discharge 
was shorter than that for patients who were not readmitted within one year (18.5 days vs. 
23.0 days) and this was statistically significant (P=0.046). 
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Table 10. Comparison ofpatients readmitted within 1 year ofhospital discharge with 
patients not readmitted within 1 year of hospital discharge (1995/96, 1998, and 2000) 
(n=639) (percentages (numerator/denominator) of patients unless otherwise indicated) 
Characteristic Readmitted with Not readmitted within P-value 
in 1 year (n=366) 1 year (n=273) 
Male 67.8 71.1 0.371 
(248/366) (194/273) 
Median age in years( min, max) 38.0 (16, 85) 39.0 (17, 88) 0.102t 
<grade 10 education 50.0 43.8 0.128 
( 175/350) (112/256) 
Social assistance 73.3 63.1 0.006* 
(264/360) (169/268) 
Year of admission: 
1995/96 (reference) 53.6 43.2 
(196/366) (118/273) 
1998 27.3 34.1 0.021 * 
(100/366) (93/273) 
2000 19.1 22.7 0.073 
(70/366) (62/273) 
Substance abuse 36.0 30.0 0.113 
(129/358) (81/270) 
First psychotic episode 6.0 5.5 0.782 
(22/366) (15/273) 
Non-adherence (%) 51.7 47.9 0.350 
( 182/352) (124/259) 
Suicidal ideation (%) 34.4 29.7 0.204 
(126/366) (811273) 
Thought Disorder (%) 80.1 81.3 0.689 
(293/366) (222/273) 
Perceptual Disorder(%) 63.9 61.5 0.535 
(234/366) (168/273) 
Affect Disorder (%) 84.7 85.3 0.820 
(310/366) (233/273) 
Disordered Behaviour(%) 2.2 3.3 0.388 
(8/366) (9/273) 
Median # previous admissions (min, max) 7.0 (1, 85) 5.0 (1, 46) <0.001 *t 
Median index LOS(min, max) 18.5 (1, 319) 23.0 (1, 336) 0.046*t 
Discharged against medical advice (%) 11.7 5.5 0.006* 
(43/366) (15/273) 
Median years of disease suffering (min, 13.0 (0, 59) 12.0 (0, 52) 0.741 t 
max) 
Recommended for ECT (%) 4.4 7.7 0.075 
( 16/366) (21/273) 
Seclusion (%) 10.7 11.7 0.671 
(39/366) (32/273) 
Atypical agent prescribed on discharge 38.4 41.2 0.481 
(%) (127/331) (108/262) 
* =Significant at ?-value< 0.05 
t =based on log transformation 
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The multivariable logistic model included 81.5% (521/639) of the entire study 
population and revealed two significant, independent predictors for re-hospitalization 
within 12 months of discharge: leaving hospital against medical advice (OR= 2.57, 95% 
CI=l.12-5.92; P=0.027), and for every 1 more previous admission there was a 5% 
increase in likelihood that a patient would be readmitted (OR= 1.05, 95% CI=l.02-1.08; 
P=0.002) (Table 11). Contrary to expectation, neither being non-adherent with 
prescribed medications on the previous admission, nor receiving a prescription for an 
atypical antipsychotic medication on last discharge influenced the probability of being 
readmitted to hospital within one year of discharge. 
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Table 11. Multi variable Logistic Regression Model for predictors influencing 
hospitalization within 1 year of discharge from the index admission 1995/96, 1998 & 
2000 (521/639, 81.5%) 
Characteristic Odds Ratio 95% CI P-value 
Sociodemographic 
Male 0.67 0.43-1.03 0.070 
Age in years 0.98 0.96-1.00 0.103 
<grade 10 education 1.33 0.90-1.97 0.157 
Year of admission 
1995 vs. 2000 1.08 0.38-3.04 0.892 
1998 vs. 2000 0.61 0.20-1.81 0.370 
Social assistance 1.09 0.71-1.66 0.670 
Psychiatric status 
First psychotic episode 1.24 0.53-2.89 0.624 
Substance abuse 1.54 1.00-2.37 0.052 
Suicidal ideation on 1.24 0.81-1.90 0.318 
admission 
Thought Disorder 1.02 0.61-1.68 0.955 
Perceptual Disorder 1.02 0.68-1.51 0.943 
Affect Disorder 0.80 0.47-1.38 0.427 
Disordered Behaviour 0.92 0.31-2.73 0.884 
Discharged AMA 2.57 1.12-5.92 0.027* 
Non-adherent with 1.10 0.73-1.65 0.648 
medication 
# previous admissions 1.05 1.02-1.08 0.002* 
Index length of stay 1.00 0.99-1.00 0.502 
Years of disease suffering 1.01 0.98-1.04 0.628 
Level of Care 
Recommended for ECT 0.70 0.32-1.52 0.364 
Seclusion 0.80 0.43-1.46 0.460 
Pharmacotherapy 
Atypical on discharge 1.14 0.38-3.41 0.814 
Year of 
admission* discharge drug 
class 
1995/96 vs. 2000 1.10 0.30-4.12 0.885 
1998 vs. 2000 1.18 0.34-4.15 0.792 
* = Significant at P-value < 0.05 
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4.2 Utilization of Newer Antipsychotic Medications by NLPDP 1995-2003 
In 2000/01, the Newfoundland and Labrador Prescription Drug Program paid for 
50,518 antipsychotic prescriptions. The atypical antipsychotic agents ( clozapine, 
risperidone, olanzapine, and quetiapine) accounted for a large share of antipsychotic 
prescriptions, making up 49% of the total. In contrast, atypicals accounted for only 3.3% 
of Program antipsychotic prescriptions in 1995/96. Between 1995/96 and 2000/01, 
prescriptions for antipsychotics grew 24% while expenditures increased by more than 
459%. Total NLPDP spending on antipsychotics was approximately $900 thousand in 
1995/96, however this therapeutic category exceeded $4.1 million in 2000/01 with the 
atypical antipsychotic agents making up 90.4% of this amount (Figure 2). Olanzapine 
accounted for the largest share of spending for antipsychotics at $2.8 million (65.7%) and 
risperidone ranked second at $707 thousand (16.8%) (Figures 2 & 3). As of2002/03, the 
use of atypical antipsychotic medications was still on the rise since the NLPDP paid for 
59,904 prescriptions for antipsychotics and spent more than $6.5 million during that 
fiscal year with the atypical antipsychotic agents making up 94.5% of this amount 
(Figures 2 & 4). Despite this continued increase in the reimbursement for atypical 
antipsychotic medications, the number of persons eligible for the NLPDP was declining. 
In fact, by 2002/03, the number of claimants for the Program was at the lowest it had 
been in a decade (Figure 4). Figure 4 demonstrates that the number of cardholders in the 
social assistance program had decreased while the number of cardholders in the seniors 
program remained constant. Despite a decline in the number ofbeneficiaries for the 
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social assistance program the number of prescriptions for antipsychotic medications 
increased by 56.0% while the percentage of claims for the seniors program only increased 
by4.0%. 
Figure 2. NLPDP expenditures for atypical antipsychotic medications vs. conventional 
antipsychotic medications 1995-2003 
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Figure 3. Share of the NLPDP expenditure by antipsychotic medication 2000/01 
Other 
9.6% Risperidone 
16.8% 
Clozapine 
4.9% 
Quetiapine 
2.9% 
Figure 4. Number ofbeneficiaries and total antipsychotic prescriptions reimbursed by 
NLPDP 1992-2003 
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4.3 Indication for Atypical Antipsychotic Use in Newfoundland 
The NLPDP database for the year 2000 revealed 2,140 NLPDP beneficiaries had 
received an atypical antipsychotic medication. A search of previous years revealed that 
1,095 (51.3%) had had a prescription for an atypical antipsychotic medication prior to 
2000. As a result, 1,045 patients were identified as first time atypical users during this 
12-month period. Seven claims were removed due to missing information and ten drug 
card numbers were duplicated in the database and thus were removed. The remaining 
1,028 patients formed the final database for 2000. The claims were sorted by the date the 
atypical antipsychotic prescription was filled and every third claim was selected for 
interview since this was a more manageable number (n=340) for this portion of the study. 
This database included 151 prescribing physicians with some having only 1 patient and 
one physician had as many as 22 patients. 3 physicians (2.1 %) wrote 11.8% of the 
prescriptions. Of the 151 physicians, 43 (28.5%) agreed to participate. This participation 
rate only provided information on 33.8% (n=115) of the patients receiving an atypical 
antipsychotic medication. Given this poor response rate, this portion of the study was not 
analyzed as it was determined that we would not be able to identify how these new 
medications were being used in the community. 
4.4 NLPDP Beneficiaries Started on an Atypical Antipsychotic Agent in 2000 
Given that we could not ascertain the reasons why atypical antipsychotic 
medications were being prescribed in the community, it was decided to look at the 
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specialty of the prescribing physician. The NLPDP files were reviewed and patients who 
had received an atypical antipsychotic medication through the drug program for the first 
time in the year 2000 were identified. Of the 1, 021 beneficiaries that were started on an 
atypical antipsychotic medication for the first time, 531 (52.0%) for olanzapine, 447 
(43.8%) for risperidone, and 43 (4.2%) for quetiapine. There were a total 276 different 
physicians who prescribed these medications. 42 (15.2%) of the physicians were 
psychiatrists and they were responsible for 427 (41.8%) of the total prescriptions. The 
remaining 84.8% (n=234) of the 'other' physicians wrote 594 (58.2%) of the 
prescriptions. This may indicate that these medications are being prescribed for other 
indications besides schizophrenia in primary care 
4.5 Atypical Antipsychotic Utilization in Canada, 2000 
Using Brogan Inc. data based on the Ontario Drug Benefit Program and Private 
Payer data, the estimated number of prescriptions dispensed for risperidone, olanzapine 
and quetiapine increased 2.2 fold from 2.4 million prescriptions to 5.3 million 
prescriptions from 2000 to 2002. During this same time period, the amount of money 
spent by Canadian drug stores and hospital pharmacies increased by 56.9%, from $218 
million to $342 million. In 2000, risperidone made up the largest portion of atypical 
prescriptions accounting for 49.7% (n=1,176,920) of the total number of claims. 
Olanzapine made up 42.5% of the claims (n=1,006,617) and quetiapine was last 
comprising the remaining 7.7% (n=183,023) (Figure 5). However, risperidone made up 
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only 27.5% of the total expenditure for these 3 drugs while olanzapine made up 67.5% of 
the expenditure at $14 7 million (Figure 6). 
The greatest proportion of atypical antipsychotic medications was prescribed to 
treat dementia (35.3%). Second, atypical agents were used for patients suffering from 
bipolar disorder (29.4%), and the third largest indication was psychosis (27.8%) (Figures 
5 & 7). 
Figure 5. National atypical antipsychotic medication utilization in 2000 (source: Brogan 
Inc.) 
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Figure 6. National atypical antipsychotic medication expenditure m 2000 (source: 
Brogan Inc.) 
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Figure 7. Total number of claims for atypical antipsychotic medications by diagnosis in 
Canada, 2000 (source: Brogan Inc.) 
900,000 
800,000 
! 700,000 
600,000 
500,000 
400,000 
300,000 
200,000 
100,000 
Bipolar 
Disorder 
ADHD Depression Psychosis Dementia 
Diagnosis 
________ ___j 
123 
CHAPTER V -UNRESTRICTED ACCESS: A POLICY ANALYSIS AND 
ECONOMIC IMPLICATIONS 
5.1 The Open Access to Atypical Antipsychotic Medications in Newfoundland: 
A Policy Analysis 
Drug coverage policy, in its broadest sense, is intended to promote value in 
medical care by using reimbursement to favour the use of effective care and to avoid the 
use of ineffective care. 178 Restrictive reimbursement policies have become increasingly 
popular in recent years as a convenient way to contain costs and the NLPDP is no 
exception. This poses the question as to why the NLPDP decided to adopt an unrestricted 
reimbursement policy for new medications to treat schizophrenia especially given that the 
evidence in the literature regarding the effectiveness of these drugs did not support the 
introduction of such a policy. A description of the sequence of events accompanied by 
interviews with the key stakeholders at the time provides some insight into the factors 
that influenced the decision by the Minister of Health to allow for the unrestricted 
reimbursement of four atypical antipsychotic medications in Newfoundland. 
The concern regarding lack of access to atypical antipsychotic medications came 
to the forefront in the fall of 1996. At that time, there were a number of groups that were 
lobbying for the special authorization policy to be abolished. Schizophrenia sufferers and 
their families believed that the newer drugs would help alleviate the suffering caused by 
the disorder and that these patients should not be denied access to therapy based on the 
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inability to pay for the newer agents. 179 Physicians felt that the restrictive policy was an 
encroachment upon their autonomy and presented an intrusion on their ability to 
prescribe when they felt it was appropriate for their patients' well-being. In addition, it 
was felt that it was a "hassle" to get coverage even when the patient met NLPDP defined 
criteria. 180 
The pressure to change the restrictive policy coincided with the time that Eli Lilly 
and Company released their atypical antipsychotic medication, olanzapine, onto the 
market. 181 This release was accompanied by a marketing campaign and information 
dissemination to physicians and drug plan managers. Restrictive policies limit 
manufacturer income. 
Shortly after this time, a chapter of the Schizophrenia Society of Canada was 
formed in Newfoundland and Labrador, with financial support from Eli Lilly, and was 
legally incorporated in May 1997. The result was the formation of a sort of informal 
coalition consisting of the Newfoundland Psychiatric Association (NP A), the 
Schizophrenia Society of Newfoundland and Labrador (SSNL), and Eli Lilly to put 
pressure on the government to eliminate the restricted policy. 
The goal of the NLPDP is to ensure that all residents of the province have equal 
access to quality health care in order to improve or maintain health status. 181 However, 
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due to the fiscal realities facing the provmce, namely fixed budgets and competing 
demands for the same funds, the Department must also attempt to ensure efficiency, and 
this reality was in conflict with the request for an umestricted policy. 
In October 1997, the NLPDP commissioned a local psychiatrist to review the 
scientific literature on the relative efficacy, safety, and incremental benefits of atypical 
antipsychotic medications and submit a report of his findings. The review concluded that 
no evidence existed for the use of these drugs as first-line treatment for schizophrenia and 
that these drugs should be used as a last resort. 182 The NP A opposed the 
recommendations of the report 180 and an Ad Hoc Committee was created to help come to 
some consensus. 
On March 31, 1998 the Schizophrenia Society of Newfoundland and Labrador 
supplied the Department of Health and Community Services with a document entitled 
"Umestricted Access to Atypical Antipsychotic Medications". 179 This document 
contained the Society's arguments for umestricted access and was put together with the 
assistance/advice of psychiatrists, other health care professionals, pharmacists, persons 
with schizophrenia and their families, and the four drug companies who manufactured the 
atypical antipsychotic medications (Novartis, Eli Lilly, Janssen Ortho, and Astra Zeneca). 
The following month, a petition signed by all psychiatrists in the province (with the 
. f ) d d h d . . f h . 1 1 . 183 184 exceptiOn o one , recommen e t e e-restnctwn o t e atyp1ca neuro eptlcs. 
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Between August and September, 1998 there was media coverage of the suicide of 
a patient with paranoid schizophrenia at a hospital in St. John's which highlighted the 
pressure to improve access to atypical antipsychotic medications. 185 Various letters to the 
editor from the SSNL and NP A followed to appeal to the NLPDP to liberalize access to 
these expensive drugs for the treatment of schizophrenia. 186-188 A second suicide at the 
same hospital later that year only served to strengthen the argument. 
In conclusion, the traditionally repressed interests of those affected by 
schizophrenia joined forces with the dominant interests of physicians and drug 
manufacturers to successfully eliminate a restricted reimbursement policy. Since the 
'coalition' started its pressure in 1996, they used various tactics to define and portray 
their policy 'problems'. For example, the successful suicide at a local hospital 
highlighted the push for a policy change and a public plea to the government via the 
media ensued. Through the use of strategically crafted causal stories, the government's 
restricted access policy was noted to be responsible for unnecessary suffering, 
discrimination (inequity), decreased quality of life and even death. These pressures, plus 
CCOHTA's economic analyses suggesting that savings on hospital costs would offset the 
costs of the new medications, finally persuaded the government to change how they 
reimbursed for these agents. 
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5.2 The Open Access to Atypical Antipsychotic Medications in Newfoundland 
and Labrador: Potential Economic Implications of an Unrestricted Policy 
Even before the results of the current study were available, there were some 
potential economic and efficiency implications that could have been foreseen following 
the introduction of an umestricted access policy for atypical antipsychotic medications. 
The following section will begin with an explanation of efficiency in the allocation of 
health care resources followed by an examination of the potential implications of this 
type ofpolicy. 
5.2.1 Economic Efficiency 
Economic efficiency can be described in at least two contexts: technical 
efficiency and allocative efficiency. Technical efficiency in the production of health 
implies that the maximum improvement in health status is obtained from a given set of 
inputs. Allocative efficiency describes the appropriateness of the mix of goods and 
services produced. This type of efficiency suggests that the best use of scarce resources 
occurs when they are used to produce the most valued commodities and, therefore, 
maximize health benefits of the community. Difficulty arises in choosing which health 
care services should be provided with limited resources. Consequently, the allocation of 
. h 1 . d b d 189-192 resources reqmres t at va ue JU gements must e rna e. 
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The issue of technical efficiency appears to be more easily addressed than those 
of allocative efficiency with respect to government drug formulary decisions. Measuring 
technical efficiency with respect to providing coverage for various drugs involves 
determining the quantity and monetary value of resource inputs used to provide a 
medication. However, allocative efficiency considerations require additional information 
such as: the effects of pharmaceuticals on outcomes; equity of outcomes; and, equity of 
access. 193 Even with this information we are still not assured of appropriately addressing 
allocative Issues. Donaldson and Gerard194 assert that allocative efficiency can be 
sacrificed if cost savmgs are achieved at the expense of quality of care and the 
subsequent well-being of the patient. In order to achieve a desired health status in the 
most technical and allocative efficient manner, it is also necessary to measure the 
relationship between health status and the consumption of pharmaceuticals. 
Unfortunately, some outcomes are difficult and costly to measure on an ongoing basis. 
Technical and allocative efficiency are especially difficult to achieve in the 
health care sector because resource allocation in many instances is undertaken on an 
incremental basis. Often programs are provided on a reactive basis to some crisis as 
opposed to being properly planned. 195 
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5.2.2 Implications 
When drug program managers make decisions whether and/or how to reimburse 
for a particular drug, other patient groups must also be considered, as money spent in one 
therapeutic area means that money is not available to fund drugs in other areas due to the 
existence of a fixed budget (opportunity costs). For example, the label recommendation 
at the time the policy change was made was that atypical antipsychotic drugs be limited 
to refractory or neuroleptic-intolerant schizophrenic patients. The de-restriction of 
atypicals by the NLPDP resulted in a decentralization of decision-making authority from 
the Program to all physicians. However, this transfer of decision-making authority from 
the NLPDP, who incurred the opportunity costs (benefits foregone), to physicians, was 
not accompanied by a decentralization of financial accountability. As a result, there was 
a high risk for over-utilization and thus an increase in costs to the drug budget. In 
essence, the new policy would not prevent the use of atypical antipsychotics for other 
schizophrenic patients and for those with non-schizophrenic psychosis, even though there 
was little evidence to support off-label uses at that time. The NLPDP allowed physicians 
to make all of the clinical decisions, which supports the doctor's freedom to use the 
medications according to clinical judgement and not be limited by labelled indications. 
This highlights the potential danger of using data from cost-effectiveness analyses 
such as the CCOTHA report7 for policy development since the total use of a medication 
or medications may not be limited to a specific disease in a specific population. If data 
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from these models are used for policy development, it is important that the clinical 
population, estimated costs, and treatment patterns in the model be similar to the 
conditions under which the policy is to be implemented. 
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CHAPTER VI- CONCLUSIONS AND DISCUSSION 
6.1 Acute Care Hospital Utilization in Newfoundland 
This study used a provincial, multi-centre, observational, retrospective hospital 
chart review to measure hospital utilization by patients with schizophrenia before and 
after a change in access to expensive atypical antipsychotic medications. The objective 
was to assess the relationship between antipsychotic treatment effectiveness and acute 
care service utilization. This study was unique in its detailed population-based 
perspective, examining multiple factors influencing outcomes that are important to the 
health care delivery sector, namely length of stay and re-hospitalization risk. 
Additionally, this study represents the first time the provincial drug program in 
Newfoundland and Labrador has evaluated a a policy decision and its impact on the acute 
care sector. 
The results of this study revealed that there were fewer admissions to hospital by 
schizophrenia sufferers during a time of increased access to and utilization of atypical 
antipsychotic medications. However, the total number of days in hospital was unchanged 
because the length of stay per admission increased with no impact on readmission despite 
similar clinical and sociodemographic characteristics of the patients in each year. 
Certain limitations of this study need to be considered. The first concerns the 
reliance upon existing records which suffer from missing, or less complete information 
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when compared to data collected prospectively. In many cases, it was assumed that if a 
particular characteristic was not noted in the chart then that finding was not present (e.g. 
suicidal on admission). The variable with the greatest proportion of missing data was 
whether a patient was non-adherent with prescribed antipsychotic medication prior to the 
current admission. However, we were still able to ascertain information for 92.7% of the 
patients in the study and thus should not bias the results. 
The second limitation has to do with the factors included in this study. It is 
possible that the variables themselves were not sensitive enough to detect changes in 
length of stay or readmission risk. For example, the dichotomous variable indicating the 
presence or absence of thought disorder may not accurately represent the severity of the 
disorder. Even if all relevant clinical information was abstracted from the chart, there are 
numerous non-clinical factors that can influence the need for admission to hospital and 
the length of time spent in hospital. For example, this study did not address physician 
factors that affect treatment practices, nor did it control for a number of social factors that 
result in hospital admission and contribute to delays in discharge for persons suffering 
from schizophrenia. Placement problems, carer stress or an unsupportive living 
environment may result in the need for hospitalization and extend a person's length of 
stay. There is evidence in the literature demonstrating that a patient's living situation or 
lack of support are important predictors of length of stay and frequent hospitalizations. 196-
201 Clinicians may be reluctant to discharge patients who live unsupported in the 
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community. However, after this study was completed, a policy was implemented to 
encourage physicians to discharge well psychiatric patients. 
The newer atypical antipsychotic medications have been linked to increased levels 
f d. . dh 82 202-204 H h f dh d . h' d o me 1catwns a erence. owever, t e rate o a erence measure m t 1s stu y 
was not altered with the increased utilization of atypical antipsychotic medications. At 
the same time, any implications of adherence in this study are difficult to conclude 
mainly due to the inadequacies in the reporting and measurement of adherence rates. We 
relied on written documentation of nonadherence in patients' charts and given that self-
reporting is frequently inaccurate and biased by a reluctance to admit "improper" 
behaviour, coupled with the fact that patients suffering from schizophrenia often lack the 
insight required to adhere to their medication regime. Nonadherence measured in this 
study may be an underestimate of the actual rate and may partly explain why 
nonadherence was not found to be a significant predictor of recidivism in the current 
study. 
Even if adherence rates could be accurately measured, the improved adverse 
effect profiles of atypical antipsychotic medications may only be part of the reason for 
continuing drug therapy. The literature suggests that there are other powerful predictors 
contributing to low adherence to schizophrenia treatment: patient-related factors (i.e. 
substance abuse); family-related factors (i.e. alienation from the patient); disease-related 
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factors (i.e. lack of insight into the disorder); and healthcare system and community 
support services (i.e. family therapy, community-based services, and general help with 
adherence strategies, may have a role in improving outcomes.205-211 An in-depth review 
of the programs offered to persons with schizophrenia in Newfoundland and Labrador 
and the effectiveness of these programs on this population was not undertaken in this 
project but would have helped to interpret some of our findings and thus provided 
invaluable information for policymakers. 
The current study used hospital readmission as the method of measuring patient 
outcome associated with antipsychotic therapy but it must be acknowledged that it was 
not possible to control or identify whether a patient changed drug therapy as an outpatient 
following hospital discharge. Additionally, while objective and not prone to error, 
readmission may not be the best measure of outcome for schizophrenia from a patient's 
or caregiver's perspective. Subtle differences in time to subjective improvements in 
violent and extreme psychotic behaviour or ability to gain employment may have been 
more relevant indicators of effectiveness. The perspective of the patient receiving the 
therapy is essential in determining its value however; this was beyond the scope of this 
study. If these outcomes had been assessed, differences associated with drug therapy 
may have been revealed. 
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The author acknowledges that there was insufficient evidence to support the 
assumption that all atypical antipsychotic agents could be categorized into one class 
which assumes that the drugs are equivalent in terms of pharmacological action or 
efficacy and side effect profile. However, given that the policy regarding reimbursement 
for these medications did not distinguish between individual drugs in this class, the 
analysis did not either. 
In addition to these limitations, a number of mitigating factors could have 
potentially been operating in the background. For example, this study was particularly 
sensitive to changes in the social policy environment since it took place during a period 
of rapid change in the health care system, particularly in the St. John's region. 
Differences in hospital admission policies, length of stay for psychiatric patients, housing 
issues, bed availability, and availability of and demands on community resources 
influence hospital utilization. However, an examination of the total separations and total 
days' stay for schizophrenia in this region suggests that the results of this study cannot be 
explained by changes in the hospital infrastructure (e.g. bed closures). While total 
separations decreased, the length of stay increased during a time when the number of 
acute care beds in the mental health program in the St. John's Region decreased by about 
7% from 1995/96 to 1999/2000.212 Additionally, the services provided by the 
Community Care Program in the St. John's region and accessibility to them remained 
stable over the course of the study and thus cannot explain any change in hospital days or 
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readmission rates.213 Perhaps inpatient savings may have been seen if an improvement in 
these outpatient programs coincided with improved drug therapies. Alternatively, 
physician practice may determine the time a patient remains in hospital regardless of 
patient symptom improvement. 
6.2 Utilization of Newer Antipsychotic Medications in Newfoundland 
The changes in the use of atypical antipsychotic medications resulting from a 
policy designed to increase access to these agents was evaluated using a retrospective 
analysis of administrative claims data between 1995/96 and 2000/01. This study 
measured only the number of claims reimbursed by the Newfoundland and Labrador 
Prescription Drug Program (NLPDP) for one of the four atypical antipsychotic 
medications (clozapine, risperidone, olanzapine, and quetiapine) listed as an open benefit. 
The analysis of the NLPDP administrative database revealed that the second 
generation antipsychotics were accepted into common use and their use grew 
dramatically between 1995/96 and 2000/01. Concomitantly, the use of antipsychotics as 
a class grew by 24% while expenditures increased by more than 459%. Total 
government spending on antipsychotic agents exceeded $4.1 million in 2000/01 and the 
four atypical agents ( clozapine, risperidone, olanzapine, and quetiapine) accounted for 
90.4% of this amount. This implies that the introduction of atypical antipsychotic 
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medications did not merely replace older therapies, but instead expanded the market for 
use ofthese agents as a category. 
The increase in antipsychotic prescriptions may be due to the fact that 
schizophrenia has long been neglected, by society and by pharmaceutical companies. For 
most patients partial remission of symptoms is the best that they can hope for. As a 
result, patients and their caregivers are always searching for something new. Any new 
medication, whether substantially better or not, is embraced with great enthusiasm, so it 
is not surprising that atypical antipsychotics have become synonymous with progress and 
hope for patients with schizophrenia. 
This trend may also reflect an increased use of atypical agents for the treatment 
and management of other diseases, such as the behavioural disturbances associated with 
dementia. According to Glick et a1.,214 as of 1999 more than 70% of prescriptions for 
these drugs are being prescribed for conditions other than schizophrenia, such as major 
depression, bipolar disorder, posttraumatic stress disorder, obsessive-compulsive 
disorder, and geriatric agitation. Another study reported that of the 6.3 million 
antipsychotic prescriptions written by psychiatrists in 2001 in the United States, 43% 
were for schizophrenia, 22% for bipolar disorder, and 16% for depression. Primary care 
physicians wrote fewer prescriptions (2.3 million) for antipsychotics, of which 23% were 
for schizophrenia, 12% for bipolar disorder, and 18% for depression.215 
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At present, there are more small, short, open-label trials and case reports than 
large, double-blind, placebo-controlled studies of atypical antipsychotics establishing the 
efficacy of these drugs for the treatment of non-psychotic psychiatric illnesses.216-221 
Additionally, data are sparse on the efficacy of novel antipsychotics in children and 
adolescents with attention deficit hyperactivity disorder (ADHD), again the few reports in 
the literature consist mainly of case reports and open, non-controlled trials. 222 223 
Atypical agents may be particularly helpful for children, the elderly, or adolescent 
patients who are especially susceptible to the side effects of medications and whose risk 
of tardive dyskinesia is high but further controlled studies are necessary? 14 
Unfortunately, the NLPDP database was created primarily for reimbursement 
purposes and as a result, there was no information regarding the patient, the patients' 
medical history, symptomology or quality of life. As well, the database was not set up to 
allow for linkages between the atypical antipsychotic prescription and any other patient-
specific information to allow for inferences about how these drugs are being used in 
clinical practice. As a result, the original study protocol was designed to interview 
physicians prescribing these medications for their patients in order to collect information 
on diagnosis, indication for use, and factors influencing the decision to prescribe. 
However, lack of study participation by prescribing physicians resulted in the inability to 
measure the appropriateness of prescribing. This is a major limitation of this study. 
Escalating costs to provincial drug formularies strengthen the necessity of determining 
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the appropriateness of drug prescriptions. Inappropriate utilization may Impose an 
economic burden on an already constrained health care budget. 
Despite efforts to increase response rates: repeated follow-up letters and phone 
calls; researcher administered questionnaire resulting in very little effort required on 
behalf of the physician, and a monetary incentive, only 28.5% of the physician sample 
consented to participate in our study. There is no gold standard for an acceptable 
response rate and there is no agreed upon standard for a minimum acceptable response 
rate. Rates as low as 50% have been noted as acceptable for providing unbiased results224 
225 however, most researchers suggest an 80% rate as being adequate.226 227 Given that 
the collection procedures produced returns from only a minority of the eligible 
population, the results would not be similar to the population as a whole, and thus would 
not provide any credible statistics. 
6.3 Summary of Results 
In conclusion, the implementation of the unrestricted access policy for atypical 
antipsychotic medications by the Newfoundland and Labrador Prescription Drug 
Program revealed that there was a significant increase in government expenditure for 
these drugs, which did not coincide with a decrease in acute care hospital utilization in 
the province by patients with schizophrenia. Although a decrease in hospital admissions 
occurred, this was negated by an increase in length of stay. 
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6.4 Policy Options 
1. There was a significant increase in expenditure for the four atypical antipsychotic 
medications by the NLPDP following the introduction of the unrestricted 
reimbursement policy which was not accompanied by a decrease in the use of 
hospital days. However, there was a decrease in the number of hospital admissions 
from baseline in both of the subsequent study years which may have been 
attributable to more atypical antipsychotic utilization. Therefore, open access for 
schizophrenia patients may have been appropriate but restricted access for other 
indications. 
2. Alternative methods to contain pharmaceutical sector costs may be worthy of 
exploration, such as price management by actively negotiating or setting drug 
prices or profits, or contracting with industry so that the manufacturer shares the 
financial risk if higher-than-expected expenditures are incurred. 
3. The number of days spent m the community decreased over the study period 
resulting in an increase in total hospital days. To complement drug therapy 
programs, those who suffer from a chronic, incurable illness and their families may 
require access to a full range of community-based services. These services include: 
housing, vocational rehabilitation programs, supportive employment programs and 
respite services for caregivers. Availability of these services should be assessed as 
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it may be necessary to consider improving and/or expanding the mental health 
programs for patients suffering from schizophrenia which may be contributing to a 
delay in the discharge of patients. This is particularly important given the current 
trend away from institutional- to community-based care. Additionally, the way in 
which physicians practice medicine may contribute to an increased length of stay 
and a policy which monitors physician practice would ensure the reduction or 
elimination of inappropriate hospital days in case this factor was contributing to 
this increase. 
4. The rate of adherence with prescribed medication did not change over the course of 
the study. Models of community care such as assertive community treatment 
(ACT) and other interventions may be necessary and should be considered. This 
multidisciplinary team approach provides people with the support, treatment, and 
rehabilitation services they need to continue living in the community. 
5 The decision to provide atypical antipsychotic medications as an open benefit on the 
NLPDP formulary was a difficult one. The development of an independent 
committee, which is at arm's length from government, the pharmaceutical industry 
and other vested interest groups, to systematically review and synthesize the clinical 
and economic literature to provide information to decision-makers may be 
warranted. For example, the National Institute for Clinical Excellence (NICE) in the 
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UK works on behalf of the National Health Service (NHS) and the people who use it. 
NICE is an independent organization responsible for providing national guidance on 
treatments and care using the best available evidence. NICE guidance is developed 
using the expertise of the NHS and wider healthcare community including NHS 
staff, healthcare professionals, patients and carers, industry and the academic 
community. 
6. This study highlights the limitations and deficiencies of the current NLPDP claims 
database, e.g. no indication for use or demographic information, to determine 
whether there was a benefit associated with any off-label use. The original protocol 
for the study had planned to identify and interview physicians who prescribed 
atypical antipsychotic medications to their patients for the first time in 2000 to obtain 
patient specific information and determine the indication for use/appropriateness. 
Unfortunately, we were unable to get enough cooperation from the physicians after 
the study was initiated and this portion of the study was abandoned. The 
development of an electronic medical record with the ability to link with various 
other health and non-health care sectors would allow for the accurate recording of 
how drugs are being used and the impact of their use. This would strengthen the 
evidence with which policymakers can make rational decisions. 
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CHAPTER VII APPENDICES 
Appendix. A. Health & Community Services Regions/Integrated Boards boundaries and 
corresponding demographic profiles 
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Appendix B. 
Characteristics of comparative studies of clozapine with conventional antipsychotic medications 
Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) of efficacy criteria 
Kane, J Double blind, Treatment BPRS total score ::::: Inpatient 6 CLZ: mean BPRS; CGI; Statistically CLZ>CHL: us 
198825 randomized resistant 45 & CGI 2: 4 on 2 600 mg/day NOS IE significant BPRS, CGI, 
schizophrenia or 4 BPRS items of: (500-900) vs. improvement &NOSIE 
(DSM-III) conceptual CHL: mean inCGI; BPRS 
(268) disorganization; 1200 mg/day total score; 
suspiciousness; (1000-1800) improvement 
hallucinating +BENZ: 6 in 2:2 of 4 
behaviour; unusual mg/day BPRS items; 2: 
thought content 20% reduction 
in BPRS total 
+ CGI ::;3 or 
BPRS total::; 
35 
Claghom, Double blind, Schizophrenia Current Inpatient 8 CLZ: mean BPRS; CGI; Changes in CLZ>CHL: us 
198739 randomized (DSM-II) hospitalization ::; 6 400 mg/day NOS IE scores from BPRS5 
(151) months; score of 4 (150-900 baseline items; total 
on::::: 3 or the 6 mg/day) vs. score; CGI 
BPRS items: CHL: mean and some 
emotional 800 mg/day NOSIE items 
withdrawal; (300-1,800 
conceptual mg/day) 
disorganization; 
hostility; 
suspiciousness; 
hallucinatory 
behaviour; unusual 
thought content 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) of efficacy criteria 
Hong, C Double blind, Treatment Persistent severe Inpatient 12 CLZ: mean BPRS; CGI; 2:20% CLZ>CHL China 
199740 randomized refractory psychotic symptoms 543 mg/day PANSS reduction in 
schizophrenia (2: 5 on the BPRS (100-900 BPRS total 
(DSM-IV) items:_emotional mg/day) vs. score I 
(40) withdrawal; CHL: mean 
conceptual 1,163 mg/day 
disorganization; (200-1,800 
suspiciousness; mg/day) 
hallucinatory 
behaviour; unusual 
thought content) for 
2: 6 months with 
adequate 
neuroleptics 
treatment with 2: 2 
classes 
Essock Open label Chart diagnosis of Failure to respond Inpatient 104 CLZ: mean BPRS 2:20% CLZ=conven us 
199641 randomized schizophrenia or to 2 adequate trials 496 mg/day reduction in tional agents 
schizoaffective of2: alternative vs. alternative total BPRS 
disorder neuroleptics; 4 antipsychotic: and either a 
(treatment months mean 1,386 total BPRS ~ 
refractory) hospitalization in mg/dayCHL 17 OR2: 20% 
(227) current episode and equivalent reduction in 
2 years in previous BPRS 
5 years psychotic 
items subscale 
(thought 
disturbance) 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) of efficacy criteria 
Pickar, D Crossover, Treatment Drug intolerance Inpatient FLU2::4 CLZ: mean BPRS; 2::20% CLZ>FLU: us 
199242 placebo- resistant (significant TD or weeks; 542.9 mg/day Bunney- reduction in BPRS total 
controlled, schizophrenia or EPS); history of CLZ2::3 vs. FLU 28.9 Hamburg BPRS; and 
double-blind, schizoaffective being refractory to weeks mg/day Global either BPRS 
randomized illness treatment (lack of Psychosis rating <36 or a 
(DSM-III-R) satisfactory clinical Rating Bunney-
(21) response to 2:: 2 Hamburg 
different Global 
antipsychotic drugs Psychosis 
Rating< 6 
RosenheckR Double blind, Schizophrenia Refractoriness; Inpatient 52 CLZ: 100- PANSS 2::20% CLZ=HAL: us 
199743 randomized (DSM-III-R); severe symptoms; 900 mg/day reduction in 2::20% 
(423) serious social vs. HAL: 5- PANSS reduction in 
dysfunction in the 30 mg/day & PANSS: 
last 2 years 2-10 mg/day 
of BENZ 
Breier, A Double blind, Chronic Partial response to Outpatient 10 CLZ: 200- BPRS sum of 2::20% CLZ>HAL: us 
199444 randomized schizophrenia neuroleptics; 2:: 8 on 600 mg/day the 4 positive reduction in BPRS 
(DSM-III-R) positive symptom vs. HAL: 10- items; SANS BPRS positive positive 
(39) score of BPRS on 4 30 mg/day symptom symptoms; 
items or 2:: 4 on any scores and SANS 
1 of the items; 2:: 20 BPRS positive 
on SANS or 2:: 2 on symptoms 
at least 1 global score< 8 at 
item on SANS week 10 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results 
(# subjects) (weeks) of efficacy criteria 
Post Policy Period 
Kane, J Double blind, Schizophrenia or Treatment failure in Inpatient 29 CLZ: target BPRS; SANS; Time to CLZ>HAL: 
2001 45 randomized schizoaffective ;::: 2 trials of & dose 500 CGI treatment time to 
disorder conventionals for ;::: outpatient mg/day discontinuatio discontinuati 
(DSM-III-R) 6 weeks; moderate (range: 200- n due to lack on & 20% 
(71) rating on ;::: 1 BPRS 800 mg/day) of efficacy; improvement 
item vs. HAL: time to 20% in4 
target dose 1 0 improvement psychotic 
mg/day in 4 psychotic symptoms 
(range: 4-16 symptoms 
mg/day) 
Abbreviations: BENZ=benztropine mesylate, BPRS= Brief Psychiatric Rating Scale, CGI= Clinical Global Impression scale, CHL=chlorpromazine; 
CLZ=clozapine; DSM-11, III, IV-R=various editions of the diagnostic and statistical manual of diseases; EPS =extrapyramidal symptoms, FLU=fluphenazine; 
HAL=haloperidol; NOS IE= nurses observational scale of inpatient evaluation; PANSS= Positive and Negative Syndrome Scale, SANS=Scale for the Assessment 
of Negative Symptoms; TD =tardive dyskinesia; 
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Appendix C. 
Characteristics of comparative studies of risperidone with conventional antipsychotic medications 
Reference Design Diagnosis Eligibility criteria Setting Duration Interventio Assessment Response Results Country 
(#subjects) _{_weeks) ns of efficacy criteria 
Claus 19924 " Double blind, Refractory Chronic Inpatient 12 RISP: 2-20 PANSS; 2:20% RISP Belgium 
randomized schizophrenia schizophrenia with mg/dayvs. SADS-C; reduction in 12>HAL 10: 
(DSM-III-R) residual symptoms HAL 2-10 CGI; NOSIE total PANSS PANSS 
(44) despite optimized mg/day score from total; 
conventional baseline PANSS 
antipsychotic negative and 
therapy SADS-C, 
NOS IE 
Peuskens Double blind, Chronic >60<120 on PANSS inpatient 8 RISP: 1, 4, PANSS; 2:20% RISP=HAL: 15 
199523 randomized schizophrenia 8, 12, & 16 CGI reduction in PANSS countries 
(DSM-III-R) mg/day vs. PANSS total Optimal 
(1,362) HAL: 10 score RISP doses: 
mg/day 4&8 
mg/day 
Moller 19974 ' Double blind, Chronic >60<120 on PANSS Inpatient 8 RISP: 1, 4, PANSS; 2:20% RISP=HAL: Germany, 
randomized schizophrenia 8,12,&16 CGI; BPRS reduction in PANSS Austria, 
(DSM-III-R) mg/dayvs. PANSS total total; BPRS Switzer-
(169) HAL: 10 score or total; RISP 4 land 
mg/day BPRS score; mg/day> 
2:20% HAL: CGI 
reduction in 
PANSS total 
score plus 
CGI < 3 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventio Assessment Response Results Country 
(# sub_jects) (weeks) ns of efficacy criteria 
Min 19934 ' Double-blind, Chronic >60<120 on PANSS Inpatient 8 RISP: 5-10 PANSS; 2:20% RISP=HAL Korea 
randomized schizophrenia and mg/day vs. BPRS; CGI reduction in 
(DSM-III-R) outpatient HAL: 5-10 PANSS 
(35) mg/day 
Marder 1994 LL Double blind, Schizophrenia >60<120 on PANSS Inpatient 8 RISP: 2, 6, PANSS; 2:20% RISP 6 & 16 us 
randomized (DSM-III-R) 10, 16 CGI; ESRS reduction in mg>HAL20 
(388) mg/day vs. total PANSS mg: PANSS 
HAL: 20 score from 
mg/day baseline 
Chouinard Double blind, Chronic >60<120 on PANSS Inpatient 8 RISP: 2, 6, PANSS; 2:20% RISP Canada 
199349 randomized schizophrenia 10, & CGI; reduction in (6mg/day) > 
(DSM-III-R) 16mg/day PANSS- PANSS total HALon 
(135) vs. HAL: GPS; BPRS; score total 
20mg/day Global PANSS; 
vs. PL Evaluations PANSS-
GPS;BPRS; 
RISP=HAL: 
2:20% 
reduction in 
PANSS total 
score 
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Reference Design Diagnosis Eligibility criteria Setting Duration lnterventio Assessment Response Results Country 
(#subjects) (weeks) ns of efficacy criteria 
Ceskova 1993'0 Double-blind, Schizophrenia or None indicated Inpatient 8 RISP: 2-20 BPRS BPRS total: RISP=HAL Czech 
randomized schizoaffective mg/day vs. very good Republic 
disorder HAL: 2-10 remission 
(ICD-9) mg/day (50-100% 
(62) relative 
change from 
baseline) or 
partial 
remission 
(25-40% 
relative 
change) 
Borison 1992' Double blind, Schizophrenia 2: 30 on BPRS; 2: 2 Not stated 6 RISP: 2-10 BPRS; CGI 2:20% RISP=HAL: us 
randomized (DSM-III-R) of BPRS 4 positive mg/day vs. reduction in BPRS 
(36) symptom items; HAL 4-20 total BPRS 
CGI rating of mg/day vs. score from 
moderate or greater PL baseline 
illness 
Blin 1996'2 Double blind, Acute Psychotic anxiety Inpatient 4 RISP: mean PANSS; 2:20% RISP=HAL: France 
randomized exacerbation of score (PAS) 2: 34 7.4 mg/day BPRS; CGI reduction in 2:20% 
schizophrenia vs. HAL: PANSS total reduction in 
(DSM-III-R) mean 7.6 score PANSS total 
(62) mg/day vs. score; 
METH: RISP>HAL 
meanlOO &METH: 
mg/day total 
PANSS; 
CGI from 
baseline to 
end point 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventio Assessment Response Results Country 
(# subjects) (weeks} ns of efficacy criteria 
Hoyberg 1993'"' Double blind, Chronic None other than Not stated 8 RISP 5-15 PANSS; Mean PANSS total Denmark 
randomized schizophrenia diagnosis mg/dayvs. BPRS; CGI change from and 
with acute PER 16-48 PANSS from baseline: Norway 
exacerbation mg/day baseline RISP=PER; 
(DSM-III-R) CGI: 
(107) RISP=PER; 
2:20% 
reduction in 
BPRS: 
RIS>PER 
Huttunen double blind, Chronic or None other than Not stated 6 RISP 4-29 PANSS; Mean RISP=ZUC Finland 
199554 randomized subchronic diagnosis mg/day, CGI change in 
schizophrenia or mean, 8 mg PANSS total 
schizophreniform VS. ZUC score from 
disorder 20-100 baseline and 
(DSM-III-R) mg/day, 2:20% 
(98) mean, 38 reduction in 
mg PANSS total 
score 
Post Policy Period 
Rabinowitz Post hoc Chronic >60<120 on PANSS Not 8 RISP:4 PANSS Difference in RISP>HAL 15 
2001 55 subanalysis of schizophrenia used data from indicated mg/day; vs. total; CGI-S initial at 1 week: countries 
double blind, (DSM-III-R) Peuskens23 HAL: 10 change from PANSS total 
randomized (453) mg/day baseline to 
first week on 
treatment 
with study 
medication 
and during 
the entire 
study 
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Reference Design Diagnosis Eligibility criteria Setting Duration lnterventio Assessment Response Results 
_(# sublects) (weeks) ns of efficacy criteria 
Rabinowitz Post hoc sub- Chronic >60<120 on PANSS Not 8 RISP: 4 PANSS Mean RISP>HAL: 
2001 228 analysis of schizophrenia used data from indicated mg/day; vs. total; CGI-S change in PANSS 
double blind, (DSM-III-R) Peuskens23 HAL: 10 PANSS and total; 
randomized (144) mg/day CGI-S from PANSS-
baseline GPS; BPRS 
between the activity and 
2 groups total BPRS 
Abbreviations: BPRS=briefpsychiatric rating scale, CGI=clinical global impression, CGI-S=clinical global impression-severity of illness, DSM-III-R=third edition 
of the diagnostic and statistical manual of diseases, ESRS= extrapyramidal symptom rating scale, HAL=haloperidol, ICD-9=intemational classification of diseases 
91h edition, METH=methotrimeprazine, NOSIE= nurses observational scale of inpatient evaluation, PANSS=positive and negative symptoms scale, PANSS-
GPS=Positive and Negative Symptom Scale for Schizophrenia-General Psychopathology, PAS= Psychotic Anxiety Scale, PER=perphenazine, PL=placebo, 
RISP=risperidone, SADS-C=schedule for affective disorders and schizophrenia-change version, ZUC=zuclopenthixol. 
153 
Country 
15 
countries 
Appendix D. 
Characteristics of comparative studies of olanzapine with conventional antipsychotic medications 
Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) of efficacy criteria 
Beasley Double blind, Schizophrenia Acute exacerbation Inpatient 6 OLZ: 5±2.5 Mean change ~40% OLZ>HAL: US and 
199658 randomized (DSM-111-R) BPRS ~24; mg/day; from baseline decrease in SANS; BPRS Canada 
(335) CGI~4 10±2.5 to endpoint in: BPRS-total neg. score 
mg/day; BPRS; SANS; score OR an 
15±2.5 CGI-S endpoint 
mg/day vs. BPRS-total 
HAL: 15±5 score~ 18 
mg/day vs. 
PL 
Beasley Double blind, Schizophrenia Acute exacerbation Inpatient 6 OLZ: 5±2.5 BPRS; CGI; ~40% OLZ=HAL: Europe, 
199759 randomized (DSM-111-R) BPRS ~24; mg/day; PANSS decrease in BPRS; PANSS South 
(431) CGI~4 10±2.5 BPRS-total Africa, 
mg/day; score OR an Israel, 
15±2.5 endpoint and 
mg/day vs. BPRS-total Australia 
OLZ 1.0 score~ 18 
mg/day vs. 
HAL:15±5 
mg/day 
Tollefson Double blind, Schizophrenia, BPRS ~18 and/or Inpatient 6 OLZ: 5-20 Mean change ~40% OLZ>HAL: Europe, 
199760 randomized schizophreniform, intolerant of current & mg/day vs. from baseline decrease in BPRS, US and 
schizoaffective, antipsychotic outpatient HAL: 5-20 to endpoint in BPRS-total PANSS-N, Canada 
disorder (DSM- mediations mg/day total score in score OR an MADRS,CGI, 
111-R) (1,996) (excluding HAL) BPRS endpoint QLS 
BPRS-total 
score~ 18 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) of efficacy criteria 
Hamilton Double-blind, Schizophrenia Treatment outpatient 24 OLZ: 5±2.5 BPRS; SANS; Change from OLZ=HAL: US and 
199861 randomized (DSM-III-R) responders from mg/day; CGI; QLS baseline to BPRS and Canada 
(95) acute phase ( 6- 10±2.5 week 24 for CGI; 
week) Beaslel8 and mg/day; BPRS; OLZ: 15±2.5 
discharged from 15±2.5 SANS; CGI; mg/day>HAL: 
hospital by 4 weeks mg/day vs. &QLS SANS; 
after acute phase HAL: 15±5 scores OLZ=HAL: 
was over mg/dayvs. QLS 
PL 
Tran Pooled data Schizophrenia, Responded to acute Outpatient 46 Pooled data Relapse Hospital- OLZ: less US, 
199862 from3 schizophreniform, therapy (BPRS total from3 RCTs: ization for relapse Canada, 
RCTs58·6o or score decreased Study 158 psycho- (P=0.034) Europe, 
schizoaffective; 2:40% from baseline OLZ: 5±2.5 pathology South 
or was :::;18) mg/day; Africa, 
Beasley, Tollefson 10±2.5 Israel, 
et al. 1996; Beasley, mg/day; and 
Hamilton et al. 15±2.5 Australia 
1997) mg/day vs. 
HAL: 15±5 
mg/dayvs. 
PL; 
Study 259: 
OLZ: 5±2.5 
mg/day; 
10±2.5 
mg/day; 
15±2.5 
mg/day vs. 
OLZ: 1.0 
mg/day vs. 
HAL: 15+5 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) of efficacy criteria 
mg/day; 
Study 360: 
OLZ: 5-20 
mg/day vs. 
HAL: 5-20 
mg/day 
Conley Double-blind Schizophrenia Treatment Inpatient 8 OLZ: BPRS; CGI; ~20% OLZ=CHL: us 
199863 randomized (DSM-III-R) resistance: ~2 25mg/day vs. SANS reduction in BPRS total; 
(84) periods of treatment CHL: 1200 total BPRS BPRS 4 items; 
in preceding 5 years mg/day+ compared to SANS; CGI; 
with ~1000 mg/day BENZ: baseline; BPRS subscale 
of CHL equivalent 4mg/day CGI scores score 
for 6 weeks 3 orBPRS 
(excluding HAL); score s35; 
no period of good total BPRS 
functioning within 5 score; score 
years; BPRS~45; on4 BPRS 
CG1~4; ~4 on items; SANS 
BPRS psychosis 
items. 
Post Policy Period 
Breier Double-blind Schizophrenia; Subpopulation of Inpatient 6 OLZ: 5-20 BPRS:PANSS ~20% OLZ>HAL: US and 
199964 randomized schizophreniform; non-responders and mg/dayvs. MADRS increase in PANSS-N; Europe 
schizoaffective from Tollefson60 outpatient HAL: 5-20 BPRS total MADRS total 
disorder mg/day score and an score (LOCF); 
(DSM-III-R) endpoint OLZ>HAL: 
(526) BPRS score BPRS total; 
s24. P ANSS total; 
PANSS-P; 
PANSS-N; 
MADRS total 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results 
(# sub_jects) (weeks) of efficacy criteria 
(completers); 
OLZ>HAL: 
::::: 20% increase 
in BPRS total 
score and an 
endpoint BPRS 
score:$ 24. 
(LOCF); 
OLZ=HAL: 
::::: 20% increase 
in BPRS total 
score and an 
endpoint BPRS 
score :o; 24 
( completers) 
Abbreviations: BENZ=benztropine, BPRS=briefpsychiatric rating scale, CGI=clinical global impression, CGI-S=clinical global impression-severity of illness, 
CHL=chlorpromazine; DSM-111-R=third edition of the diagnostic and statistical manual of diseases, HAL=haloperidol; LOCF=last observation carried forward, 
MADRS=Montgomery-Asberg Depression Rating Scale, OLZ=olanzapine; P ANSS= Positive and Negative Symptom Scale for Schizophrenia, P ANSS-
N=Positive and Negative Symptom Scale for Schizophrenia-Negative Symptoms; PANSS-P=Positive and Negative Symptom Scale for Schizophrenia-Positive; 
Symptoms; PL=placebo; QLS= quality of life scale; RCTs=randomized clinical trials, SANS=Scale for the Assessment ofNegative Symptoms. 
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Appendix E. 
Characteristics of comparative studies of quetiapine with conventional antipsychotic medications 
Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) of efficacy criteria 
Arvanitis, LA Double blind, Acute 2:27 onBPRS; Inpatient 6 QTP: 75, 150, BPRS total; 2':30% QTP 75- US and 
199766 randomized exacerbation of score of3 on2': 2 300,600,750 CGI; SANS reduction in 750=HAL: Canada 
chronic or sub BPRS positive mg/day vs. BPRS total BPRS, CGI, 
chronic symptom items; 2: 4 HAL: 12 score at any SANS 
schizophrenia CGI mg/dayvs. time 
(DSM-III-R) PL 
(361) 
Peuskens Double-blind Acute 2: 27 on BPRS; 2: 3 Inpatient 6 QTP:::; 750 BPRS total BPRS total QTP=CHL: Belgium 
199767 randomized exacerbation of on 2 or more BPRS mg/day vs. score; CGI score: CGI; BPRS total; ,UK, 
chronic or sub positive symptoms; CHL:::; 750 BPRS2: QTP>CHL: Spain, 
chronic 2:4CGI mg/day 50% 50% reduction France 
schizophrenia, or reduction in onBPRS from and 
schizophreniform BPRS total baseline South 
disorder score from Aftica 
(DSM-III-R) baseline 
(201) 
Post Policy. Period 
Copolov Double blind, Acute 2: 60 on PANSS; Inpatient 6 QTP: mean PANSS;CGI PANSS QTP=HAL: 14 
200068 randomized exacerbation of score of 4 on 2:2 455 mg/day total; 2:30% P ANSS total; 2': countries 
chronic or sub P ANSS items; 2':4 vs. HAL: PANSS total 30% PANSS 
chronic CGI meanS total 
schizophrenia mg/day 
(DSM-III-R) 
(448) 
Emsley Double blind, Schizophrenia Persistent positive Outpatient 8 QTP: 600 PANSS; CGI Mean QTP=HAL: UK and 
200069 randomized (catatonic, symptoms while on mg/day vs. PANSS PANSS South 
disorganized, therapeutic doses of HAL: 20 score after 4 Africa 
paranoid or antipsychotics; 2': 15 mg/day weeks and 8 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results 
(# sub_jects) (weeks) of efficacy criteria 
undifferentiated on P ANSS; score of weeks; 2: 
type 2: 4 on 2: 1 BPRS 20% 
(DSM-IV) positive symptom reduction in 
(288) items; 2: 3 on CGI PANSS total 
score from 
baseline; 
CGI::; 3 at 
week 8 
. . .. Abbrev1atwns: BPRS=bnefpsych1atnc ratmg scale, CGI=chmcal global1mpresswn, CHL=chlorpromazme, DSM-111, IV-R=vanous ed1twns of the diagnostic and 
statistical manual of diseases, HAL=haloperidol, P ANSS=positive and negative symptoms scale, PL=placebo, QTP=quetiapine, SANS=Scale for the Assessment 
ofNegative Symptoms. 
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Appendix F. 
Characteristics of head-to-head comparisons of atypical antipsychotic medications 
Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) of efficacy criteria 
CLOZAPINE VS. RISPERIDONE 
Bondolfi Double blind, Chronic Resistant to or Inpatient 8 RISP: mean PANSS; CGI 2':20% RISP=CLZ: Switzer-
1998 70 randomized schizophrenia intolerantto2':2 6.4 mg/day reduction in PANSS land and 
(DSM-III-R) different classes of (3-10 PANSS total total; CGI; 2': France 
(86) antipsychotics; mg/day) vs. reduction in 
>60<120 on PANSS CLZ: mean PANSS total 
291.2 mg/day 
(150-400 
mg/day) 
Post Policy Period 
Breier 1999 Double-blind, Chronic Partial response to Not 6 RISP: mean 4 positive Efficacy CLZ>RISP: us 
randomized schizophrenia traditional indicated 5.9 mg/day symptom compared at BPRS 
(DSM-IV) antipsychotics: 2': 8 (2-9 mg/day) items on end of study positive 
(29) for 4 BPRS positive vs. CLZ: BPRS;BPRS with symptoms; 
symptom items; 2': mean403.6 withdrawaVret baseline; 2': RISP=CLZ: 
20 on SANS mg/day (200- ardation and 20% SANS score; 
600 mg/day) anxiety/depres reduction in BPRS 
sion factor BPRS total withdrawaV 
scores; BPRS retardation 
total score; score; BPRS 
SANS total anxiety/depr 
score; HAM- ession score; 
D HAM-D;2': 
20% 
reduction in 
BPRS total 
Azorin 200 1'L Double blind, Schizophrenia 2': 4 on CGI; 2': 45 on Inpatient 12 RISP: 2-15 BPRS; CGI; Magnitude CLZ>RISP: France 
randomized (DSM-IV) BPRS total score; and mg/day PANSS, PAS; of improve- BPRS; CGI and 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(# subjects) (weeks) of efficacy criteria 
(273) and 2: 4 on 2 or outpatient vs. CLZ: 200- Psychotic ment in scores; Canada 
more of the 4 core 900 mg/day Depression BPRS and PANSS; 
symptoms (unusual Scale; Calgary CGI scores; Calgary 
thought, Depression tmprove- Depression 
hallucinations, Scale ment in Scale; PAS 
conceptual BPRS total 
disorganization, score of 
suspiciousness) 20%,30%, 
Poor previous 40%, or 
treatment response: 50%; 2:20% 
continuous reduction in 
treatment in BPRS total 
preceding 6 months score and 
without significant either post-
improvement; at treatment 
least 1 unsuccessful CGI::; 3 or 
trial of post-
antipsychotic for at treatment 
least 6 weeks; no BPRS total 
period of good score::; 35 
functioning for at 
least 2 years with 
use of2 
antipsychotics in 2 
chemical classes (or 
5 years despite 3 
antipsychotic trials) 
RISPERIDONE VS. OLANZAPINE 
Tran Double-blind Schizophrenia, BPRS 2: 42; at least Inpatient 28 OLZ: 10-20 PANSS total; Mean OLZ>RISP Belgium 
199773 randomized schizophreniform minimally & mg/day vs. PANSS change in on SANS; 2: France; 
disorder or responsive to 3 outpatient RISP: 4-12 sub scales; PANSS total 40% Ger-
schizoaffective anti psychotics mg/day PANSS score;> 40% decrease in many; 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) ofefficacv criteria 
disorder depression; decrease in PANSS total The 
(DSM-IV) BPRS; CGI; PANSS total score Nether-
(339) SANS score lands; 
Spain; 
UK; 
South 
Africa, 
and US 
Post Policy Period 
Conley Double-blind Schizophrenia or >60<120: PANSS Inpatient 8 OLZ: 5-20 P ANSS total; ;:::20% OLZ=RISP: us 
2001 74 randomized schizoaffective (hospital- mg/dayvs. PANSS 5 reduction PANSS 
disorder ized :S 4 RISP: 2-6 factors; CGI PANSS total total;;::: 20% 
(DSM-IV) weeks) & mg/day reduction 
(377) outpatient PANSS 
total; 
RISP>OLZ: 
PANSS 
scale 
positive and 
anxiety/depr 
ession 
factors 
Ho 1999'' Open label, Schizophrenia Not receiving Inpatient 24 OLZ (5-20 SANS; SAPS; None stated RISP>OLZ: us 
non- (DSM-IV) neuroleptic mg/day, BPRS; quality reduction of 
randomized (42) treatment mean=12.4 of life psychotic 
mg/day) vs. measures symptoms 
RISP (2-6 
mg/dayrng/da 
y, mean=4.8 
mg/day) 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results Country 
(#subjects) (weeks) of efficacy criteria 
QUETIAPINE VS. RISPERIDONE 
Post Policy Period 
Mullen Open-label, Schizophrenia; Suboptimal efficacy Outpatient 16 QTP: mean CGI; PANSS CGI; QTP=RISP: us 
2001 76 randomized schizophreniform of previous 253.9 mg/day total; HAM-D PANSS PANSS; 
disorder; antipsychotic agents vs. RISP: total; HAM- CGI 
schizoaffective or patient mean4.4 D QTP>RISP: 
disorder; intolerance of other mg/day differences HAM-D 
delusional medications from 
disorder, major baseline 
depressive 
disorder with 
psychotic 
features, dementia 
of the 
Alzheimer's type 
with psychotic 
symptoms, 
vascular 
dementia, or 
dementia due to 
substance abuse 
(DSM-IV) 
(728) 
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Reference Design Diagnosis Eligibility criteria Setting Duration Interventions Assessment Response Results 
(#subjects) _iweeksl of efficacy criteria 
CLOZAPINE VS. OLANZAPINE VS. RISPERIDONE 
Post Policy Period 
V olavka 200211 Double-blind, Chronic Suboptimal Inpatient 14 CLZ: mean PANSS Change in CLZ& 
randomized schizophrenia or response to previous 526.6 mg/day PANSS at OLZ>HAL: 
schizoaffective treatment; >60 on vs. OLZ: endpoint PANSS total 
disorder PANSS mean 30.4 score 
(DSM-IV) mg/day vs. 
(157) RISP: mean 
11.6 mg/day 
vs. HAL: 
mean 25.7 
mg/day 
Abbreviations: BPRS=brief psychiatric rating scale, CGI=clinical global impression, CLZ=clozapine; DSM-III, IV-R=various editions of the diagnostic and 
statistical manual of diseases, HAL=haloperidol, HAM-D=Hamilton Rating Scale for Depression, OLZ=olanzapine, P ANSS=positive and negative symptoms 
scale, PAS=Psychotic Anxiety Scale, QTP=quetiapine, RISP=risperidone, SANS=Scale for the Assessment of Negative Symptoms; SAPS=Scale for the 
Assessment of Positive Symptoms; 
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Appendix G. 
Cost comparisons of full economic evaluations of atypical antipsychotic medications 
Reference Population Country Perspective Study Alternatives Cost Effectiveness Nature Time Discount Results 
(n) (currency Design considered elements measure of horizon rate 
& year) stud_y; 
Chouinard Chronic Canada Drug payer 8 week, RISP(6 Cost of QALY CUA lifetime None CAD$24,259/ 
199787 schizophrenia usmg double mg/day) vs. medicat- stated QAL Y for RISP 
(135) CAD($) blind, HAL(20 ions VS. HAL 
(year of placebo- mg/day) 
values control-
used not led 
stated) 
Oh Hospitalized, Canada Government Meta CLZvs. Costs of QALY CUA 1 year 5% Cost savings of 
19977 treatment- year of payer analysis CHLand medica- and CAD$52,5611 
resistant medicatio results HAL tions; lifetime QALY 
schizophrenia ns using from3 physician 
(157) 1995 CAD studies visits and 
($)values; lab tests; 
doctor commun-
visits and ity care 
lab test (nursing, 
usmg social 
1992 CAD work, 
($)values; case 
commum- manager, 
ty care residential 
usmg care); 
1996 CAD hospital-
($)values; ization 
hospital-
ization 
using 
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Reference Population Country Perspective Study Alternatives Cost Effectiveness Nature Time Discount Results 
(n) (currency Design considered elements measure of horizon rate 
& year) studyi 
1995 CAD 
($)values 
Oh Hospitalized, Canada Government Meta RISP vs. Costs of QALY CUA 1 year 5% Cost savings of 
19977 chronic Year of payer analysis HAL, HAL medicat- and CAD$11,713/ 
schizophrenia medicat- results deconate, ions; lifetime QALY 
(645) ions using from8 FLU physician 
1995 CAD studies deconate visits and 
($)values; lab tests; 
doctor commun-
visits and ity care 
lab test in (nursing, 
1992 CAD social 
($)values; work, 
commun- case 
ity care in manager, 
1996 CAD residential 
($)values; care); 
hospital- hospital-
ization in ization 
1995 CAD 
($) 
Tunis Inpatient and US, UK, Health Double- OLZvs. Hospital- Functional CEA 1 year NIA Savings of 
199990 outpatient Canada system payer blind HAL ization status (SF- $US 1,632.50/ 
Schizo- using Random- costs 36) unit improve-
phrenia; 1995 USD ized ment in SF-36 
schizo- ($) values clinical physical & 
phreniform trial functioning 
disorder; score ; savings 
schizo- of $US5,654. 74/ 
affective unit improve-
disorder ment in mental 
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Reference Population Country Perspective Study Alternatives Cost Effectiveness Nature Time Discount Results 
(n) (currency Design considered elements measure of horizon rate 
& y_ear}_ study; 
(DSM-III-R) & functioning 
(812) composite 
Davies Chronic Australia Payer Clinical RlSP vs. Hospital- Response; CEA 2 years N/A Cost savings of 
199888 schizophrenia AU($) decision HAL ization; partial AU$11,395/ 
(DSM-III-R) (year of analytic outpatient response; favorable 
values model ; drugs; increased outcome for 
used not health dose response RlSP than HAL 
stated) care pro- over the 2-year 
fessionals period 
; govern-
ment 
subsidized 
hostel 
accomm-
odation 
Essock Chart US using Department Open- CLZvs. Drugs; Change in CEA 2 years N/A CLZ increased 
200091 diagnosis of 1993 us of mental label, Conventional hospital- BPRS total; cost $1 , 112 in 
schizophrenia ($)values health; random- agent ization; quality of year 1 but 
or schizo- society; state ized, lab; life; EPS; $7,149less cost 
affective of con- nursing hours in in year 2 than 
disorder and Connecticut trolled home; special patients in usual 
failure to study outpatient observation ; care 
respond to and occurrence of 
adequate residential problematic 
trials of 2: 2 care; ER; behaviour 
different anti- product-
psychotics; ivity 
hospital-
ization of2: 4 
months; total 
hospital-
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Reference Population Country Perspective Study Alternatives Cost Effectiveness Nature Time Discount Results 
(n) (currency Design considered elements measure of horizon rate 
& year) study; 
ization time 
of2: 2/5 
preceding yrs; 
no medical 
contra-
indication to 
CLZ 
(227) 
Schiller Outpatient us Payer Before/ RISP vs. Medi- GAF CEA 1 year N/A RISP=standard 
199992 schizophrenia Mental after, Standard cations; therapy with 
or schizo- heatlh retro- therapy outpatient cost increasing 
affective services spective, serv1ces; of 
disorder using quasi- acute US$370/month 
(DSM-111-R) 1994 USD experime hospital in RISP over 
(112) ($) ntal, services; standard 
values; matched- lab therapy; 
lab in comp- No difference in 
1995 USD anson GAF between 
($)values; the two groups 
medicatio 
ns using 
1995 USD 
($)values 
Guest Chronic UK using Payer (NHS) Before/ RISP vs. Hospital- PANSS; CGI CEA 1 year N/A Total mean cost 
199693 schizophrenia 1993/94 after HAL ization, (n=31) savings of 
(DSM-111-R) GBP (£) design residential and2 £ 1, 18 8/pt in 
PANSS>60< values accommo year year 1 ; 
120 dation; (n=18) Total mean cost 
(31) medi- savings of 
cation £7,426 in year 2 
costs; 
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Reference Population Country Perspective Study Alternatives Cost Effectiveness Nature Time Discount Results 
(n) (currency Design considered elements measure of horizon rate 
& year) study; 
outpatient 
Galvin Outpatient US using Payer Retro- CLZ&RISP Medi- Severity of CEA 1 year NIA Cost savings 
199995 psychotic 1997 USD spective, vs. cations; general $3,000/pt/yr 
disorder ($) values uncon- Conventional lab; symptoms & with atypicals 
(n=37, 34/37 trolled, hospital side effects 
with schizo- open, services; 
phrenia) non- mental 
random- health 
ized, clinic; 
within transit-
subjects ional 
living 
placement 
Almond Simulated UK using Payer Markov OLZ&RISP Medi- BPRS& CEA 5 years 6% 3 therapies were 
200096 population 1996/97 model vs. HAL cations; relapse cost neutral 
GBP (£) hospital-
values izaitons; 
supported 
accommo-
dation 
Hamilton Inpatient and US using Health Double- OLZvs. Hospital- NIA CA 6 weeks N/A Cost savings of 
199997 outpatient 1995 USD system payer blind HAL izations; (acute $US388 for 
schizophrenia ($)values Random- ER visits; phase) & OLZ vs. HAL in 
; schizo- ized day 46 weeks acute phase; 
phreniform clinical hospital; (main- Cost savings of 
disorder; trial outpatient tenance $US636 for 
schizo- visits; phase) OLZ vs. HAL in 
affective home maintenance 
disorder visits; phase 
(DSM-III-R) medi-
(817) cations 
169 
Reference Population Country Perspective Study Alternatives Cost Effectiveness Nature Time Discount Results 
(n) (currency Design considered elements measure of horizon rate 
& year) study; 
Albright Schizophrenia Canada Payer Retro- RISP Medi- NIA CA 10 N/A Cost savings of 
199698 (ICD-9) using spective cations; months $7,925/pt.yr 
(146) CAD($) cohort physician after initiation 
(year of data ; mental ofRISP 
values from5 health; 
used not sources hospital-
stated) to see ization 
change 
in 
resource 
use 
before 
and after 
nspen-
done use 
Glazer Hypothetical US using Payer Clinical Traditional Medi- Not included CA 1 year N/A Total cost of 
199699 schizophrenia USD ($) decision oral agents cations; traditional oral 
patient (year of analytic VS. clinic agent was 
requiring values model Traditional visits ; $US11,157 & 
repeat used not depot agents hospital- oral atypical 
hospital- stated) vs oral izaiton; agent was 
izations atypical case $US2,567 more 
agents manage- than depot in 
ment; first year 
manage-
ment of 
moderate/ 
severe 
side 
effects 
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Reference Population Country Perspective Study Alternatives Cost Effectiveness Nature Time Discount Results 
(n) (currency Design considered elements measure of horizon rate 
& year) study; 
Finle~ Veterans with US using Veteran's Retro- RISP Hospital- N/A CA 1 year N/A Decrease in 
1998 °0 treatment 1994/95 inpatient spective ization, hospitalization 
resistance or USD ($) psychiatric cohort, RISP days after 
treatent values treatment intention acqm- initiation of 
intolerant facility -to-treat sition RISP resulted in 
psychiatric analysis costs a net saving of 
disorders Before US$149,962 for 
(schizo- and after the institution 
phrenia, the 
bipolar, initiation 
depression ofRISP 
with 
psychotic 
features) 
Edgell Schizophrenia US using Payer Data OLZ (10-20 Drugs; NIA CA 28 weeks N/A Health service 
2000 101 , schizo- 1997 USD from mg/day) vs. hospital- costs were 
phreniform ($)values RCT RISP (4-12 ization; US$3,774 less 
disorder, used to mg/day) ER visits; in the OLZ-
schizo- measure day treated group 
affective health hospital; compared with 
disorder care psych- the RISP-treated 
(DSM-IV) service iatrist group 
(150) utili- visit; 
zation health 
care pro-
fessionals 
;home 
visits 
Blieden Schizophrenia US using Public payer Before & CLZ vs.other Hospital- N/A CA 6 months N/A Cost savings of 
1998 102 (DSM-III-R); 1993 us after treatment ization; $3,267 /person 
hospitalizaed ($)values outpatient after 6 months 
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Reference Population Country Perspective Study Alternatives Cost Effectiveness Nature Time Discount Results 
(n) (currency Design considered elements measure of horizon rate 
& year) studyi 
with no and 
previous CLZ residential 
treatment care 
within 6 
months; 
ability to be 
interviewed; 
refractory to 
at ~2 different 
antipsychotics 
Drew Schizophrenia Australia Payer Open- 2 years Hospital; N/A CA 3 years N!A No significant 
1999103 or schizo- usmg label before vs. 3 hostel bed increase or 
affective 1996/97 retro- years after ;CLZ; decrease 
disorder and AU($) spective the start of lab and following CLZ 
started on values study of CLZ CLZCo- treatment 
clozapine com- treatment ordinator 
munity-
based 
clinical 
practice 
.. AbbreviatiOns: AU=Austrahan dollars, BPRS=bnefpsych1atr1c ratmg scale, CAD=Canadmn dollars CGI=chmcal global ImpressiOn, CHL=chlorpromazme, 
CLZ=clozapine, DSM-III, IV-R=various editions of the diagnostic and statistical manual of diseases, EPS=extrapyrarnidal side effects, FLU=fluphenazine, 
GAF=Global Assessment ofFunctioning, GBP=pound sterling, HAL=haloperidol, NHS=National Health Serive, OLZ=olanzapine, PANSS=positive and negative 
symptoms scale, QAL Y=Quality Adjusted Life Year, RISP=risperidone, RCT=randornized clinical trial, SF-36=Short Form-36, USD=US dollars. 
i Nature of the study: 
Full economic evaluation: 
CBA Cost Benefit Analysis 
CEA Cost Effectiveness Analysis 
CUA Cost Utility Analysis 
Partial Evaluation: 
CA Cost Analysis 
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APPENDIXH Letter of intent to prescribing physicians 
GOVERNMENT OF 
NE~OUNDLANDANDLABRADOR 
Department of 
Health and Community Services 
Drug Programs and Services Division 
Dear Dr.<>, 
I am writing to enlist your participation in an important research project that will attempt 
to define the current patterns of practice in the treatment of schizophrenia in 
Newfoundland and Labrador. The Department of Health and Community Services has 
commissioned the Patient Research Centre, Health Sciences Centre, to conduct this 
project. The Pharmaceutical Manufacturer's Association of Canada (PMAC) has agreed 
to fund the study. There is great interest in this research endeavour from all stakeholders: 
those who fund our health care system, GPs and psychiatrists who are entrusted with the 
care of schizophrenic patients, the Schizophrenia Society of Newfoundland (including 
patients and their families), objective researchers within the Faculty of Medicine, and 
industry representatives. 
In the proposed study, appropriateness of atypical anti-psychotic medication utilization 
and prescribing practices will be determined by a third party academic panel of experts, 
blinded to physician specialty and patient and physician name, using practice guidelines 
derived from published evidence concerning efficacy. We are hoping to have a high 
percentage of participation of the GPs and psychiatrists in the province in order to 
describe past and current patterns of practice in the treatment of schizophrenia. 
Governments and third party insurers are all seeking ways to limit their expenditures and 
one popular means is by not listing new agents or removing existing expensive agents 
from formularies. This serves to limit physician choice and increase the amount of paper 
work needed for justification of exception. Nonetheless, it can be argued that escalating 
costs to provincial drug formularies strengthen the necessity of conducting drug 
utilization reviews to determine the appropriateness of drug prescriptions. In this 
particular situation it is possible that over-utilization of atypical agents could occur 
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through prescription for disorders other than schizophrenia, even though there is little 
evidence to support these alternative uses. It is also possible that underutilization could 
occur if patients who benefit from these drugs don't get them. Inappropriate utilization 
may impose an economic burden on an already constrained health care budget. 
New patients started on atypical antipsychotics will be identified in 2000/1 and an 
interview with the physician will be completed to determine diagnosis and indication for 
use. You will be paid for your time and inconvenience at a rate of $15.00 per case. A 
case is defined as an instance identified by the Newfoundland and Labrador Prescription 
Drug Program database in which a client of the Drug Program was prescribed an atypical 
antipsychotic medication. We anticipate physician interviews will average 3 minutes per 
case. There is no maximum number of cases to be reviewed by each individual 
physician. In other words the number of cases to be reviewed per physician will depend 
on the number of patients prescribed atypical anti-psychotic medications by each 
individual physician. 
All analysis of data will be identified in a completely anonymous fashion and no 
physician or patient will be identified to any outside agency. The intent of this study is 
not to identify individual physician's practices but to describe in a global sense, the 
prescribing patterns of psychiatrists and GPs. 
A protocol synopsis is included for your perusal. 
We look forward to working with you and having Newfoundland and Labrador general 
practitioners and psychiatrists lead the way to identifying patterns of practice based on 
published practice guidelines. If you have any queries please call either Dr. Patrick 
Parfrey directly at (709) 737-7261 or Pager 553-6218, his research associate Daria 
O'Reilly at (709) 737-6738, or Ann Rideout research nurse, study coordinator for the 
project at (709) 737-5031. 
Sincerely, {$(/W'l,;. 
Mr. John Downton 
Department of Health and Community Services 
Government ofNewfoundland and Labrador 
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APPENDIX I Physician consent form 
Faculty of Medicine, Memorial University of Newfoundland, 
St. John's, Newfoundland AlB 3V6 
CONSENT TO PARTICIPATE IN HEALTH CARE RESEARCH 
RESEARCH STUDY TITLE: The Impact of Open Access to "Atypical' Anti-
psychotic Medications in Newfoundland and Labrador on Physicians Prescribing 
Practices 
INVESTIGATOR: Dr. Patrick Parfrey 
Telephone: 73 7-7261 
Please read this information carefully. It will tell you about the project we are 
undertaking, and help you decide if you want to participate. 
Please ask the study staff to explain information that you do not clearly understand. You 
have been asked to participate in a research study. Participation in this study is entirely 
voluntary. You may decide not to participate or may withdraw from the study at any 
time. 
A copy of the study protocol is available upon request. 
Confidentiality of information concerning participants will be maintained by the 
investigator. The investigator will be available during the study at all times should you 
have any problems or questions about the study. 
Purpose of the Study: The current study is being undertaken at the request of the 
Deaprtment of Health and Community Services, Government of Newfoundland and 
Labrador. The department requires accurately collected data, interpreted by objective 
health scientists, as a method of evaluating the impact of open access to atypical anti-
psychotic medications in Newfoundland and Labrador, subsequent to the infusion of 
additional funding. The present study proposes: 
(1) to evaluate the impact of an open access policy to atypical anti-psychotic medications 
(2) to measure resource use (i.e., hospital admissions, drug utilization) due to 
schizophrenia, in Newfoundland and Labrador 
(3) to measure the current patterns of care, and 
( 4) to determine the appropriateness of atypical antipsychotic prescribing. 
Description of Study: The proposed study will address the following research questions: 
Phase I: What has been the trend regarding the number of hospital admissions, length of 
hospital stay, quantity of antipsychotics used in the treatment of patients with 
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schizophrenia during the 1995/6 fiscal year and the 1998 calendar year in the province of 
Newfoundland and Labrador? 
Phase II: What is the impact of an 'open access' policy to atypical antipsychotic therapy 
in Newfoundland and Labrador commencing in January, 1999? 
Description of Procedures and Tests: The study will be conducted from January 1999 
to April 2002. The study will consist of two phases. Patients with a diagnosis of 
schizophrenia will be identified through hospital admissions; patients prescribed atypical 
antipsychotic agents will be identified through the Newfoundland and Labrador 
Prescription Drug Program. Interviews with the individual's general 
practitioner/psychiatrist will be conducted to obtain information such as demographics 
(e.g., sex, age, employment status), history of present illness, relevant past history, (e.g., 
previous psychiatric hospitalizations, case management, previous medications) 
symptoms, drug allergies/intolerance. Subsequent to the data abstraction and at a time 
deemed convenient by the participating physician an interview will be conducted to 
determine diagnosis and indication for prescribing the atypical anti-psychotic agent. 
There will be no assessment of individual physician accuracy of diagnosis; a panel of 
experts will determine appropriateness of prescription based on conformation to the 
Canadian Clinical Practice Guidelines and the American Psychiatric Association 
Guidelines for the treatment of schizophrenia. 
Duration of Participation: The study will take place from January 1999 to April 2002. 
You will be asked to designate a period of time from your practice to review identified 
cases of patients in your practice prescribed atypical antipsychotics in 2000. It will take 
approximately 3-4 minutes to review each case. There is no maximum number of cases 
to be reviewed by each individual physician. In other words the number of cases to be 
reviewed per physician will depend on the number of patients prescribed atypical anti-
psychotic medications by each individual physician. 
New patients started on atypical antipsychotics will be identified in 2000 and an 
interview with the physician will be completed to determine diagnosis and indication for 
use. The only time you will need to be directly involved with the study is during the 
interview process. You will be paid for your time and inconvenience at a rate of $15.00 
per case. A case is defined as an instance identified by the Newfoundland and Labrador 
Prescription Drug Program database in which a client of the Drug Program was 
prescribed an atypical anti-psychotic medication. 
Inconveniences: The inconvenience is associated with the giving of your time for the 
interviews. You will be paid a stipend of $15.00 to review each identified case in your 
practice. 
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Other Information: Findings of this study will be available to you upon request. 
Findings may be published but you and patients under your care will not be identified. 
The investigator will be available during the study at all times should you have any 
questions or concerns about your continued participation. All information that you 
provide will be kept strictly confidential, secured in a locked file, and accessible only to 
the investigators and research nurses. 
Your signature on this form indicates that you have understood to your satisfaction 
the information regarding your participation in the research project and agree to 
participate as a subject. In no way does this waive your legal rights nor release the 
investigators, sponsors, or involved institutions from their legal and professional 
responsibilities. 
I, ________________ , the undersigned, agree to my participation 
in the research study described. 
Any questions have been answered and I understand what is involved in the study. I 
realize that participation is voluntary and that there is no guarantee that I will benefit 
from my involvement. I acknowledge that a copy of this form has been given to me. 
Signature of Participant Date 
Signature of Witness Date 
To the best of my ability, I have fully explained the nature of this study to the participant. 
I have invited questions and provided answers. I believe that the participant fully 
understands the implications and voluntary nature of the study. 
Signature of Interviewer Date 
Phone Number 
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APPENDIXJ Health record review for hospitalized patients 
Study #: ___ _ Year of Present Admission: 
---
Patient Demographics: 
Age in Years: Education Level attained: 
Attending Psychiatrist: 
Admitting Psychiatrist: 
Institution: 
Region ofDomicile when first diagnosed: 
Region ofDomicile for current admission: 
Income source: Occupation: 
Date &/or age of first diagnosis: 
(d/m/yr) 
Date of 1st admission: 
(d/m/yr) 
Presenting Complaints (researcher's narrative): ---------------
ICD-9 code & description: ______________________ _ 
Reason for admission: Y N 
1. Potential danger to self, others or property D D 
2. Acute disturbance of affect, behavior or thinking D D 
3. Impaired social, familial or occupation functioning D D 
4. Elective admission for observation, investigation or treatment changes 
5. 
6. 
Legally mandated admission 
Inappropriate admission (Reason: 
D D 
D D 
) D D 
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Admission Number to this institution: Index admission? YIN 
If index, date of last die: _______ _ 
Total # of admissions since first admission to first ofthis study period: 
Date admitted to Hospital: Date Discharged from hospital: 
Reason for die this admission: If transferred, dates of episode: 
Reason for die of episode: 
outcome following die:________ date of outcome: ______ _ 
Actual Length of stay (in days): Did patient expire? YIN Suicide? YIN 
Genetics 
Family history (genetics): 
Relationship? 
Referred b : 
Self 
Family member 
Friend 
RNC Lockup 
Physician 
Other medical facility 
Other 
y 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. Court ordered assessment 
N not indicated 
Validation of Diagnosis (MSE documents): 
1. 
2. 
3. 
4. 
Thought disorder 
Perceptual Disorder 
Affect Disorder 
Disordered behaviour 
First Break (DIMlY) I I 
Substance abuse 
Admission preceded by 
adherence 
Yes No 
non-
Yes 
D 
D 
D 
D 
D 
D 
D 
D 
Yes 
D 
D 
D 
D 
Comments 
No 
D 
D 
D 
D 
D 
D 
D 
D 
No 
D 
D 
D 
D 
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Non-specific Indicators Yes No 
Suicide ideology D B Suicide Attempt (Prior to admission) D 
Suicide Attempt (In Hospital) D D 
Left prior to discharge D D 
Discharged against medical advice (AMA) D D 
Time spent in TQ 
< 8 hours D D 
> 8 hours D D 
None D D 
Drugs on Admission Drugs on Discharge 
Drugs on admission: Drugs on discharge: 
New ------------------------------------------- New -----------------------------------
Old Old 
Not indicated Not indicated 
Non-adherent 
Adherence not indicated 
No antipsychotic 
left prior die-none, new, old, no antipsychotic 
N/A first break 
No meds at all 
left AMA-none, new, old, no antipsychotic 
none giVen 
suicide completed 
patient expired 
no antipsychotic 
transferred-no drugs 
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Complications 
Yes No N/A 
Regression D D 
Complications of medication D D D 
Specify: 
Drug History completed by pharmacy? D D 
Did patient receive ECT during admission? D D 
Complications ofECT D D D 
Specify: 
Improvement in admitting symptoms by the 7th day D D D 
Improvement in symptomology at 4 weeks D D D 
Improvement in symptomology at 6 weeks D D D 
Reason for change to atypical if stated: _______________ _ 
Negative Symptoms Present? 1. Yes 2. No 
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All d rugs d h "t I t urmg osp1 a s ay: 
Drug 
Inpatient drugs: 
New 
Old 
Dosage 
None- 1) already on long acting 
2) short stay (<24 hours) 
3) patient refused meds 
Route Date started 
(dimly) 
4) none-overdose prior to admission 
5) NPO surgery 
Not indicated 
No antipsychotic 
Hypnotic medication after 7th day 
lJ\1 Neuroleptic >10 days (excluding depot medications) 
Date stopped N days Comments 
(d/m/y) Treated 
Yes No 
D D 
[ 
Patient started on an atypical antipsychotic during this hospital stay? [ 
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Treatment strategy on admission: Yes No Comments 
1. ECT prior to out-patient/in-patient trial 
of anti-psychotic? (this admission) 
2. ECT following out-patient/in-patient 
trial of anti-psychotic? (this admission) 
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APPENDIXK Outpatient interview with prescribing physician 
Interview with Physician 
Date of Physician Interview _____ _ Doctor# ______ _ 
Case# _______ _ Place ofResidence (Pt) ______ _ 
Age in Years: _____ _ 
New Patient 1. Yes 2. No 
History of presenting illness (as per psychiatrist's chart) 
Relevant past history (e.g., prevwus psychiatric hospitalizations, case management, 
previous medications, etc.) 
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Symptoms: 
Diagnosis (interview): 
Atypical Antipsychotics & Dosage Prescribed: ---------------
Indications for use: 
--------------------------
Concomitant medications (e.g., psychotropics, mood stabilizers, sedatives, anti-
epileptics, benzodiazepines, other anti-psychotics): 
Anti-psychotic Allergy/Intolerance: 1. Yes 2. No 3. Unknown 
Specify: ------------
Factors influencing anti-psychotic prescription decision: Please circle appropriate 
factor(s). 
1. Clinical Judgment 
2. Patient/Family Request 
3. Allergy 
4. Intolerance to Medications 
5. Reason Not Provided 
6. Patient non-compliance 
7. Worsening of symptoms 
8. No improvement in symptoms 
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APPENDIX L Algorithms to determine indication for use by Brogan Inc. 
Bipolar Indication: Claimants must have a previous claim (within 2 years) for one of 
the selection of drugs: lithium, valproic acid (and related chemicals), carbamazepine, 
phenytoin, gabapentin, topiramate, and lamotrigine. These patients will always remain 
bipolar. 
ADHD Indication: Patients who are not bipolar and who have recent claims (within 2 
years) for methylphenidate, dextroamphetamine are classified under ADHD. New 
psycho-stimulants indicated for ADHD will be added to this list as they enter the market. 
These patients remain in ADHD, unless they claim a drug indicating bipolar. 
In addition, patients under 13 not in the bipolar group are automatically categorized 
ADHD. These patients are re-assessed when they tum 13 and if a more likely indication 
is know, they will be mobbed to the other category for subsequent claims. 
Depression Indication: Refractory depression is counted where a patient is not 
classified as bipolar or ADHD, and is known to have received antidepressants at least 30 
days prior to ever starting any antipsychotic. In the event the patient subsequently drops 
the antidepressant, they are kept in this group. Once the patient turns 65, they are moved 
to dementia. No patient over 64 is included in this group. 
Other Psychoses Indication: Claimants under 65 and WITHOUT previous 
bipolar, ADHD, cognitive enhancers or refractory depression indication. These patients 
will remain as Schizophrenia throughout their years in the database. If these patients ever 
receive a mood stabilizer, they will be moved to bipolar. Patients who initiate their first 
ever antipsychotic at age 60+ will be classified as dementia rather than schizophrenia. 
Dementia Indication: The fifth criterion is for dementia. Anything not bipolar, 
ADHD, refractory depression or schizophrenia AND greater than and equal to the age of 
65. 
Brogan have taken refractory depression out of the limiting criteria. Prior refractory 
depression patients move to dementia once they reach 65. In addition, any patient with a 
record of taking cognitive enhancers (Aricept, Reminyl, Exelon) will be classified as 
dementia, regardless of age or other drug use. 
Patients who initiate their first ever antipsychotic (minimum 2 years is searched) at age 
60 or above, will be classified as dementia rather than other psychoses. 
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